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1. INTRODUCTION 
The measurement of single metabolites as a source of information related to 
health and disease has a long history. Ancient Chinese cultures (1500–2000 BC) 
recognized urine as an important material for assessment well-being, for 
example, sweet-tasting urine was indicative of a disease, which now is known 
as diabetes. However, the word metabolism originates from the Greek word 
“μεταβολή“, which means “change” and the concept of metabolism was first 
mentioned by Ibn al-Nafis 1260 AD, who stated that “the body and its parts are 
in a continuous state of dissolution and nourishment, so they are inevitably 
undergoing permanent change” [van der Greef et al. 2013]. 
The next revolution in the field of metabolism was the discovery of enzymes 
by German chemist Eduard Buchner at the beginning of the 20th century. This 
realization led to the focus on intracellular chemical reactions and inspired the 
development of biochemistry, like enzymatic reactions and intracellular bio-
chemical pathways. The following fundamental change came right after, when 
the British physician Sir Archibald Garrod proposed the detection of changes in 
metabolic pathways caused by a single inherited gene defect. This concept 
became the basis for the field of inborn errors of metabolism [van der Greef et 
al. 2013]. Most of these inherited conditions are not clinically evident at birth, 
because accumulating metabolites cross the placenta and are cleared by the 
mother during gestation, therefore affected infants usually appear normal at 
birth but lead to significant irreversible harm or death.  
Some conditions, like phenylketonuria (PKU), are effectively treatable if 
detected early enough. Therefore another breakthrough in diagnosing metabolic 
disorders took place at the beginning of the 1960s, when Dr Robert Guthrie 
described a method of testing newborns for PKU for the first time [Guthrie and 
Susi 1963]. This testing was performed during the asymptotic period and it is 
valued as the beginning of the newborn screening (NBS).  
A crucial impact in the advancements of NBS came in the 1990s with the 
adaption of electro-spray ionization tandem mass spectrometry (MS), which 
examines multiple metabolites in one analytical run. Therefore, many biochemi-
cally related disorders could be detected in one test, allowing screening for 
extremely rare disorders that might not otherwise have been considered suitable 
for separate testing, and more likely allow to better characterize a particular 
metabolic disease or other iatrogenic influence such as total parenteral nutrition. 
Consequently, this approach left behind the principle of a one-method, one-
metabolite, one-disease conception [Chace D.H. 2005].  
In Estonia, the NBS program was initiated in 1993 for only one disorder – 
PKU, which belongs to the group of aminoacidurias. Phenylalanine (Phe) was 
measured from dried blood spots (DBS) by a modified fluorometric method 
based on enhancement of the fluorescence of a phenylalanine-ninhydrin 
reaction product by L-leucyl-L-alanine [Ounap et al. 1998]. The first thorough 
systematic review in the field of inborn error of metabolism (IEM) in Estonia 
was composed by Õunap et al., who concluded that the incidence of PKU in 
Estonia identified during retrospective studies was lower than the identified 
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prospectively during newborn screening – the incidence of PKU was estimated 
1:6,010 live births [Ounap 1999]. Congenital hypothyroidism (CHT) was added 
to the screening program three years later [Mikelsaar et al. 1998] and the above 
described screening program lasted in Estonia for more than 20 years.  
Nowadays, in Europe, most of the countries are using tandem MS for new-
born screening and the number of disorders included in nation-wide screening 
programs were expanded up to 29, like in Austria [Burgard et al. 2012]. One of 
the most important group of disorders in the NBS program seems to be fatty 
acid β-oxidation defects (FAOD). The first diagnostic test in Estonia for FAOD 
was molecular genetic testing for the common mutations in genes responsible 
for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) and long-
chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). The carrier 
frequency for the mutation c.985A>G (p.K329E) in the ACADM gene, 
responsible for the MCADD, is 1:220 in Estonia, and the frequency of possibly 
affected homozygotes is 1:193,000 [Lillevali 2000]. The carrier frequency for 
the mutation c.1528G>C (p.E510Q) in the HADHA gene, responsible for the 
LCHADD, is much higher than expected – 1:173 [Joost et al. 2012a]. There-
fore, taking into account that the c.1528G>C mutation makes up 87.5% of 
disease alleles in Estonian LCHADD patients, the estimated prevalence of 
LCHADD in Estonia would be 1:91,700 [Joost et al. 2012a]. The prevalence of 
other disorders which are presented in most of the NBS programs are unknown 
in Estonia. 
However, not all inherited metabolic disorders that begin in childhood can 
be screened and treated in the asymptomatic period. For example, in case of 
mitochondrial disorders, where genetic analysis, counselling and prenatal diag-
nosis in further pregnancies is essential; yet it is difficult to reach molecular 
genetic result considering that this IEM may present an extremely nonspecific 
clinical and biochemical picture at any age and the phenotype varies tre-
mendously among family members.  
Joost et al. in 2012 worked out a diagnostic algorithm for better identi-
fication of patients with possible mitochondrial disorder (MD) among Estonian 
pediatric neurology patients [Joost 2012]. This algorithm is based on clinical 
presentation specified with instrumental investigations and the biochemical 
phenotype, which resulted in single gene sequencing [Joost et al. 2012b]. 
During the study period (2003–2009), the live-birth prevalence for childhood 
onset MDs was 1:20,764 in Estonia [Joost 2012; Joost et al. 2012b]. However, 
the landscape of diagnosing MDs has been changing within the last couple of 
years due to the discovery of novel diagnostic methods like whole exome 
sequencing (WES), which were not being mentioned and used in the previous 
study by Joost et al. 
The aims of our study were to evaluate new diagnostic methods and their 
effectiveness of expanded NBS by tandem MS in Estonia; and to determine the 
effectiveness of WES in clinical practice with patients suspected to have child-
hood onset MD. In addition, we have added three interesting and thoroughly 
investigated cases to illustrate the research processes and the outcome, as well 
as to confirm the effectiveness of WES. 
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2. REVIEW OF LITERATURE 
2.1 Newborn screening for inborn errors  
of metabolism by tandem MS 
2.1.1 Tandem MS introduction to expanded NBS programs 
The introduction of tandem MS technology to newborn screening in the 1990s 
gave a tremendous impulse to expand and develop the range of disorders to be 
included in the standard NBS panel in many countries [Millington et al. 1991]. 
Therefore, the use of this methodology broke the traditional paradigm in NBS 
of one test for one disorder and permitted a range of conditions to be identified 
using a single analytical run to identify newborns with severe disorders that are 
relatively preventable and treatable (or controllable).  
Tandem MS high sensitivity and specificity can be used for qualitative and 
quantitative analysis of many analytes, such as amino acids and acylcarnitines, 
organic acids, homocysteine, orotic acid, purines and pyrimidines, steroids, and 
vitamin D to name a few, with appropriate internal standards [Ombrone et al. 
2016]. Therefore, the usage of tandem MS gives an opportunity to get the refe-
rences for more than 50 different conditions [Therrell et al. 2015].  
Still, tandem MS just provide the method for analysis, but NBS does not 
include only testing, it is a thoroughly elaborated system, which requires 
additional equipment, transport and tracking the test results, supplying special 
diets and care; personnel for clinical follow-up and counseling parents, experts 
like lab technicians, chemists, biologists and nutritionists. Besides, they all need 
constant training. 
The expansion of NBS gives us an opportunity to identify more affected 
children, but it produces also some difficulties like the increase in the recall rate 
[Tarini et al. 2006]. One of the reasons is that some metabolites that are markers 
for diseases, have proven to have poor specificity [Ombrone et al. 2016] and for 
some metabolites have an overlap between controls and patients ranges 
[McHugh et al. 2011]. At the same time, one should not forget that in the period 
of introducing the NBS program, there is no experience (including no in-house 
cutoff values). 
Whereas, the experiences in expanded NBS area is also accompanied by 
identification of more affected individuals than previously known from clinical 
ascertainment [Joost et al. 2012a; Ounap et al. 1998; Wilcken et al. 2003]; by 
unpredictable prognosis [Wilcken 2008]; and by insufficient knowledge of 
natural history [Fernhoff 2009; Levy 2010; McCabe and McCabe 2008]. It is 
also important to note that some presently screened disorders may involve little 
benefit or seem to be benign and their inclusion in NBS detection might be re-
considered as perhaps unnecessary and even harmful. Some publications 
describe the anxiety and the potential medicalization for these families [Landau 
et al. 2017; Wilcken 2008]. The false-positive screening results are also causing 
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needless parental stress and may influences the child–parent relationship 
[Bonham 2014]. 
On the other hand, all NBS laboratories have to face a number of false-
negative cases [Estrella et al. 2014; Wilcken et al. 2003], which highlights the 
next cornerstone on the NBS – the range and calculation of cutoff values for 
screening. The result of this test should be a good compromise between 
sensitivity and specificity. A good sensitivity could result in a high false 
positive rate, while having high specificity could cause false negative results. 
Some screening programs first set their cutoffs for mean ± 2SD [la Marca 2014] 
or establish initial cutoffs from 1st to 99.0th (or 0.05th to 99.95th) percentile 
[Couce et al. 2011; Lindner et al. 2011; Lund et al. 2012; McHugh et al. 2011; 
Vilarinho et al. 2010]. Most of the screening laboratories report that all cutoff 
values were adjusted over time to optimize the performance, including false 
positive rate, and to compensate for changes in analytical method [la Marca 
2014; Lund et al. 2012; Vilarinho et al. 2010]. 
 
 
2.1.2 Worldwide standards and practice for NBS by tandem MS 
There is only some limited advice available from national advisory committees 
and national medical or public health professional organizations regarding NBS 
policies. Even the conditions and the criteria for an acceptable screening 
program are still controversial; giving arises to greatly varying worldwide NBS 
panels. Different economic environment of countries, but mostly the way how 
national decisions are made in relation to determining newborn screening 
policy, have led to divergent choices in different countries. Those administ-
rations in which decisions were strongly influenced by metabolic physicians 
and scientists or geneticists including Australia and the United States (US) 
tended to use a wide selection expanded programs at an early stage [Hoffmann 
et al. 2014; Landau et al. 2017; Therrell et al. 2015]. Whereas countries, 
including most in Europe, where the policy decisions are determined more by 
public health officials, the NBS programs include a relatively limited number of 
disorders [Burgard et al. 2012; Loeber et al. 2012; Therrell et al. 2015].  
Therefore, divergence has resulted in significant disparities in screening 
services available to newborns in all over the world and there is no worldwide 
“golden standard” for NBS [Bonham 2014; Burgard et al. 2012; Lehotay et al. 
2011; Loeber et al. 2012; Pollitt 2006].  
A positive example of a unity in the field of NBS has been created in the US, 
where currently 49 congenital metabolic disorders are in the core and secondary 
NBS panel using tandem MS [Ficicioglu 2017; Janeckova et al. 2012; Rinaldo 
et al. 2008]. The prerequisites for that kind of accordance was made by creating 
the Recommended Uniform Screening Panel (RUSP) that is accepted and 
recommended by the US Secretary of Health and Human Services Advisory 
Committee of Heritable Diseases in Newborns and Children (SACHDNC) for 
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all the NBS programs in the US. [Ficicioglu 2017; Landau et al. 2017]. This 
screening program is available to all newborns born in US. 
The opposite situation is in Europe, where there is little unity. For example, 
the screening situation in Italy is very fragmented – several regions regulate 
their NBS programs in place and list of coverage conditions vary between 20 
and 40 (Tuscany, Umbria, Liguria, Sardinia, Emilia Romagna, Sicily, Veneto), 
while some other regions have experimental programs ongoing (Lazio). 
Approximately one third of newborns currently undergo expanded screening in 
Italy [Burlina and Corsello 2015]. Belgium has been divided into two separate 
jurisdictions (Flemish respectively French Community), where different 
screening programs are used, and The Liechtenstein newborns are screened in 
Switzerland [Loeber et al. 2012].  
The nearest countries in our regions like Finland, Latvia and Lithuania, 
continue to have little experience in the field of expanded NBS. Latvia are 
screening newborns only for PKU and CHT [Loeber et al. 2012], Lithuania 
added galactosemia and congenital adrenal hyperplasia (CAH) to the NBS panel 
at the beginning of the 2015, while screening for PKU and CHT continues as 
before [personal contact with J. Songailiene]. In Finland, until January 1, 2015 
the only disorder screened for comprehensively in the whole country was CHT, 
which was performed from the umbilical cord blood; and just recently the 
screening program expanded by five congenital metabolic disorders: glutaric 
aciduria type 1 (GAI), MCADD, LCHADD, PKU and CAH [Therrell et al. 
2015]. 
Therefore, the NBS is taking place to some extent in most European 
countries [Burgard et al. 2012; Loeber et al. 2012] and most of these programs 
claim to be based on the screening principles first developed by Wilson and 
Jungner on behalf of the World Health Organization in 1968 [Wilson and 
Jungner 1968]. At the same time, many expert groups have turned their 
attention to screening panels which include a large number of disorders that 
may not meet all of these criteria and therefore, these principles have been 
revisited in regard to medical advances [Dhondt 2007; Dhondt 2010; Pollitt 
2006; Pollitt 2007]. The incidence of a disease is a less compelling criterion 
when the disorder can be detected at no additional cost with multiplex 
technology, but inclusion of diseases with no effective treatment remains 
questionable [Dhondt 2010]. In the light of this knowledge, it is also important 
to point out that the list of the screened disorders is unlikely to be final in the 
long run. Many programs have re-evaluated this list because of the added 
experience and knowledge [Lindner et al. 2011; Lund et al. 2012]. For example, 
3-methylcrotonyl carboxylase deficiency (3MCCD) was thought to be a rare 
disorder with severe neurological pathology, but during the NBS, this disorder 
was detected in an appreciable number of newborns and in their clinically 
unaffected mothers [Stadler et al. 2006]. Although, there is also some 
contradiction, because some reports are describing patients with 3MCCD 
having acute metabolic decompensation [Ficicioglu and Payan 2006; Grunert et 
al. 2012]. A similar discussion takes place with short-chain acyl-CoA dehydro-
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genase deficiency (SCADD), which is considered as benign condition, while 
there is reports that suggest being aware of hypoglycemia in patients with 
SCADD to prevent adverse consequences [Waisbren et al. 2008]. 
Therefore, many screening programs have made reassessments for one 
reason or another. Like Germany, where nationwide expanded newborn screening 
was started in 2000 with more than 29 conditions [Lindner et al. 2011; Maier et 
al. 2005; Schulze et al. 2003]. In 2005, German health authorities decided to 
limit the number of disorders to be detected by tandem MS up to ten and 
decided that all results of metabolites, which are not needed for this purpose, 
must be suppressed or deleted immediately after analysis [Bodamer et al. 2007; 
Lindner et al. 2011]. This highlights the next difference between the approaches 
in NBS – the full-profile approach or the limited access approach (like in 
Germany). The full-profile approach allows to use the maximum amount of 
information without the regard to the distinction between appropriate and 
inappropriate target conditions. This is accompanied by a disadvantage – the 
full-profile mode increases the risk of incidental detection of abnormal con-
ditions, for which the clinical significance of a positive screening result is very 
much in doubt [Dhondt 2010].  
Furthermore, the length of DBS storage varies considerably, which is 
between 3 months (Germany) to more or less indefinite (Denmark, Norway and 
Sweden) [Loeber et al. 2012]. While it is known that most of the metabolites are 
degraded in months [Adam et al. 2011], therefore the DBS can be used for 
DNA extraction only. According to this, maybe the storage of full-profile of 
metabolites is useful by giving availability for retrospective investigation.  
Each NBS performing center or country in Europe can consider these afore-
mentioned topics and their drawbacks as well as advantages to make the most 
appropriate decision for them. However, nobody doubts that NBS is a very 
important and extraordinarily positive initiative, especially for rare and serious 
inherited disorders. This is also confirmed by medical specialist/scientists and 
families where the affected child grows. For example, a short-term assessment, 
based on a parental survey, found that patients diagnosed clinically showed a 
higher incidence of intellectual disability (ID) and their parents experienced 
greater stress than when the disorder was detected by NBS [Waisbren et al. 
2013; Waisbren et al. 2002]. In a longer-term outcome, evaluation reported 
fewer deaths and fewer clinically significant disabilities at 6 years of age when 
detection resulted from NBS [Wilcken et al. 2009]. Moreover, NBS is also 
evaluated as an economically advantageous engagement [Schoen et al. 2002].  
Lessons learned from current ongoing worldwide NBS programs indicate 
that we are still far from perfectionism. We believe that in the future NBS area 
expands and overlaps with many other fields of science. The approach will 
change because of rapidly developing technology and the addition of genetic 
tests with extra biomarkers into NBS will make it possible to detect many more 
genetic conditions [Solomon et al. 2012]. Besides, the genomic sequencing 
could open up new opportunities for increasing the specificity of current tandem 
MS screening tests by bringing out only the true-positive results and enabling to 
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screening the rare disorders that currently lack methods for conventional 
biochemical NBS [Berg et al. 2017]. Furthermore, our knowledge is insufficient 
for completely understanding the complexity of diseases. Therefore, we believe, 
that the collaboration between the area of genes as genomics, messenger 
ribonucleic acids (RNAs) as transcriptomics, proteins as proteomics, and meta-
bolites as metabolomics are inevitable. 
 
 
2.2 Expanded newborn screening for detection  
of vitamin B12 deficiency 
2.2.1 The distribution of vitamin B12 deficiency 
Vitamin B12 is a water-soluble vitamin, which is a micronutrient essential for 
cellular growth, differentiation and development. Humans are unable to 
synthesize it by themselves and thus rely on dietary intakes and a complex intra-
cellular route for vitamin B12 processing and delivery [Hannibal et al. 2009]. 
Vitamin B12 deficiency seems to be worldwide problem, especially in 
developing countries where deficiency is common in all age groups [Allen 
2009]. In developed countries, it is most frequently found in the elderly age 
group; however, the prevalence in all age groups may be higher than previously 
thought [Allen 2009; Irevall et al. 2017]. This condition is frequently under-
diagnosed in pregnancy and in infants from mothers having insufficient levels 
of this micronutrient [Sarafoglou et al. 2011; Wheeler 2008].  
The worldwide spread of NBS programs using tandem MS has also greatly 
contributed to highlighting the high incidence of vitamin B12 deficiency even in 
industrialized countries [Irevall et al. 2017], and it has also been pointed out that 
non-inherited conditions are mainly secondary to maternal deficiency [Dror and 
Allen 2008; Hinton et al. 2010; Marble et al. 2008; Refsum et al. 2004; 
Sarafoglou et al. 2011; Scolamiero et al. 2014].  
Maternal vitamin B12 deficiency during pregnancy is a strong predictor of 
neonatal vitamin B12 deficiency as the active transport of cobalamin in the 
fetus serum is carried out through the placenta [Duggan et al. 2014; Monsen et 
al. 2001]. Mothers’ inadequate dietary intake and malabsorption are the most 
common causes of congenital acquired vitamin B12 deficiency. Dietary patterns 
with reduced intake of animal sourced foods, such as vegetarian, vegan, or low-
cost diets, and religiously or culturally motivated avoidance of animal products, 
are associated with an increased risk for above described condition [Allen 2008; 
Koebnick et al. 2004; Murphy and Allen 2003]. Additionally, gastrointestinal 
disorders, gastric bypass and pernicious anemia can lead to malabsorption and 
deficiency of vitamin B12 [Allen 2008; Hinton et al. 2010]. Nowadays, the 
maternal B12 deficiency can be subclinical, which is defined as a total serum 
B12 concentration of 150–249 pmol/L [Carmel 2012; Carmel 2013]. These 
mothers may not be anemic and their vitamin B12 levels are normal or low-
normal, therefore, the diagnosis and management of it, is a matter of great 
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interest, due to its much higher prevalence (up to 40% of the population in 
western countries) compared to clinical deficiency [Carmel 2012; Carmel 2013]. 
An Ontario study group reported that 10% of pregnant women (> 28 days) 
are vitamin B12 deficient [Ray et al. 2008]. Increased rates of up to 51% 
vitamin B12 deficiency during pregnancy have been found for India [Duggan et 
al. 2014], Australia [Hure et al. 2012] and Mexico [Allen et al. 1995], 
potentially leading to a high prevalence of congenital acquired vitamin B12 
deficiency. Therefore, it seems that this problem is quite common in different 
regions and treatment is relatively simple – the only question is how to find 
patients in need of treatment as quickly as possible. 
 
 
2.2.2 The vitamin B12 deficiency related changes in NBS profile 
Along with folate, vitamin B12 is necessary for the synthesis of DNA, lipids 
and proteins, and an essential step in this process of conversion the homo-
cysteine (Hcy) to methionine (Met) [Rasmussen et al. 2001]. These processes 
are crucial during the growth and brain development [Dror and Allen 2008]. In 
addition, this vitamin has a significant role in odd-chain fatty acid and branched 
chain amino acid metabolism for isomerization of methylmalonyl-CoA to 
succinyl-CoA. Intracellular B12 deficiency leads to an increase in methyl-
malonyl-CoA, which converts into methylmalonic acid (MMA) and is released 
into the blood stream. Therefore, plasma MMA concentration may serve as a 
functional biomarker of vitamin B12 status and reflects intracellular deficiency 
[Carmel 2011; Hannibal et al. 2016; Refsum et al. 2004; Savage et al. 1994]. 
While it must be remembered that the measurement of total circulating vitamin 
B12 alone may not be enough to give an assessment of the actual situation, 
because ~80% is bound to haptocorrin, and therefore it is not bioavailable for 
cellular uptake and does not reflect the cellular vitamin B12 status [Carmel 
2000; Devalia et al. 2014; Lysne et al. 2016; Solomon 2005]. 
The acylcarnitine profile of DBS samples from NBS includes a propionyl-
carnitine (C3), a compound of odd-chain fatty acid metabolism [Thompson 
1992], which is widely used analyte as a marker for propionic- and methyl-
malonic acidemia, but at the same time it may also be indicative for vitamin 
B12 deficiency. Therefore, some newborn screening programs have started to 
use C3 as the first marker for congenital acquired vitamin B12 deficiency. 
[Hinton et al. 2010; Sarafoglou et al. 2011; Scolamiero et al. 2014]. However, it 
is important to emphasize that the C3 is a primary maker used to detect organic 
acidurias and remethylation defects and its level alone is not sensitive or 
specific enough to detect all newborns with congenital acquired vitamin B12 
deficiency. Moreover, C3 levels may not be sufficiently high during the first 
few days of life when the DBS is collected [Campbell et al. 2005]. Therefore, 
there is some evidence that the C3 to acetylcarnitine (C2) ratio and/or C3 to 
palmitoycarnitine (C16) ratio together with C3 are better than C3 level alone for 
detecting or identifying the babies with nutritional B12 deficiency [Armour et 
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al. 2013; Sarafoglou et al. 2011; Scolamiero et al. 2014]. The MMA, measured 
from DBS as a secondary test, might also add value to increase sensitivity and 
specificity in detection of vitamin B12 deficiency [Sarafoglou et al. 2011; 
Schroder et al. 2016]. Some authors like Gramer et al. have also suggested 
using total homocysteine (tHcy) from DBS as a first marker to detect 
remethylation disorders and additionally congenital acquired vitamin B12 
deficiency. The second-tier markers like Met, Met/Phe, C3 and C3/C2 should 
be evaluated afterwards to confirm the initial hypothesis [Gramer et al. 2017]. 
Considering that this topic is recently increasingly debated, it is very likely that 
new approaches will be available in the near future. 
 
 
2.2.3 The congenital acquired vitamin B12 deficiency diagnosed by NBS 
The results of congenital acquired vitamin B12 deficiency diagnosed by NBS, 
published for so far (intentionally or coincidentally found), have shown a 
relatively high incidences (Table 1). Sarafoglou et al. described a population-
based study of 363,649 infants born in Minnesota. During the six-year study 
period, 11 newborns with vitamin B12 deficiency were found, therefore the 
incidence was 3.02/100,000 live births (1:33,113) and the lower cutoff level of 
C3 was 5.25 μmol/L [Sarafoglou et al. 2011]. Higher incidence was detected in 
the Italian population, where a six-year expanded metabolic newborn screening 
pilot project showed an incidence of congenital acquired vitamin B12 
deficiency of 20/100,000 (1:5,000) and the lower cutoff level of C3 was 
3.16 μmol/L, [Scolamiero et al. 2014]. The most exceptional statement was 
proposed by Refsum et al., who concluded that 10% of screened newborns had 
low vitamin B12 levels [Refsum et al. 2004]. Therefore, numerous recent 
publications show that NBS with tandem MS has great potential to identify 
congenital vitamin B12 deficiency, an important and treatable condition in 
asymptomatic stage [Campbell et al. 2005; Hinton et al. 2010; Marble et al. 
2008; Sarafoglou et al. 2011; Scolamiero et al. 2014]. 
 
Table 1. Summary of publications about the congenital vitamin B12 deficiency. 
* – calculated results; n.a. – not available 
Study group 
No. of 
screened 
newborns
No. of newborns 
with congenital 
acquired vitamin 
B12 deficiency  
Incidence of congenital 
acquired vitamin B12 
deficiency  
Hinton et al.[2010] n.a. n.a. 0.88/100,000 (1:113,636*) 
Sarafoglou et al.[2011] 363,649 11 3.02/100,000 (1:33,113*) 
Gramer et al.[2017] 26,202 5 19.08/100,000* (1:5,241*) 
Scolamiero et al.[2014] 35,000 7 20/100,000* (1:5,000) 
Reinson et al.[2017] 41,453 14 33.8/100,000 (1:2,959) 
Refsum et al.[2004] 4,992 ~10% (500*) 10,000/100,000* (1:10*) 
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Early detection and intervention of vitamin B12 deficiency is critical to prevent 
irreversible neurologic damage. Unrecognized neonatal vitamin B12 deficiency 
worsens if the infant is exclusively breastfed by a vitamin B12 deficient or sub-
clinical deficient mother due to decreased fetal stores and insufficient intake 
through breastmilk [Rasmussen et al. 2001]. Infantile vitamin B12 deficiency 
often presents with nonspecific symptoms, such as muscle hypotonia, 
irritability, or failure to thrive [Dror and Allen 2008; Rasmussen et al. 2001]. It 
is difficult to make the diagnosis on the clinical ground and there tends to be 
substantial diagnostic delay [Graham et al. 1992], which can easily be avoided. 
Prolonged vitamin B12 deficiency during infancy has been associated with 
negative long-term health outcomes in children [Molloy et al. 2008], including 
impaired cognitive function and developmental delay (DD) [Bhate et al. 2008; 
Garcia et al. 2009], however, the extent and degree of disability depend on the 
severity and duration of the deficiency [Rasmussen et al. 2001]. Therefore, it 
would be beneficial to improve NBS, so that most of those children could be 
detected in the symptom-free phase. 
 
 
2.3 Diagnostic approach to mitochondrial disorders 
2.3.1 Mitochondrial function and genes regulating it 
Mitochondria are double-membrane-bound organelles, which are of bacterial 
origin, and during the historical symbiotic relationship, they became normal 
component of eukaryotic cells [Ochman and Moran 2001]. They are essential 
for a wide range of cellular processes, including iron-sulfur cluster formation, 
amino acid and fatty acid synthesis and degradation, the tricarboxylic acid 
cycle, heme synthesis, and production of adenosine triphosphate (ATP) via 
oxidative phosphorylation (OXPHOS). The primary MDs are considered to 
describe diseases with a primary disorder in the entire route of the OXPHOS. 
The origin of mitochondria remains exposed with their multicopy genetic 
material – mitochondrial DNA (mtDNA), which is exclusively maternally 
inherited. The mtDNA copy number varying greatly between individuals and 
across different tissues from the same individual [Giles et al. 1980]. The 
multicopy nature of mtDNA gives rise to heteroplasmy, a condition in which 
mutant and wild-type mtDNA molecules coexist. While, homoplasmy occurs 
when all of the mtDNA molecules have the same genotype. Heteroplasmic 
mutations often have a variable threshold – a level to which the cell can tolerate 
defective mtDNA molecules [Stewart and Chinnery 2015]. But it is not just 
about it – more than 289 nuclear genes are currently known to be associated 
with MDs [Wortmann et al. 2017] and this list is not finished yet.  
Mutations in these genes may result in a defect in the corresponding 
subunit(s), causing an isolated or complex deficiency in the OXPHOS enzymes. 
Hundreds of different proteins are required for the biosynthesis of the 
OXPHOS, including assembly factors and mitochondrial translation factors 
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[Koopman et al. 2012; Mimaki et al. 2012; Nouws et al. 2012; Smits et al. 
2010]. A defect in one of these proteins often leads to a deficiency of OXPHOS 
enzymes as well. Furthermore, a large number of defects outside the OXPHOS 
have been described that directly or indirectly affect the mitochondrial oxidative 
ATP production.  
Taking the above mentioned into account, mitochondrial dysfunction is 
implicated in a broad spectrum of diseases, affecting various tissues. The clinical 
spectrum of MDs is extremely broad and the underlying biochemical and 
genetic defects are heterogeneous [Koopman et al. 2012; Morava et al. 2006b; 
Munnich et al. 1996]. Identical clinical signs and symptoms can be caused by 
mutations in different mitochondrial or nuclear genes and the same mutation 
can lead to different phenotypes. However, the majority of children with MD 
presents at least one or more neurological signs or symptoms (e.g., muscle 
weakness, peripheral neuropathy, ophthalmoplegia, movement disorder, epi-
lepsy or migraine), which are all non-specific [Munnich et al. 1996]. 
Therefore, it is often a major challenge to diagnose MDs and discover their 
molecular cause, but the introduction of new diagnostic methods has greatly 
contributed to this. 
 
 
2.3.2 Traditional diagnostic approach for MDs 
For a long period of time the MDs diagnostic was initially based on measure-
ment of the biochemical markers like lactic acid in serum and cerebrospinal 
fluid (CSF), high serum alanine levels, and increased excretion of the meta-
bolites of the tricarboxylic acid cycle – these were represented in patients with 
mitochondrial dysfunction [Rubio-Gozalbo et al. 2000], but not always as they 
were not specific to MDs. 
For example, lactic acidemia may be present only in 50% of patients 
[Koenig 2008] and up to 87% of patients with neonatal onset of MD [Honzik et 
al. 2012]. Valuable information can be obtained from brain magnetic resonance 
imaging (MRI) and muscle biopsy: light microscopy for structural changes, 
evaluated by histochemical, immune-histochemical and ultrastructural investi-
gations with biochemical analysis of respiratory chain enzymes [Kisler et al. 
2010]. This approach has already been thoroughly described in advance [Joost 
2012] and a number of guidelines and algorithms have been developed to 
improve the diagnostic field [Joost et al. 2012a; Morava et al. 2006b; Nissen-
korn et al. 1999; Wolf and Smeitink 2002], but none of them guaranteed the 
detection of most of the patients with MDs. For example, the molecular diag-
nosis by using Sanger sequencing were achieved only in 11% of the patients 
with suspected MD [Neveling et al. 2013]. Besides, mitochondrial dysfunction 
may occasionally be a secondary phenomenon, which occurs alongside to a 
primary genetic syndrome and/or neuromuscular disorder [Valenti et al. 2014; 
Wortmann et al. 2009]. Therefore, the final diagnosis could take years. 
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2.3.3 WES as a new diagnostic approach for MDs 
Nowadays, many scientists have raised a question – would the WES make a 
difference and be as a first-line diagnostic test in patients suspected to have MD; 
especially in children to save the time and avoid the need for invasive 
procedures like skin and muscle biopsy. 
WES is the analysis of all coding gene regions, which comprises approxi-
mately 1.6% of the human genome and this technology is increasingly used in 
clinical practice [Bamshad et al. 2011; Fokstuen et al. 2016; Kaname et al. 
2014; Majewski et al. 2011]. This method analyzes about 30 million base pairs 
that are translated into functional proteins. Mutations in base pairs may impair 
protein expression or function, thereby causing disease [Ficicioglu 2017].  
Compared with traditional diagnostic testing for MDs, which are described 
by Joost et al. [Joost 2012], the recent evaluations of WES for diagnosing MDs 
have shown that this approach is more likely to provide a final diagnosis. 
Moreover, it seems to be quicker and cheaper as the amount of genetic infor-
mation that can be obtained in a single test is considerably larger compared to 
previous approach, which required several different tests. This is also indicated 
by studies that report the success rate of big exome sequencing up to 40% and 
in selected subgroups it can be up to 60% [Haack et al. 2012; Neveling et al. 
2013; Wortmann et al. 2015]. Still, it is important to note that most of the above 
described work with WES is research based, particularly the studies describing 
novel genetic defects [Galmiche et al. 2011; Haack et al. 2014; Yarham et al. 
2014]; or selected patient cohorts who have beforehand confirmed OXPHOS 
enzyme deficiency in fibroblasts or muscle [Calvo et al. 2012; Ohtake et al. 
2014; Taylor et al. 2014]. 
Publications about WES as a tool for routine diagnostic work have just 
recently been issued. The first of them described the findings in 109 patients 
with a suspected MD [Wortmann et al. 2015]. This cohort consisted of patients 
with ID (most frequent finding), DD, myopathy/exercise intolerance, and 
mitochondrial dysfunction in muscle; the genetic diagnosis was confirmed in 42 
patients (39%). This research also has been emphasizing the patient’s thorough 
investigation before performing the WES. For these patients, the inclusion 
criteria were suspicion of a MD by the referring physician, absence of large 
scale mtDNA deletions, mtDNA point mutations and lacking of copy number 
variations [Wortmann et al. 2015]. 
Several studies have attempted to evaluate how successful WES is for the 
molecular diagnosis of MDs and come to the conclusion that this method has its 
own advantages and disadvantages, and often we need biochemical and 
functional studies too. For example, 42 infantile mitochondrial patients with 
biochemically proven OXPHOS deficiency, the molecularly confirmed diagnosis 
was made in 24% of patients and almost half of the patients remained without a 
diagnosis or a prioritized candidate [Calvo et al. 2012]. A significant number of 
undiagnosed cases might indicate a very wide spectrum of genetic disorders in 
patients suspected of MD. Therefore, even WES makes sometimes a clinical 
24 
and molecular diagnosis challenging. Still, there are authors who recommend 
the approach using exome sequencing in leukocyte extracted DNA in all 
individuals suspected of MD, irrespective of age, gender, and stage of the 
disease [Wortmann et al. 2017].  
Concurrently, the functional and biochemical studies (including a muscle 
and skin biopsy) remain important due to unknown variants of uncertain 
pathogenicity in genes not reported earlier, although they may lead to MD. Even 
variants in known disease causing genes may require functional validation, for 
example, in the case of an unusual clinical presentation. This validation may 
consist of a relatively simple test, such as a Western blot or a specific enzyme 
assay. As well as genetic complementation studies, in which the wild type gene 
is introduced in patient’s cultured cells to test if this restores the cellular or 
 
2.4 CACNA1A -related disorders and  
genotype-phenotype associations 
The CACNA1A gene (OMIM 601011) encodes the pore-forming alpha-1A 
subunit of the calcium channel Cav2.1 acting as an ion pore and a voltage sensor 
[Strupp et al. 2007; Vahedi et al. 2000]. These channels have been shown to 
have an essential role to mediate synaptic release from a variety of neuronal cell 
types, both excitatory and inhibitory, in the cortex, hippocampus, thalamus and 
cerebellum [Damaj et al. 2015]. Particularly in the CACNA1A gene, several 
mutations like nonsense mutations, missense mutations and expansion of 
cytosine-adenine-guanine (CAG) repeats have been described earlier and they 
lead to variable clinical phenotypes – including episodic ataxia type 2 (EA2, 
OMIM 108500), familial hemiplegic migraine type 1 (FHM1, OMIM 141500) 
and spinocerebellar ataxia type 6 (SCA6, OMIM 183086). It is important to 
bring out that there is no strong correlation between phenotype and genotype 
[Strupp et al. 2007], although expansion of the CAG repeats causes mainly 
SCA6 [Jen et al. 2001]. However, channel function and its relation to phenotype 
are not well studied in most of the cases, leaving a need for functional 
annotation of CACNA1A and its variants in a model organism [Luo et al. 2017].  
Over times, the descriptions of CACNA1A-related phenotypes only expand 
and an increasing number of publications have been associating it with epilepsy. 
This may occur during severe hemiplegic migraine attacks or as an independent 
epileptic event [Haan et al. 2008; Holtmann et al. 2002; Jouvenceau et al. 2001]. 
There are also rare case reports from patients having been diagnosed with 
epileptic encephalopathy [Damaj et al. 2015; Hayashida et al. 2017; Hino-
Fukuyo et al. 2015; Ohmori et al. 2013]. In addition, ID has also been 
previously described [Freilinger et al. 2008; Kors et al. 2003] causing mental 
biochemical defect [Danhauser et al. 2011; Huigsloot et al. 2011; Jonckheere et 
al. 2013]. All of these approaches have also been used extensively by our study 
group. 
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dysfunction varying from a profound [Curtain et al. 2006; Vahedi et al. 2000] to 
a mild ID [Damaj et al. 2015]. 
All the above-mentioned conditions are inherited in an autosomal dominant 
pattern (Table 2).  
 
Table 2. CACNA1A-related disorders in the OMIM database 
Location Phenotype 
Phenotype 
OMIM number Inheritance 
19p13.13 Epileptic encephalopathy, early infantile, 42 617106 AD 
Episodic ataxia, type 2 108500 AD 
Migraine, familial hemiplegic, 1 141500 AD 
Migraine, familial hemiplegic, 1,  
with progressive cerebellar ataxia 141500 AD 
Spinocerebellar ataxia 6 183086 AD 
 
Our workgroup is describing for a first time the clinical picture and molecular 
finding of patients with the semidominantly inherited mutations in the 
CACNA1A gene, which are likely to cause early epileptic encephalopathy, 
progressive cerebral, cerebellar, and optic nerve atrophy with severe muscular 
hypotonia and reduced lifespan [Reinson et al. 2016b]. Therefore, this is a novel 
finding, which expands the CACNA1A-related disorders phenotypic spectrum. 
 
 
2.5 A novel mutation is causing the third distinct 
phenotypic group associated with SLC25A4 gene 
Humans have four tissue-specific isoforms of ADP/ATP translocase, which are 
encoded by four closely related nuclear genes [Dolce et al. 2005]. Solute carrier 
family 25, member 4 (SLC25A4) gene (OMIM 103220) is located on the sub-
telomeric region of chromosome 4q and encodes the AAC1 (also known as 
ANT1) protein. This gene is expressed at high level in heart, skeletal muscle, 
brain and in organs with low mitotic regeneration, but at low level in 
proliferating cells such as myoblasts during muscle development [Clemencon et 
al. 2013]. AAC1 protein is homodimer of 30-kD subunits embedded in the 
mitochondrial inner membrane. This dimer forms a gated pore, which plays a 
central role to import ADP across the inner membrane into the mitochondrial 
matrix and export ATP from the matrix into the intermembrane space, which is 
confluent with the cytosol. In this way, the ADP/ATP ratio is regulated in 
mitochondrial oxidative phosphorylation [Fiore et al. 1998; Klingenberg 1989]. 
Several mutations in SLC25A4 have been linked to mitochondrial disorders 
and fall into two distinct clinical phenotypes. Firstly, null recessive mutations 
causing a mitochondrial DNA depletion syndrome 12B presenting myopathy 
and cardiomyopathy phenotype in childhood or early adulthood and it is 
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characterized by lactic acidosis, fatigue and exercise intolerance (OMIM 
615418) [Echaniz-Laguna et al. 2012; Korver-Keularts et al. 2015; Strauss et al. 
2013]. Secondly, several single heterozygous mutations are reported in cases of 
adult-onset autosomal dominant progressive external ophthalmoplegia (adPEO, 
OMIM 609283) [Deschauer et al. 2005; Kaukonen et al. 2000; Siciliano et al. 
2003].  
The advent of WES has greatly improved the prospect of achieving a genetic 
diagnosis for patients suspected of MD and therefore, the spectrum of mito-
chondrial disease causing mutations continues to expand [Taylor et al. 2014]. 
One of the latest accomplishments by using WES was previously undocumented, 
recurrent, de novo, dominant mutations in SLC25A4 gene [Thompson et al. 
2016], which is causing the third distinct phenotypic group and is discussed in 
detail in results section. 
 
 
2.6 Diverse phenotype in patients with mutations  
in the NDUFB11 
The mammalian complex I (NADH-ubiquinone oxidoreductase) is the largest 
multi-subunit enzyme of the mitochondrial electron-transport chain and catalyses 
the first step in the respiratory chain, transferring two electrons from NADH to 
ubiquinone, coupled to the translocation of four protons across the membrane 
[Carroll et al. 2002].  
Complex I (CI) is the most frequently observed single enzyme deficiency 
causing OXPHOS disorders [Rodenburg 2011]. Usually, it does not cause only 
a deficiency of the NADH:ubiquinone oxidoreductase enzyme activity, but it 
also leads to several additional defects at the cellular level, including altered 
mitochondrial network morphology, altered membrane potential, changes in 
intracellular calcium homeostasis and elevated formation of mitochondrial 
reactive oxygen species (ROS) production [Luo et al. 1997; Verkaart et al. 
2007]. This gives rise to the pathogenesis of numerous hereditary and degene-
rative disorders [Hoefs et al. 2012] with no clear genotype-phenotype corre-
lation [Koene et al. 2012; Pagniez-Mammeri H. 2012; Tucker et al. 2011].  
The most recently identified gene defects causing CI deficiency are in the 
NDUFB11 gene, which is located in the short arm of the X-chromosome 
(Xp11.23) [Rodenburg 2016]. This gene encodes a relatively small integral 
membrane protein, which belongs to the supernumerary group of subunits, and 
proved to be essential for the assembly of an active CI [Fassone and Rahman 
2012]. Over the last three years, there have been published few papers with 
patients whose clinical problems are presumably caused by mutation in 
NDUFB11 gene – six females and seven males with four asymptomatic female 
carrier. Our study group reported the clinical, biochemical, and molecular 
characterization in additional two male patients without skin manifestation.  
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2.7 Summary of the literature 
The NBS program has remained unchanged in Estonia for more than 20 years. 
At the same time, the tandem MS has been used and far more than two 
disorders are tested in most of European countries. Therefore, we believe that 
the next reasonable step in Estonia would be to expand the newborn screening 
program and start to use tandem MS method. Whereas, the method has been 
available in Estonia since 2008 for measuring the acylcarnitines form serum in 
symptomatic patients [Joost et al. 2012a]. Besides, our knowledge about the 
FAOD and intoxication type of metabolic disorders like aminoacidurias and 
organic acidurias (OA), are limited in Estonia. At the same time, the need for 
early identification is important, as the clinical outcome in some of those 
disorders is generally favorable, but they are related with significant morbidity 
and mortality if they remain undiagnosed [Sim et al. 2002]. 
In the field of IEM there are also a large number of disorders that can not be 
diagnosed by NBS, although they start in childhood and often need an urgent 
intervention. One of the largest such group consists of MDs, which are 
complicated to diagnose, because of lack of specific markers and a highly 
variable phenotype. For so far, many different algorithms are used for that, but 
they tend to be time-consuming, require invasive procedures, and more than 
half of the cases do not achieve a molecularly validated diagnosis. While, a 
novel diagnostic method like WES seems to be suitable for replacing the old 
approach. At the same time, only very few groups have applied it in clinical 
practice, although, we believe that in this particular field, the introduction of 
this method can bring the greatest benefits.  
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3. AIMS OF THE PRESENT STUDY 
The aims of the present study were: 
- To evaluate the methodology and the effectiveness of the expanded newborn 
screening program in Estonia (Paper I and VI); 
- To assess the effectiveness of the whole exome sequencing analysis in 
clinical practice in Estonia in patients with an unsolved suspected mito-
chondrial disorder (Paper II); 
- To investigate the clinical effect of compound heterozygous mutation in the 
CACNA1A gene (Paper III); 
- To ascertain the functional and clinical effect of a novel de novo mutation in 
the SLC25A4 gene (Paper IV); 
- To characterize the NDUFB11-related phenotypes and functional studies 
(Paper V). 
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4. MATERIALS AND METHODS 
4.1 Study subjects 
4.1.1 Expanded newborn screening for selected inborn errors  
of metabolism in Estonia (Paper I and VI) 
In Estonia, a population-based expanded newborn screening for congenital 
metabolic disorders by using tandem MS was introduced on January 1, 2014. 
For the first 12 months (01/01/2014-31/12/2014) it was a pilot project and since 
2015 this project was financed by the Estonian Health Insurance Fund. During 
the four years (2014–2017), we have screened 54,899 newborns and >99% of 
them were Caucasian. Parents were provided with information leaflets and 
booklets during the pregnancy and before the bloodspots were obtained, without 
the need to sign an informed consent form. If the parents did not allow their 
child to participate in the newborn screening program, an empty and signed 
screening card were sent to the screening laboratory. 
For the first 12 months, we conducted screening as a pilot project and 
investigated 13,643 newborns. Forty-nine parents (0.36% of all births) refused 
to participate in the project, and thus expanded NBS during the pilot study 
included 99.64% of the newborns in Estonia [Reinson et al. 2016a]. In the year 
2015 the number of screened patients was 13,915 and 58 (0.42%) parents 
refused; in the year 2016 it was 13,881 newborns and 42 (0.3%) parents refused; 
and last year we screened 13,460 newborns and 61 (0.45%) parents refused. 
Screening samples consisted of capillary blood drawn from heel prick, and 
were collected on Whatman 903® filter paper. The samples were dried and sent 
by mail or courier from local hospitals to the Department of Clinical Genetics, 
Tartu University Hospital for analysis. This is the only laboratory in Estonia, 
which performs the NBS. The recommended age for obtaining a screening 
sample was 3rd to 5th day of life; most of the bloodspots were collected between 
2nd to 7th day of life.  
After three years of expanded NBS in Estonia, we re-evaluated thoroughly 
all the cases of congenital acquired vitamin B12 deficiencies, which were 
diagnosed in our laboratory. Therefore, the prevalence of vitamin B12 defi-
ciency is calculated based on 3-year (2014–2016) data and the prevalence of all 
other screened disorders is based on 4-year data.  
 
 
4.1.2 Study group of patients with suspicion of mitochondrial 
disorders, including three patients who are characterized  
in detail (Paper II–V) 
The retrospective study group (N=21) was selected from a database of 181 
patients whose fibroblast cell cultures have been stored during January 2003 – 
December 2013 in the Department of Clinical Genetics, Tartu University 
30 
Hospital. All those patients were consulted by a clinical geneticist and had a 
definite diagnosis or a suspicion of a metabolic disease. The fibroblasts were 
cultivated from a skin biopsy either to carry out necessary enzyme analyses or 
for future diagnostic purposes. In our study group, we included patients in 
whom referring physician suspected a mitochondrial disease, but the exact 
etiology was not established. Four patients were excluded due to consent 
withdrawal, loss of clinical symptoms, no DNA or no contacts with the family. 
The WES analysis was not performed to any of these patients as it was not 
available in Estonia before 2013. The prospective study group (N= 11) was 
selected during January 2014 – March 2016. The main inclusion criteria were 
the childhood onset of the symptoms and a strong clinical suspicion of MD, 
which were made by consulting clinical geneticist or pediatrician working in the 
Department of Clinical Genetics, Tartu University Hospital. In total, we had 28 
patients in our study group.  
We re-examined all the medical history charts of each included patient to 
obtain their clinical signs and symptoms, results of metabolic and imaging 
studies and other medical investigations including a muscle biopsy. Those 
retrospective patients who were alive were invited for a follow-up genetic 
consultation. Afterwards, we scored each patient according to the mitochondrial 
disease criteria (MDC) developed by Wolf and Smeitink, 2002 [Wolf and 
Smeitink 2002] and Morava et al. 2006 [Morava et al. 2006a].  
 
 
4.2 Methods 
4.2.1 Method for expanded newborn screening for selected inborn 
errors of metabolism in Estonia (Paper I and VI) 
Amino acids and acylcarnitine analysis of dried blood spots were performed on 
a Xevo TQD Triple Quadrupole Mass Spectrometer (Waters, Milford, MA, 
USA) using MassChrom Kit (Chromsystems, Grafeling, Germany), which is a 
commercial in vitro semi-quantitative diagnostic kit. This method enables to 
determinate 13 amino acids, 30 acylcarnitines (including free carnitine). The kit 
consists of 27 stable isotope labelled internal standards for calibration and 
results are derivatized. Since tyrosine (tyr) alone is not sufficient to diagnose 
tyrosinemia type I (TYR I), we were convinced that our method choice should 
also allow the determination of succinylacetone (SucA). During the preparation 
and analysis of samples, the manufacturer’s protocol was followed; the exact 
parameters of the method and mass transfer are available on the manufacturer’s 
website: https://www.chromsystems.com/products/newborn-screening.html – 
11/12/2017.  
The disorders included in our NBS panel are: phenylketonuria (PKU), maple 
syrup urine disease (MSUD), tyrosinemia type I (TYR I), homocystinuria 
(HCY), argininemia (ARG), citrullinemia type I (CIT I), isovaleric aciduria 
(IVA), propionic aciduria (PPA), methylmalonic aciduria (MMA), glutaric 
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aciduria type I (GA I), congenital vitamin B12 deficiency, medium chain acyl-
CoA dehydrogenase deficiency (MCADD), long-chain 3-hydroxyacyl-CoA 
dehydrogenase deficiency (LCHADD), very long chain acyl-CoA dehydro-
genase deficiency (VLCADD), carnitine uptake deficiency (CUD), carnitine-
acylcarnitine translocase deficiency (CACT), carnitine palmitoyltransferase I 
deficiency (CPT I), carnitine palmitoyltransferase II deficiency (CPT II) and 
glutaric aciduria type II (GA II). 
All the cutoff values for amino acids and acylcarnitines (including C3) 
which we used in the first months, were originally taken from the literature 
[Lindner et al. 2011; Lund et al. 2012; McHugh et al. 2011; Vilarinho et al. 
2010]. After screening for the first thousand newborns, we calculated the first 
in-house cutoff values: 1st and 99th percentile. Mostly we use only upper cutoff 
values, except for arginine (Arg), citrulline (Cit), methionine (Met), free 
carnitine (C0), acetylcarnitine (C2), palmitoycarnitine (C16), oleylcarnitine 
(C18:1) and stearylcarnitine (C18), in which, for diagnostic purposes, we also 
needed a lower cutoff values. For data processing, we used two programs: Excel 
(Microsoft Corp., Redmond, Oregon, USA) and SAS 9.2. (SAS Institute Inc., 
North Carolina, USA).  
Above described calculation for cutoff values was performed repeatedly to 
improve the quality of newborn screening and last time it was done based on 
almost 30,000 newborn’s screening results, which are currently in use. 
In the second half of the pilot project, we joined with the worldwide 
collaboration project – Region 4Stork (R4S) [McHugh et al. 2011] and all 
flagged results were compared with this database and the likelihood of 
occurrence of the suspected disorder was calculated. All newborns, whose cal-
culation results indicated the possible presence of the disease, were called out. 
The ratios of some metabolites like C3/C2 and C3/C16 were still taken from 
the literature [Scolamiero et al. 2014]. Folate and vitamin B12 were measured 
on Cobas 601 Immunoassay Analyzer (Roche Diagnostics GmbH, Mannheim) 
and tHcy measurement was performed by enzymatic assay on Cobas Integra 
400 Plus Analyzer (Roche Diagnostics GmbH, Mannheim) and their age-
appropriate reference intervals were taken from the CALIPER database 
(http://www.sickkids.ca/caliperproject/index.html – 22/03/2017). 
 
 
4.2.2 DNA and mtDNA investigations performed to the patient  
with suspicion of mitochondrial disorders (Paper II–V) 
The DNA of all the patients was extracted from blood lymphocytes. The WES 
analysis was carried out using different methods due to availability and cost-
effectiveness at different time points. The WES enrichment kits were SureSelect 
XT Human All Exon v5 for patient with CACNA1A mutations – Paper III, v4 
for patient with SLC25A4 mutation – Paper IV (Agilent Technologies, Santa 
Clara, CA, USA) or Nextera Rapid Capture Exome 37 Mb kit (Illumina Inc., 
San Diego, CA, USA) for patient with the NDUFB11 mutation – Paper V.  
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All patients were sequenced as proband only, except the family with a 
patient having mutation in the NDUFB11, in whom offspring-parent trios were 
sequenced. After the sequencing, the reads were aligned to hg19 reference 
genome using Burrows-Wheeler Aligner (BWA) [Li and Durbin 2010]. Further 
data processing, variant calling, and annotation was performed following 
Genome Analysis Toolkit (GATK) best practice guidelines [Van der Auwera et 
al. 2013] using Picard, GATK [DePristo et al. 2011; McKenna et al. 2010], 
Annovar [Wang et al. 2010] and SnpSift [Cingolani et al. 2012]. All reported 
variants were confirmed, and familial segregation analysis was done by using 
Sanger sequencing. 
The mtDNA analysis was performed to all patients. Each patient’s reads 
generated during standard WES, but mapped to mtDNA, were specifically 
analyzed to detect mtDNA variants, and to assess the feasibility of investigating 
mtDNA from standard WES reads. In order to study mtDNA, SAMtools [Li et 
al. 2009] were used to extract reads mapped to chrM. These reads were aligned 
to the b37 reference genome (GRCh37 including rCRS mitochondrial sequence) 
using BWA MEM [Li and Durbin 2009], and subsequently sorted and marked 
for duplicates by Picard. The variants were called by combining SAMtools [Li 
et al. 2009] mpileup with VarScan [Koboldt et al. 2009], and then annotated 
using Annovar [Wang et al. 2010]. The analysis of guided variants along with 
haplogroup calling was guided by Mitomap and Mitomaster [Lott et al. 2013]. 
The mtDNA coverage was calculated using the GATK DepthOfCoverage tool. 
The only exception was made by a patient with SLC25A4 mutation, whose 
complete mtDNA was screened for mismatches and rearrangements using Long 
Template PCR and Affymetrix Human Mitochondrial Resequencing array 2.0 
(Santa Clara, CA, USA). 
Mitochondrial respiratory chain complex activities were measured spectro-
photometrically in cultured fibroblasts or muscle, using previously described 
methods [Rodenburg 2011]. 
 
 
4.3 Statistical analysis 
The statistical analysis for descriptive statistics (mean, median, and range etc.) 
and data processing were made with two programs: Excel (Microsoft Corp., 
Redmond, Oregon, USA) and SAS 9.2. (SAS Institute Inc., North Carolina, 
USA).  
The annual live-birth data was obtained from the database of Statistics 
Estonia, which is a government agency in the area of administration of the 
Ministry of Finance in Estonia (https://www.stat.ee – 01/03/2018) to calculate 
the incidence of screened disorders.  
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4.4 Ethics 
At the beginning of 2014, the newborns screening in Estonia was firstly 
introduced as a pilot project (Papers I and VI), which was approved by the 
Research Ethics Committee of the University of Tartu (approval date 
18/11/2013 and number 231/T-5) in agreement with the Declaration of Helsinki. 
Testing of healthy newborns involves many risks, but few doubt the necessity 
and usefulness of newborn screening programs. However, this field is becoming 
slightly more complicated as the range of disorders being tested increases, and 
new technologies becoming available. Therefore, many bioethics have 
increasingly highlighted three principles that are still important to follow when 
adding new diseases to the screening list or changing the approach. Firstly, the 
natural history of the condition, including development from latent to declared 
disease should be adequately understood. Secondary, there should be a suitable 
test or examination for diagnosing the disorder and an agreed policy concerning 
whom to treat as patients. Thirdly, there should be an accepted and available 
treatment for patients with recognized disease [Dhondt 2010; Johnston et al. 
2018]. Therefore, adding any new disease or technology to the newborn 
screening program requires careful consideration. All disorders that were added 
to the newborn screening panel in Estonia meet the criteria described above. 
The study of diagnostic approach to mitochondrial disorders (Papers II–V) 
was approved by the Research Ethics Committee of the University of Tartu 
[approval date 17/11/2014 and number 242/M-10; renewal date 20/11/2017 
number 242/M-11(2)] in agreement with the Declaration of Helsinki. An 
informed consent was obtained from all the patients, their parents and/or legal 
guardian (including three cases, which were characterized in detail), except 
from those who had deceased. Participants in this study group already had 
symptoms, so the implementation of the new diagnostic method was 
indispensable, since previous studies had not identified a molecularly confirmed 
diagnosis. Still, it is important to point out that while reporting the results, the 
recommendations of the American College of Medical Genetics and Genomics 
were followed [Green et al. 2013].  
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5. RESULTS AND DISCUSSION  
5.1 Newborn screening for inborn errors of metabolism  
by tandem MS in Estonia (Paper VI) 
During four years, we screened 54,899 newborns and confirmed the diagnosis 
of 29 children, therefore the overall prevalence of a metabolic disorders 
(including congenital acquired vitamin B12 deficiency) identified on newborn 
screening in Estonia is 1:1,893 newborns.  
In the first year (pilot project), the diagnosis was confirmed in eight children 
(Table 3) and surprisingly, the congenital acquired vitamin B12 deficiency was 
identified in seven children. This diagnosis continues to be most common in 
tested disorders and this topic will be discussed more widely in the next chapter.  
In the four-year summary, the second most commonly diagnosed condition 
was hyperphenylalaninemia (HPA) (including classical phenylketonuria, tetra-
hydrobiopterin-deficient HPA and benign HPA). This result was expected 
because it was previously known that the incidence of this condition in Estonia 
is relatively common – 1:6,700 newborns [Lillevali et al. 2017]. In the course of 
four years, we also diagnosed glutaric aciduria in one case. 
 
Table 3. Disorders diagnosed on NBS during the four-year screening period. 
 2014 2015 2016 2017 Total 
No. of tested newborns 13,643 13,915 13,881 13,460 54,899 
Disorder      
Congenital acquired vitamin B12 
deficiency 7 3 4 7 21 
HPA 1 0 4 2 7 
Classical PKU 0 0 3 2 5 
Tetrahydrobiopterin-deficient 
HPA     1 0 0 0 1 
Benign HPA 0 0 1 0 1 
Glutaric aciduria type I 0 1 0 0 1 
 
None of the diagnosed child had any symptoms at the first appointment, and all 
diagnosed patients remained symptomatic free for 48 observed months. The 
amount of incidence is slightly higher compared to other regions like in 
Germany, where it is 1:2,712 screened newborns [Harms and Olgemoller 2011] 
[Schulze et al. 2003]; in Portugal it is 1:2,396 [Vilarinho et al. 2010], and in 
Austria it is 1:2,855 [Kasper et al. 2010]. However, at the moment there are still 
too few children screened to draw a long-term conclusion about the incidence of 
screened disorders in Estonia.  
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As expected, the incidence of HPA in Estonia is relatively high. Over the four 
years, we have diagnosed seven cases, including one patient with tetrahydro-
biopterin-deficient form [c.1222C>T (p.R408W)/ c.782G>A (p.Arg261Gln)], 
and one with benign HPA [c.1222C>T (p.R408W)/ c.1208C>T (p.Ala403Val)]. 
Four of five patients with PKU (severe form of HPA) were homozygotes for the 
p.R408W mutation in the PAH gene and one child were compound 
heterozygous for c.143T>C (p.L48S)/ c.838G>A (p.E280K) mutations in the 
PAH gene. Our results overlap with the study of retrospective overview of 
Estonian PKU patients which revealed that our region has exceptionally high 
genetic homogeneity, as 80% of all PKU alleles carry the p.R408W mutation 
which is typical of Eastern Europe [Lillevali et al. 2017].  
In one case, the phenylalanine remained altered at first post-NBS evaluation, 
but later became spontaneously normal and were considered as transitory HPA. 
Her PAH gene was sequenced and she was carrier of the p.R408W mutation. 
The multiplex ligation-dependent probe amplification (MLPA) analysis was 
also performed and no duplication or deletion was found in the PAH gene. She 
will stay under our observation until the end of her third year. At the last 
evaluation, when she was two years old (without any treatment), her develop-
ment was age appropriate and biochemical markers (including amino acids in 
the serum) were without aberrances. 
In the NBS, we also detected a child with glutaric aciduria type I and she was 
compound heterozygous for c.1204C>T (p.Arg402Trp)/ c.1262C>T (p.Ala421Val) 
mutations in the GCDH gene. The older child in this family, who was born before 
the initiation of the expanded NBS, received an etiologic diagnosis after 
confirmation of a younger child’s diagnosis. At that point, she was at the age of 
six and it was thought that her moderate physical disability was caused by an 
intrauterine infection. Her motor function improved noticeably after the onset of a 
reduced lysine-containing diet and administration of L-carnitine. 
Based on four-year screening, we can affirm that the incidence of MCADD in 
Estonia remains rare as it was described before by Lillevali et al. [Lillevali 2000]. 
During that period, we did not diagnose any newborn with this diagnosis, which 
distinguish us from the rest of Europe where the MCADD seems to have quite 
high incidence. For example, in Portugal the incidence is 1:9,036 [Vilarinho et al. 
2010], in Denmark and Faroe Islands it is 1:9,164 [Lund et al. 2012], in Germany 
it is 1:10,610 [Harms and Olgemoller 2011] and in Austria it is 1:24,900 [Kasper 
et al. 2010]. Unfortunately, we do not have any relevant data about this disorder 
in neighboring countries, because there is no nation-wide expanded newborn 
screening or it was initiated in 2015 and the data has not been published yet. 
Regrettably, we have to report that in one case LCHADD was not diagnosed 
with NBS, because the child died prior to collection of DBS (before the age of 
72 hours). This information came to us because the parents of the deceased 
child turned to the Department of Clinical Genetics, Tartu University Hospital 
for obtaining recurrence risk. Based on anamnesis, the consulting geneticist had 
a suspicion of LCHADD, therefore, the parents were examined for the presence 
of the common c.1528G>C mutation in the HADHA gene, and both were 
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carriers. Thereafter, their child’s autopsy material was further investigated and it 
revealed the homozygosity for the c.1528G>C mutation in the HADHA gene, 
which confirmed the persistence of LCHADD of deceased child. 
In the first year, due to the abnormalities, found in the primary results of the 
newborn screening test, 33 newborns with their guardian were called out to 
additional analyses. During the first 6 months of the pilot project, the number of 
these patients was 22, while the sum of screened children was 6344. The cases, 
in which biochemical markers were abnormal at NBS but normal upon diag-
nostic testing, were considered as false positives. The false positive rate (FPR), 
during that period, was 0.28% and the positive predictive value (PPV) was 18%. 
Within the next 6 months, the number of children called out was 11 and total of 
screened children during that period were 7299. The FPR decreased to 0.09% 
and the PPV increased up to 36%. Summarizing the results of both half-year the 
total of false positive results were 25 and the FPR were 0.18%, while the PPV 
were 24%. In four years’ time, the FPR has remained to 0.1% and the PPV has 
risen to 36.7%. In the last (fourth) year, the FPR was 0.07% and the PPV 
52.6%. An overall specificity is 99.9% and since we still have not diagnosed 
any false negative case, then the overall sensitivity of tandem MS screening 
remains 100%. At the same time, we will continue our annual analysis of data 
and make conclusions to introduce improvements in our program. 
When comparing our results with other NBS programs, we can find 
similarities. The FPR in Germany over a 42-month period was 0.33% therefore 
the specificity was 99.67% and the PPV was found to be 11.31% [Schulze et al. 
2003]. In Austria, during the first 93 months, the overall PPV was 12.62% and 
specificity was 99.76% [Kasper et al. 2010]. Significantly higher PPV were 
calculated in Galicia in Spain, where the summary of 10-year data showed that 
the PPV was 76.11%, sensitivity was 97.16% and the specificity was 99.98%, 
[Couce et al. 2011]. These results also indicate that the longer the screening is 
ongoing, the more experience will be added, and therefore the PPV will 
increase and the FPR will decrease. 
Before the nation-wide expanded newborn screening could be started in 
Estonia, a thorough preliminary work was needed. In Estonia, we did not have 
any overview of most of the diseases, which are being screened in the USA and 
European countries, due to the small population size – 1.3 million inhabitants 
(https://www.stat.ee – 01/06/2018) and recent availability of accurate diagnostic 
methods. Therefore, the panel of the tested disorders in Estonia was put together 
according to the literature and experience of the closest countries, where 
extensive screening has been ongoing and detailed articles have been published, 
such as Denmark [Lund et al. 2012] and Germany [Lindner et al. 2011; Schulze 
et al. 2003]. Both regions started the NBS with a wide range of diseases to be 
test, and this approach is compatible with our team’s perspective as well. It was 
important for us to learn from the experiences of others to avoid screening such 
disorders, which seemed to involve little or no benefit; at the same time, the list 
should cover most of the disorders, which can be screened by tandem MS 
method. The expected incidence of diseases were taken from literature [Garg 
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and Dasouki 2006] and it had a modest impact on our decision, since adding 
one disease to the list does not increase the total cost of the test. 
Therefore, in addition to PKU, 18 new congenital metabolic disorders 
(Table 4) were added to the list of the diseases to be screened in Estonia. It was 
a consensus decision among most of the specialists working in the field of IEM 
in Estonia. 
Taking into account the relatively low birth rate in Estonia – the decision 
was to use a commercial kit to determinate 13 amino acids, 30 acylcarnitines 
and SucA. The NBS strategy was right from the beginning to apply a full-
profile approach, which means that we gathered maximum information form 
one sample in one run, without regard to the distinction between appropriate 
and inappropriate target conditions. This decision was thoroughly discussed and 
the decisive factor was the fact that in Estonia, there is only one laboratory that 
is responsible for NBS and it is part of the Department of Clinical Genetics, 
Tartu University Hospital, therefore, the trained specialists, including 
pediatricians specialized in congenital metabolic disorders, work in the same 
center. In Estonia, all children’s genetic counseling, including those which 
involve IEM and the follow-up of those disorders, were made by same center, 
therefore we believe that wide profile of metabolites are rather an advantage 
that enables faster and more accurate information exchange. This does not mean 
that we do not follow strictly the rule to inform newborns’ families only for 
disorders that we screen, while in an emergency situation the consulting 
specialist can have full-profile immediately. Another positive aspect for storage 
of full-profile of metabolites is the availability for retrospective investigation, 
because most of the metabolites are degraded in months [Adam et al. 2011], and 
after that, the DBS can only be used for DNA extraction. According to this, we 
have stated that we will keep the DBS for at least 25 years; therefore, we have 
stored all of them.  
It was important to compose an optimal list of the analyses which should be 
performed at the first appointment after being called out (Table 5), to prevent 
excessive work and cost for the medical team; and take into account the socio-
economic capacity of the families. Therefore, one of the principal decisions was 
to take the sample for DNA extraction already in the first appointment to carry 
out molecular-genetic analyses when necessary, since we do not have the 
opportunity to perform enzyme analyses in our own laboratory.  
We are aware that the correct interpretation of metabolic profiles calls for 
well-balanced cutoffs and it is often necessary to accept a certain number of 
false positives in order to ensure sufficient sensitivity. Therefore, the next step 
was technical interpretation. A decision limit (cutoff value) for each metabolite 
was initially set according to the literature [Lindner et al. 2011; Lund et al. 2012; 
McHugh et al. 2011]. Each metabolite crossing the cutoff value was flagged 
automatically. These values could not be used for long period, because the popu-
lation-based differences and differences in laboratory methods could be observed. 
We therefore used a multistep process to establish in-house cutoff values.  
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Table 4. Disorders screened in Estonia since 2014.  
Arg – arginine, C0 – free carnitine, C2 – acetylcarnitine, C3 – propionylcarnitine, C4 – 
butyrylcarnitine, C5 – isovalerylcarnitine, C5DC – glutarylcarnitine, C5OH – 3-OH-
isovalerylcarnitine, C6 – hexanoylcarnitine, C8 – octanoylcarnitine, C10 – decanoylcarnitine, 
C14 – myritoylcarnitine, C14:1 – tetradecenoylcarnitine, C14:2 – tetradecadienoylcarnitine, 
C16 – palmitoycarnitine, C16OH – 3-OH-plamitoylcarnitine, C18 – stearylcarnitine, C18:1 – 
oleylcarnitine, C18:1OH – 3-OH-oleylcarnitine, C18:2 – linoleylcarnitine, C18OH – 3-OH-
stearoylcarnitine, Cit – citrulline, Leu – leucine, Met – methionine, Phe – phenylalanine, 
SucA – succinylacetone, Tyr – tyrosine, Val – valine, & – [Garg and Dasouki 2006] ; * – 
[Ounap et al. 1998]; ** – [Joost et al. 2012a]. 
Metabolic disorder 
Abbre-
viation OMIM 
Expected 
incidence& Key metabolites 
Aminoacidurias 
Phenylketonuria PKU 261600 
1:10,000 
1:6,010* ↑ Phe 
Maple syrup urine disease MSUD 248600 1:200,000 ↑ Val; ↑Leu 
Tyrosinemia type I TYR I 276700 1:100,000 ↑ SucA (↑ Tyr) 
Homocystinuria HCY 236200 1:150,000 ↑ Met 
Argininemia ARG 207800 1:350,000 ↑ Arg 
Citrullinemia type I CIT I 215700 1:60,000 ↑ Cit; ↓ Arg 
Organic acidurias 
Isovaleric aciduria IVA 243500 1:100,000 ↑ C5 
Methylmalonic aciduria MMA 1:75,000 ↑ C3 
Propionic aciduria PPA 606054 1:75,000 ↑ C3 
Glutaric aciduria type I GA I 231670 1:50,000 ↑ C5DC 
Congenital vitamin B12 
deficiency ↑ C3 
Beta oxidation defects 
Medium chain acyl-CoA 
dehydrogenase deficiency MCADD 201450 1:15,000 ↑ C6; ↑ C8; ↑ C10 
Long-chain 3-hydroxyacyl-
CoA dehydrogenase 
deficiency LCHADD 609016 
1:75,000 
1:94,864** 
↑ C16OH; ↑ C18OH; ↑ 
C18:1OH 
Very long chain acyl-CoA 
dehydrogenase deficiency VLCADD 201475 1:75,000 ↑ C14:1; ↑ C14; ↑ C14:2 
Carnitine uptake deficiency CUD 212140 1:75,000 ↓ C0; ↓ C16; ↓C18 
Carnitine-acylcarnitine 
translocase deficiency CACT 212138 1:1,000,000 
↑ C16; ↑ C18:1 ↑ C18; ↑ 
C18:2 
Carnitine palmitoyl-
transferase I deficiency CPT I 255120 1:1,000,000 ↑ C0; ↓ C16; ↓ C18 
Carnitine palmitoyl-
transferase II deficiency CPT II 255110 1:1,000,000 ↑ 16; ↑ C18; ↑ C18:1; ↑ C18:2
Glutaric aciduria type II GA II 231680 ↑ C5DC; ↑C4; ↑C5; ↑ C5OH 
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The initial cutoff values were set on the 1st and 99th percentile based on data 
collected and analyzed from 1,000 sequential and healthy newborn samples. 
These cutoffs were firstly modified after six months of screening; next were 
after 12 months, then after 15 months, as more clinical data became available. 
Currently, we are using the calculation, which is based on almost 30 000 
newborn’s screening results. 
 
Table 5. An optimal list of confirmatory analyses for each suspected disorder. 
DNAs – DNA for storage; mSAC – serum acylcarnitines from mother; SAA – serum 
amino acids; SAC – serum acylcarnitines; SOA – serum organic acids; UAA – urine 
amino acids UOA – urine organic acids; * added in 2018 
Metabolic disorder An optimal list of confirmatory analyses 
Aminoacidurias 
PKU SAA, DNAs, urine sample for storage 
MSUD SAA, UAA, UOA, DNAs 
TYR I SAA, UOA, DNAs 
HCY SAA, UAA, UOA, DNAs, vitamin B12, homocysteine 
ARG SAA, UAA, UOA, DNAs 
CIT I SAA, UAA, UOA, DNAs 
  
Organic acidurias  
IVA UOA, SAC, DNAs 
GA I SAA, SAC, UOA, DNAs 
MMA SOA*, SAC, UOA, DNAs, vitamin B12, folic acid, 
homocystein, holotranscobalamin*; vitamin B12, folic acid, 
homocystein from mother 
PPA SOA*, SAC, UOA, DNAs, vitamin B12, folic acid, 
homocystein, holotranscobalamin*; vitamin B12, folic acid, 
homocystein from mother 
Congenital Vitamin 
B12 deficiency 
SOA*, UOA, DNAs, vitamin B12, folic acid, homocystein, 
holotranscobalamin*; vitamin B12, folic acid, homocystein 
from mother 
Beta oxidation defects 
MCADD SAC, UOA, DNAs 
LCHADD SAC, UOA, DNAs 
VLCADD SAC, UOA, DNAs 
CUD SAC, UOA, DNAs, mSAC 
CACT SAC, UOA, DNAs 
CPT I SAC, UOA, DNAs 
CPT II SAC, UOA, DNAs 
GA II SAC, UOA, DNAs 
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In the first 6 months when the results of the primary analyses were clearly 
aberrant and suggestive of a severe disorder, the patient was immediately 
referred to our clinical unit. If the results lay outside the cutoff range but were 
not as aberrant as to constitute clear proof of a severe disease, a second sample 
was requested form the same test card but from another blood spot. If the 
second sample also tested positive, the patient was called out. Such tactics was 
necessary in order to gain experience and make sure the result was correct, 
although it was not the best solution, since the number of false positives remained 
high. Therefore, the first year passed mainly by collecting experiences, which is 
also reflected in the percentages of FPR and PPV. 
The whole world is moving in the direction of cooperation, since the 
occurrence of diseases is relatively rare, and experience is therefore worth 
sharing. Our improvement of the recall rate and the FPR of the second half of 
the pilot project year was strongly influenced by the introduction of worldwide 
collaboration project R4S, which was launched in 2005 [McHugh et al. 2011]. 
The R4S project was initiated as a large collection of information to generate 
data for NBS programs to improve tandem MS screening by achieving uni-
formity of tandem MS testing panels, improving analytical performance, and 
reducing false-positive and false-negative screening results. This is a custom-
designed and -coded application for the collection and reporting of possibly any 
type of newborn screening data based on numerical results. The system is a 
web-based application and tools are generating a score reflecting the likelihood 
of a diagnosis based on condition-specific disease ranges of all informative 
analytes. Site-specific customization of these tools is available to correct for 
differences in analyte panels and sample preparation (derivatized versus 
underivatized method). [McHugh et al. 2011]. The international participation in 
the R4S project includes 1,050 NBS programs from 64 countries, and the true-
positive database has exceeded up to 17,000 cases, with more than 1.2 million 
NBS results. The results of Estonian newborns are also included in the database. 
All newborn screening laboratories are strongly recommended to participate 
in quality control networks, because most programs actually never encounter 
30–80% of the conditions that they are testing for [McHugh et al. 2011]. 
Therefore, since 2014, we have also participated annually in external quality 
control specimens for acylcarnitines and amino acids. The testing panels were 
received from the Newborn Screening Quality Assurance Program organized by 
the US Centers for Disease Control and Prevention (CDC), our laboratory 
number is 0606, and the European Research Network for evaluation and 
improvement of screening, Diagnosis and treatment of Inherited Disorders of 
Metabolism (ERNDIM), our laboratory number is 0322. Every year, we have 
passed the Newborn Screening Quality Assurance Program organized by CDC; 
and in most ERNDIM quality control schemes, we have achieved the maximum 
score or lost only one point.  
Since the 2015, our laboratory is also internationally accredited to perform 
NBS and our screening program results meet the criteria of adequate analytical 
and postanalytical performance, which were developed by Rinaldo et al. This 
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includes detection rate at least 1:3,000 or higher, PPV >20%, and FPR <0.3% 
[Rinaldo et al. 2006]. 
Many NBS laboratories carry out fundamental changes after a certain 
amount of data has been analyzed. For example, in Denmark, after seven years 
of NBS, the time interval for obtaining samples was changed from 4 to 9 days 
to 2 to 3 days postpartum and biotinidase deficiency with TYR I were added to 
the screening panel. In addition, because of the high FPR and late screening 
results compared with the rapid progression of the disease, screening for CIT I 
was stopped at that point [Lund et al. 2012]. Since 2018, we have also added 
some extra analyses for newborns, who were called out because of increased C3 
and according to the new protocol, a serum holotranscobalamine and organic 
acids should be measured (Table 5). Nevertheless, in the long run, the changes 
in our screening panel will definitely not be limited.  
For a better understanding of the advantages and effectiveness of NBS for 
certain entities, there should be longer-term studies of disorders screened and 
cases diagnosed in our population, however the first four years of expanded 
NBS has given very important knowledge of the incidence of some diseases in 
our region and expanded the phenotype of these disorders. Therefore, the 
continuation of the developed scale of screening seems to be beneficial and in 
the future, it is worth looking at ways to expand the range of screened diseases.  
 
 
5.2 Congenital acquired vitamin B12 deficiency among 
Estonian newborns (Paper I) 
The first thorough analysis about the congenital acquired vitamin B12 defi-
ciency was conducted after three years of screening in Estonia and the result 
was unexpected – the incidence of this condition is 33.8/100,000 (1:2959) 
newborns.  
We identified all newborns with a C3 value higher than 4.31 μmol/L (up to a 
year and a half the cutoff value of C3 was 4.6 μmol/L) on DBS analysis, with or 
without altered C3/C2 (abnormal value > 0.18) and/or C3/C16 (abnormal value 
> 1.80) ratios. They underwent pediatric evaluation and further laboratory 
testing, including the measurement of vitamin B12, folate and tHcy in serum, 
and the MMA content in urine. At that period, we could not implement the 
MMA measurement as a second-tier test from the same DBS. Instead, this was 
done from fresh urine samples collected during the first pediatric consultation. 
MMA from serum was measured posteriorly in eight of them, in the rest, there 
was not enough serum left. In these eight newborn’s serums contained elevated 
amount of methylmalonic acid: 2.41 – 17.02 μmol/L (abnormal value >0.3) and 
these results are reported in Table 6.  
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None of the newborns had any clinical symptoms associated with vitamin B12 
deficiency before the treatment. All biochemical markers normalized after 
treatment, which strongly suggests the presence of impaired vitamin B12 status. 
After a thorough prospective clinical follow-up and laboratory testing, we can 
confirm that all well-known genetic disorders that could cause neonatal onset of 
elevated MMA were also excluded in all of the treated children.  
As the most common cause for vitamin B12 deficiency among newborns is 
maternal vitamin B12 deficiency, the blood tests for mothers were also per-
formed. Most of the mothers showed values of vitamin B12 within the reference 
interval (141–489 pmol/L) with tendency towards lower normal limit and they 
described themselves as healthy and nourished, without serious chronic medical 
conditions, except for one mother who had been diagnosed with systemic lupus 
erythematosus. Her autoimmune disease was well-controlled during the 
pregnancy. In our study, only one mother had low vitamin B12 level without 
any clinical complaints and she was mainly vegetarian for religious reasons. All 
mothers, except one, used prenatal folic acid supplements, mostly 400 micro-
grams per day (Table 6), which is quite widespread practice in Estonia.  
Although the study period was quite short, we believe that the three-year 
experience is long enough to reflect the current situation of this condition in 
Estonia since Italy’s newborn screening program showed that the incidence of 
congenital acquired vitamin B12 deficiency remained similar over the years 
[Italian Society for the Study of Inborn Metabolic Diseases and Newborn 
Screening 2015]. 
Our incidence of congenital acquired vitamin B12 deficiency is 33.8/100,000 
(1:2959), which is higher than reported in most of the literature [Hinton et al. 
2010; Italian Society for the Study of Inborn Metabolic Diseases and Newborn 
Screening 2015; Sarafoglou et al. 2011; Scolamiero et al. 2014]. Sarafoglou et 
al. described a population-based study of 363,649 infants born in Minnesota. 
During the six-year study period, 11 newborns with vitamin B12 deficiency 
were identified, thus the incidence was 3.02/100,000 live births (1:33,113). All 
of them had secondary changes due to maternal vitamin B12 deficiency 
[Sarafoglou et al. 2011]. Higher incidence was detected in the Italian popu-
lation, where a six-year expanded metabolic newborn screening pilot project 
showed an incidence of congenital acquired vitamin B12 deficiency of 
20/100,000 (1:5,000) and evidenced that this condition is also mainly a 
consequence of maternal vitamin B12 deficiency [Scolamiero et al. 2014]. 
Unfortunately, we did not measure any other biochemical parameters for most 
of the mothers in our study group. Therefore, we could miss the borderline 
vitamin B12 deficient mothers. 
The most exceptional hypothesis was proposed by Refsum et al., who 
concluded that 10% of screened newborns had vitamin B12 levels below 
150 pmol/L, which is the lower reference limit for adults [Refsum et al. 2004]. 
Therefore, it would be beneficial to detect most of those children in the 
symptom-free phase. For this purpose, some newborn screening programs have 
lowered their cutoff level of C3 and started to use more actively the ratios of 
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some metabolites. For example, Minnesota Department of Health, Mayo Clinic, 
and University of Minnesota markedly lowered the cutoff level of C3 from 9.2 
μmol/L to 5.25 μmol/L and the vitamin B12 detection rate increased more than 
three times [Sarafoglou et al. 2011]. A similar decision was also made by 
Scolamiero et al. [Scolamiero et al. 2014]. Although, Campbell et al. pointed 
out that the C3 is a maker used to detect only organic acidurias and 
remethylation defects and its level alone is not sensitive or specific enough to 
detect all newborns with congenital acquired B12 deficiency, moreover C3 
levels may not be sufficiently high during the first few days of life when the 
DBS is collected [Campbell et al. 2005]. Therefore, there is evidence that the 
C3 to C2 ratio and/or C3 to C16 ratio together with C3 are better than C3 level 
alone for detecting or identifying the babies with nutritional B12 deficiency 
[Armour et al. 2013; Sarafoglou et al. 2011; Scolamiero et al. 2014]. Some 
authors have also suggested measuring tHcy from the first DBS and if it is 
elevated, then evaluate the second-tier markers like Met, Met/Phe, C3 and 
C3/C2, which is considered to be valuable method to detect remethylation 
disorders and vitamin B12 deficiency [Gramer et al. 2017]. The MMA, 
measured from DBS as a secondary test, might also add value to increase 
sensitivity and specificity in detection of congenital acquired vitamin B12 
deficiency [Sarafoglou et al. 2011].  
During the study period in Estonia, we could not implement the second-tier 
testing of MMA from DBS; however it will be introduced in our laboratory in 
the near future. We measured the MMA level in freshly collected urine (most of 
the urine samples were collected at least a week after the first DBS) and only 
three of the fourteen children with congenital acquired vitamin B12 deficiency 
had elevated MMA in urine. The MMA concentration in serum were measured 
posteriorly, therefore, there were not enough serum left from all newborns who 
underwent the first pediatric evaluation but still it is notable that all eight 
newborns, with whom we could measure serum MMA, had it elevated. (Table 6). 
For a long time, the causes of maternal B12 deficiency were considered to be 
associated with a strict vegan diet, poverty and malnutrition, occult pernicious 
anemia, previous gastric bypass surgery, and short gut syndrome [Kuhne et al. 
1991]. Nowadays, the maternal B12 deficiency can be subclinical, mothers may 
not be anemic and their vitamin B12 levels are normal or low-normal. Maternal 
vitamin B12 concentrations during pregnancy are thought to be closely 
associated with fetal [Muthayya et al. 2006; Obeid et al. 2006] and early infant 
[Deegan et al. 2012; Finkelstein et al. 2014] vitamin B12 status. Some authors 
even suggest that maternal dietary intake during pregnancy is a stronger 
determinant of infant vitamin B12 status than are maternal vitamin B12 stores 
[Duggan et al. 2014].  
Interestingly, most of mothers included in our study group had normal or 
low-normal levels of serum vitamin B12, which is similar to reports providing 
evidence of subclinical vitamin B12 deficiency in presence of normal serum 
B12 levels [Klee 2000]. This phenomenon is explained by the fact that tissue 
levels become depleted before serum levels. Some people with borderline or 
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low-normal serum vitamin B12 levels may have symptoms that resolve with 
B12 treatment, suggesting that levels previously considered borderline or 
normal may represent deficiency in some patients [Lindenbaum et al. 1988]. 
Therefore, it is important to highlight that all 14 children were exclusively 
breast-fed. 
In Estonia, a majority of women uses folic acid supplementation during 
pregnancy, as recommended by clinicians. The standard dose is 400 micro-
grams of folic acid per day and most of them are taking their supplements 
conscientiously. That is reflected in our study group as well – most of the 
mothers had taken pure folic acid during their pregnancy. Only in one case, we 
could not verify mother’s supplementation status (Table 6, Pt. No 7). Selhub et 
al. suggested that both pathways of vitamin B12 metabolism are adversely 
affected by high serum folate, despite the fact that folate is directly involved 
only in methionine synthase activity [Selhub et al. 2007]. A similar finding was 
described by Monsen et al., concluding that high serum folate during infancy is 
attributable to low B12 status and resulting the methyl folate trap phenomenon 
[Monsen et al. 2003]. More extensive studies are needed for specifying the 
precise connection between folic acid supplementation during pregnancy and 
newborns’ low vitamin B12 level to make any fundamental conclusions. 
In addition, we should not forget that vitamin B12, folate, tHcy and MMA 
undergo marked changes during childhood. In the first weeks of life, there is a 
considerable decrease in serum vitamin B12 level, accompanied by a marked 
increase in plasma tHcy and MMA [Minet et al. 2000; Monsen et al. 2001]. The 
lowest vitamin B12 levels and the highest tHcy and MMA levels in childhood 
are seen in infants 6 weeks to 6 months of age [Monsen et al. 2003]. Therefore, 
the use of correct age-appropriate reference values is indispensable to prevent 
hyper-diagnostics. Although, we believe that significantly more harm can be 
done by diagnostic delay, since vitamin B12 deficiency is associated with 
biomarkers of genomic instability. Global DNA hypomethylation and decreased 
purine and pyrimidine synthesis impair genomic stability, causing chromosomal 
breaks and aberrations [Fenech 2012]. A study in Turkey noted that DNA 
damage was increased in vitamin B12 deficient children and their mothers 
[Minnet et al. 2011]. Equally important is the fact that vitamin B12 deficiency is 
associated with retardation of neural myelination in some studies [Black 2008; 
Lovblad et al. 1997; McCaddon 2013], and long-term consequences of 
neurological deterioration may persist even after vitamin B12 deficiency has 
been treated [Celiker and Chawla 2009; Graham et al. 1992; von Schenck et al. 
1997]. In addition, it is difficult to make the diagnosis on the clinical ground 
and there tends to be substantial diagnostic delay [Graham et al. 1992] . 
In the light of the results obtained, we will continue to screen the congenital 
acquired vitamin B12 deficiency among our NBS program. Therefore, each 
child with aberrant C3 and C3/C2 or C3/C16 will be thoroughly examined to 
exclude congenital acquired vitamin B12 deficiency, which can easily be 
corrected in most cases. 
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5.3 Effectiveness of WES as a diagnostic method  
in clinical practice for patients with suspicion  
of mitochondrial diseases (Paper II) 
To evaluate the effectiveness of WES in Estonia, we analyzed 28 patients with a 
suspected MD who had been referred to a clinical geneticist in the Department 
of Clinical Genetics, Tartu University Hospital during the years 2003–2016. A 
disease-causing variant was found in 16 patients (57%) by WES in nuclear 
DNA. A mitochondrial disorder was detected in four patients (14%) with 
variants in SLC25A4, POLG, SPATA5 and NDUFB11 genes. Other variants 
found were associated with a neuromuscular disease (SMN1, MYH2 and LMNA 
genes), a neurodegenerative disorder (TSPOAP1, CACNA1A and ALS2 and 
SCN2A genes), a multisystemic disease (EPG5, NKX1-2, ATRX and ABCC6 
genes), and one in an isolated cardiomyopathy causing gene (MYBPC3). An 
mtDNA point mutation was found in one patient in the MT-ATP6 gene in the 
mtDNA analysis. Therefore, the overall efficiency of WES was 61% (Table 7). 
In addition, we analyzed the mtDNA of 27 patients using exome sequencing 
data. The coverage of mtDNA was highly dependent on the enrichment kit 
used, thus all samples analyzed using the SureSelect enrichment kits had 
markedly lower coverage. For the samples sequenced with the SureSelect kits, 
the 1x coverage ranged from 96.5% to 99.9% of the mtDNA nucleotides, with 
one outlier of 38.3%, but the 20x coverage ranged only from 0–9%. Regarding 
the Nextera kits, the sequence depth of 1x was achieved in 100% of the mtDNA 
positions, and the 20x coverage ranged from 63% to 100%, with 12/15 samples 
achieving the 20x coverage of > 95%. In two sibs sequenced using the TruSeq 
kits, the 1x coverage was 100%, and the 20x coverage was 51% and 76%. We 
detected one disease-causing variant in the MT-ATP6 gene (Table 7, Pt No 3), 
although the sample was sequenced after SureSelect enrichment, so the 
coverage was lower (10 reads out of 12 supported the variant).  
The patient selection bias in our study group is quite low since the 
Department of Clinical Genetics, Tartu University Hospital is the only 
department in Estonia, offering the counseling of clinical genetics, and our 
routine approach to patients with an unsolved suspected MD is to take a skin 
biopsy for further studies. Although, we have to admit that our cohort is rather 
small and in the retrospective study group, we preliminary excluded patients 
who have an MD formerly been confirmed by molecular genetic studies. 
Therefore, this could influence the final results.  
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Table 7. The list of the patients investigated in our study with detailed description of the phenotype-related 
gene and protein function (BOLD font marks the mitochondrial disorder).  
Pt 
no Sex 
Current 
age Onset MDC Gene Function of the gene and protein, disease causality 
1 F 6y At birth 11 SLC25A4 
(NM_001151.3)
Encodes the ADP/ATP translocase 1 protein, which 
imports ADP into the mitochondrion and exports ATP 
into the intermembrane space. Its dysfunction causes 
insufficient adenine nucleotide availability for 
deoxyadenosine triphosphate (dATP) synthesis and 
imbalanced deoxynucleotide triphosphate (dNTP) pools, 
leading to mtDNA depletion. Its defects are associated 
with mitochondrial DNA depletion syndrome type 12 
(OMIM 615418), adPEO (OMIM 609283) and a third 
distinct phenotypic group described by us [Thompson et 
al. 2016].  
2 M 25y 6y 10 POLG 
(NM_002693.2)
Encodes the DNA polymerase subunit gamma-1 protein, 
which is essential for mtDNA replication and repair. Its 
deficiency can cause mtDNA depletion and/or multiple 
deletions and is associated with Alpers syndrome 
(OMIM 203700), Mitochondrial neurogastrointestinal 
encephalopathy syndrome (OMIM 613662), 
mitochondrial recessive ataxia syndrome (OMIM 
607459), adPEO (OMIM 157640) and autosomal 
recessive PEO (OMIM 258450) [Hikmat et al. 2017]. 
3 F 24y 2y 8 MT-ATP6 
(NC_012920.1) 
Encodes subunit alpha of the ATP synthase or complex 
V which produces most of the ATP in human cells. Its 
defects are associated with neuropathy, ataxia, retinitis 
pigmentosa (OMIM 551500), Leigh syndrome (OMIM 
256000) and mitochondrial infantile bilateral striatal 
necrosis (OMIM 500003) [Kucharczyk et al. 2010]. 
4 F Died at 
3m 
Pre-
natal 
8 SMN1 
(NM_000344.3)
Encodes the survival motor neuron protein which directly 
and indirectly via spliceosomal snRNP biogenesis (is 
critical for snRNP assembly) is involved in general cellular 
RNA processing [Lorson and Androphy 1998]. Its 
deficiency is associated with spinal muscular atrophy 
(OMIM 253300). 
5 F Died at 
4y11m 
Early 
infancy 
7 SPATA5 
(NM_145207.2)
Encodes the spermatogenesis-associated protein 5, 
which is a member of the ATPases associated with 
diverse activities protein subfamily. SPATA5 deficiency 
leads to imbalance of mitochondrial fusion-fission 
events, mitochondrial shortening, decreased ATP 
production at axonal endings and impaired axogenesis 
in primary cortical neurons in vitro, and results in an 
autosomal recessive syndrome with severe global 
developmental delay, severe speech impairment, 
hearing loss, abnormal EEG and microcephaly (OMIM 
616577) [Puusepp et al. 2018].  
6 M 5y After 
birth 
7 Unsolved  
7 M 2y8m At birth 6 NDUFB11 
(NM_019056.6)
Encodes the NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 11, a component of the respiratory 
chain complex I. Its defects are associated with isolated 
mitochondrial complex I deficiency (OMIM 252010) 
and linear skin defects with multiple congenital 
anomalies (OMIM 300952). (Paper V)  
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Pt 
no Sex 
Current 
age Onset MDC Gene Function of the gene and protein, disease causality 
8 M 9y 3 weeks 6 MYH2 
(NM_017534.5)
Encodes the myosin-2 protein, a heavy chain isoform that is 
expressed in fast type 2A muscle fibers and is essential for 
muscle contraction. Its defects are associated with autosomal 
recessive and autosomal dominant proximal myopathy and 
ophthalmoplegia syndrome (OMIM 605637) and an unusual 
phenotype of neonatal-onset congenital myopathy matching 
our patient’s phenotype [D’Amico et al. 2013].  
9 M Died at 
1y 
After 
birth 
6 EPG5 
(NM_020964.2)
Encodes the ectopic P granules protein 5 homolog protein, 
which has a key role in the autophagy pathway [Cullup et 
al. 2013]. Its deficiency is associated with Vici syndrome 
(OMIM 242840). 
10 M 9y After 
birth 
6 Unsolved  
11 M 27y 2m 6 Unsolved  
12 M 11y 1.5m 6 Unsolved  
13 M 29y Early 
infancy 
6 Unsolved  
14 M 1y2m At birth 6 Unsolved  
15 F Died at 
5y 
2m 5 LMNA 
(NM_170707.2)
Encodes the structural protein prelamin A/C, which 
underlie the inner nuclear membrane and determine nuclear 
shape and size. Its defects are associated with various 
diseases, including Emery-Dreifuss muscular dystrophy 2 
(OMIM 181350), Emery-Dreifuss muscular dystrophy 3 3 
(OMIM 616516), congenital muscular dystrophy (OMIM 
613205), limb-girdle muscular dystrophy type 1B (OMIM 
159001), cardiomyopathies, lipodystrophies, peripheral 
neuropathies and progeria syndromes [Fisher et al. 1986]. 
16 M 5y 4m 5 CACNA1A 
(NM_023035.2)
Encodes the voltage-dependent P/Q-type calcium channel 
subunit alpha-1A acting as an ion pore and a voltage 
sensor. Impairment of this calcium channel leads to 
synaptic dysfunction and profound neuronal loss 
throughout the cerebellum. Its defects are associated with 
early infantile epileptic encephalopathy (OMIM 617106), 
episodic ataxia type 2 (OMIM 108500), familial hemiplegic 
migrane (OMIM 141500) and spinocerebellar ataxia 6 
(OMIM 183086).[Reinson et al. 2016b] 
17 M 20y 7y 5 TSPOAP1 
(BZRAP1) 
(NM_004758.3)
Encodes the peripheral-type benzodiazepine receptor-
associated protein 1. RIMs and RIM-BPs are multidomain 
scaffolding proteins that bind directly or indirectly to nearly 
all other presynaptic active zone proteins and Ca2+ channels 
and are essential to all active zone functions. (Acuna et al, 
2016). This protein has so far not been associated with any 
Mendelian disorders, but we have described a novel AR 
dystonia syndrome [Pajusalu et al. 2017] 
18 M 8y At birth 5 NKX2-1 
(NM_003317.3)
Encodes the homeobox protein Nkx-2.1 a transcription 
factor that is expressed during early development of 
thyroid, lung, and forebrain regions, particularly the basal 
ganglia and hypothalamus. Defects in this protein are 
associated with choreoathethosis, congenital 
hypothyroidism with or without lung dysfunction syndrome 
(OMIM 610978) and benign hereditary chorea (OMIM 
118700)[Thorwarth et al. 2014]. 
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Pt 
no Sex 
Current 
age Onset MDC Gene Function of the gene and protein, disease causality 
19 M 18y Early 
infancy 
5 Unsolved  
20 F 2y At birth 5 Unsolved  
21 M Died at 
16y 
Early 
infancy 
4 ALS2 
(NM_020919.3)
Encodes alsin protein which is a member of the guanine 
nucleotide exchange factors for the small GTPase RAB5 
and plays a role in intracellular endosomal trafficking 
[Hadano et al. 2006]. Its defects are associated with 
juvenile amyotrophic lateral sclerosis (OMIM 205100), 
juvenile primary lateral sclerosis (OMIM 606353) and 
infantile onset ascending spastic paralysis (OMIM 607225).
22 M 6y At birth 4 ATRX 
(NM_000489.3)
Encodes the transcriptional regulator ATRX an ATP-
dependent chromatin remodelling factor, which is thought 
to play a variety of key roles at tandem repeat sequences 
within the genome. Its defects are associated with X-linked 
alpha-thalassemia/ mental retardation syndrome (OMIM 
301040), mental retardation – hypotonic facies syndrome 
(OMIM 309580) and tumorigenesis [Clynes and Gibbons 
2013]. 
23 F Died at 
1y3m 
At birth 4 SCN2A 
(NM_021007.2)
Encodes the alpha-subunit of the voltage-sensitive sodium 
channel NaV1.2, which is responsible for the generation 
and propagation of action potentials early in development 
in neurons in hippocampus and cortex. Its defects are 
associated with early infantile epileptic encephalopathy 
(OMIM 613721) and benign familial infantile seizures 
(OMIM 607745) [Liao et al. 2010]. 
24 F Died at 
7m 
Prenatal 4 Unsolved  
25 F Died at 
1y5m 
3m 3 Unsolved  
26 M Died at 
26y 
1y 3 Unsolved  
27 M 2y 1.5m 2 ABCC6 
(NM_001171.5)
Encodes the multidrug resistance-associated protein 6. Its 
defects are associated with pseudoxanthoma elasticum 
(OMIM 264800) [Germain 2017]. 
28 F 7y 6y 1 MYBPC3 
(NM_000256.3)
Encodes cardiac myosin-binding protein C, which is 
arrayed transversely in sarcomere A-bands and binds 
myosin heavy chain in thick filaments and titin in elastic 
filaments. Phosphorylation of this protein appears to 
modulate contraction. Its defects are associated with dilated 
cardiomyopathy (OMIM 615396), hypertrophic 
cardiomyopathy (OMIM 115197) and left ventricular 
noncompaction (OMIM 615396) [Previs et al. 2012]. 
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From this study, we have published five articles reporting cases, which provided 
new information on the specific disease/gene. We have described a new 
inheritance pattern for CACNA1A associated disorders (Table 7, Pt. No 16) in 
cooperation with the scientists from the Radboud University Medical Center, 
Nijmegen, The Netherlands. The details are described and discussed in Chapter 
5.4. In collaboration with the Wellcome Trust Centre for Mitochondrial 
Research, Institute of Neuroscience, Newcastle University, United Kingdom, 
we have shown that autosomal dominant SLC25A4 variants can cause early-
onset severe MD (Table 7, Pt. No 1), which is described and discussed in detail 
in Chapter 5.5. We have also expanded the phenotype of patients with mutation 
in the NDUFB11 gene and presented a broad phenotypic divergence between 
these patients with scientists from Institute of Human Genetics, Technical 
University of Munich, Germany. Further information about the NDUFB11-
related phenotype (Table 7, Pt. No 7) can be found in Chapter 5.6. Additionally 
we have carried out functional studies to elucidate the pathomechanisms of 
SPATA5 gene deficiency (Table 7, Pt. No 5) in cooperation with the Institute of 
Biomedicine and Translational Medicine, University of Tartu, Estonia; and have 
concluded SPATA5-related diseases can be indirectly categorized under MDs 
[Puusepp et al. 2018]. In addition, we have described a novel genotype 
phenotype association of biallelic mutations in the BZRAP1 gene (Table 7, Pt. 
No 17), causing an autosomal recessive dystonia syndrome. The delineation of 
the BZRAP1-associated syndrome and the results of functional studies are 
shown elsewhere [Pajusalu et al. 2017]. As written above, international and 
local cooperation between research institutions becomes more and more 
important. The networking is required to optimize identification of molecular 
causes of rare disorders (including MDs), in both research and clinical settings. 
Such networks will help advance the genetic diagnosis for patients with rare 
disorders, and hopefully will be followed by an era of development of effective 
treatments for them. However, as stated above, WES is not the magic tool 
leading to an effortless diagnosis in all cases, especially in clinical work. The 
ordering physician should be aware of its pitfalls and limitations. In Estonia, 
clinical geneticists work in the same department with the research laboratory 
and their cooperation is close, it is highly likely that the details related to the 
patient are thoroughly discussed before and after ordering the analysis, 
including secondary findings and rare finding, which may need additional 
(international) investigation. 
One part of this study was also to observe the association between the MDC 
score (12–8 points were definite, 5–7 points were probable, 2–4 points were 
possible and <2 points were unlikely) and effectiveness of WES. The outcome 
was expected – the higher the MDC score, the greater the probability of MDs 
(Table 7). Three out of four cases with a definite MDC scoring were confirmed 
as having MD and one patient with spinal muscular atrophy type I (SMA I). 
In case of patients with a probable MD scoring, the results vary widely. Two 
patients were confirmed to have MD; two patients had variants in myopathy/ 
muscular dystrophy-causing genes, two in synaptic dysfunction-causing genes, 
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one in an autophagy-related gene, and one in a transcription factor encoding 
gene, with the latter two causing a multisystemic disease. In the group with 
possible MD scoring, no patients were confirmed to have MD. Four confirmed 
cases had variants in genes with different functions and heterogeneous pheno-
types. 
In our group, six patients died before establishing a diagnosis; only one of 
them before the age of one year and she had mutation in SMN1 gene. Unfor-
tunately, in our group there were also three deceased patients, whose cases 
remain unresolved. 
All these details show that we cannot clearly differentiate MDs from other 
diseases on clinical grounds and metabolic/imaging studies alone. Verity et al. 
have also shown that children do not have many of the symptoms that are 
characteristic of MDs when they first present, and the typical features may only 
appear later in life [Verity et al. 2010]. Therefore, using WES as a first-tier 
genetic analysis for patients with neuromuscular, neurological, and/or multi-
system signs and symptoms should be a standard protocol. This is especially 
true in children because regarding MDs, nuclear gene defects are over-
represented in pediatric cases [Alston et al. 2017; Wortmann et al. 2017]. 
A muscle biopsy is an excellent choice for detecting mtDNA mutations, 
deletions, and depletion [Wortmann et al. 2015], but it is an invasive and quite 
traumatizing procedure for the child and often, parents would like to postpone it 
whenever possible. There is currently a scientific debate on whether the WES 
analysis should precede the muscle biopsy [Narayanaswami et al. 2014; Phadke 
2017; Schuelke et al. 2017; Soden et al. 2014]. Based on our current study, we 
suggest that WES is performed prior to the muscle biopsy; however, the muscle 
analysis might be needed afterwards for confirmation of the variants found, or 
to obtain additional information about the patient’s phenotype. 
A less invasive procedure to study respiratory chain enzyme activity is the 
analysis of cultured fibroblast cells derived from the skin biopsy. However, 
there might be cases with decreased activity in muscle, but not in fibroblasts 
[Phadke 2017], as was the case in our patient no. 1 (Table 7). 
For patients with no findings with WES, the next step should be the mtDNA 
analysis. Presently, laboratories are already working on methods to analyze 
nuclear DNA (nDNA) and mtDNA concomitantly from blood lymphocytes 
using commercially available exome sequencing kits [Picardi and Pesole 2012]. 
Dinwiddie et al. have shown that using exome sequencing without specifically 
enriching for mitochondrial sequences also provides sufficient coverage for 
mtDNA, and both homoplasmic and heteroplasmic mitochondrial variants may 
be detected [Dinwiddie et al. 2013]. We have also developed a bioinformatics 
pipeline for analyzing mtDNA from the data of WES. We experienced large 
differences between samples, depending on which enrichment kit was used for 
the WES library preparation. The SureSelect kits (Agilent) had poor coverage, 
whereas the Nextera and TruSeq (Illumina) had quite good coverage. However, 
the SureSelect enrichment kit was used in the patient with a known mtDNA 
mutation, which we also detected using WES, despite the low coverage. There-
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fore, this is a promising technique to analyze mtDNA, without the invasive 
procedure of the muscle or skin biopsy. However, we should bear in mind that 
with this technique we analyze blood lymphocytes, which may not contain the 
mtDNA variants, especially in patients with mitochondrial myopathy. Another 
bottleneck is mitochondrial heteroplasmy – a low level of the variant may not 
be detected [Phadke 2017] and in the leukocytes, the level of heteroplasmy of 
mtDNA mutations tends to decrease during life, whereas it can increase in 
postmitotic tissues like in muscle [Wortmann et al. 2017]. In addition, mtDNA 
deletions and mtDNA depletion may be missed. Therefore, a negative mtDNA 
analysis from the WES data does not exclude the possibility of an mtDNA 
mutation, which can only be achieved with certainty by examining DNA from 
clinically affected tissue. On the other hand, if a mutation is detected by WES, 
this likely prevents the need for further (invasive) procedures. The simplified 
diagnostic algorithm for patients with neuromuscular, neurological, and/or 
multisystem symptoms is shown in Figure 1. 
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Figure 1. Diagnostic algorithm for children with any multisystem, neurological and/or 
neuromuscular problem. 
 
 
 
Functional testing with 
functional confirmation 
THE DIAGNOSIS 
No disease causing 
variant could be 
identified 
A novel variant in known 
disease gene or variant 
in candidate gene 
Known variant, known 
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THE DIAGNOSIS 
Whole exome 
sequencing 
Functional testing 
without confirmation 
Known variant, known 
disease gene 
THE DIAGNOSIS 
Functional testing 
without confirmation 
 
A novel variant in known 
disease gene or variant 
in candidate gene 
Functional testing with 
functional confirmation 
THE DIAGNOSIS 
No disease causing 
variant could be 
identified 
The mtDNA analysis 
(concomitantly) 
 
Investigate clinically 
affected tissue, and 
exclude mtDNA 
depletion 
 
The case could currently 
remain unresolved 
 Known deletion(s)/ 
duplication(s) 
THE DIAGNOSIS 
A novel variant 
Functional testing 
without confirmation 
 
The mtDNA deletions 
/duplications analysis 
(MLPA) 
Functional testing with 
functional confirmation 
THE DIAGNOSIS 
No deletion(s)/ 
duplication(s) 
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In conclusion, the effectiveness of WES in Estonia for patients with a clinical 
suspicion of MDs is 61% and therefore, we suggest the WES analysis as the 
first-tier method in clinical genetic practice for children with any multisystem, 
neurological, and/or neuromuscular problems. This recommendation is also 
supported by the fact that many patients in our study group have reached the 
age of adulthood before the molecular diagnosis was confirmed. As nDNA 
variants are more common in children with MDs, a large number of patients 
harbor disease-causing variants in genes other than mitochondria-related ones, 
and the clinical presentation might not always point towards MDs. Based on our 
experience, the higher the MDC score, the more probable it is to find not only 
MDs, but an overall genetic diagnosis by the WES analysis. Therefore, we 
believe that the MDC scoring is useful, but it only serves its purpose, when the 
patients are clinically, biochemically and instrumentally thoroughly investigated.  
 
 
5.4 Early onset epileptic encephalopathy with progressive 
cerebral, cerebellar and optic nerve atrophy caused  
by biallelic mutations in the CACNA1A gene (Paper III) 
This patient (Table 7, Pt. No 16) was born from uneventful labor as the sixth 
child of non-consanguineous Estonian parents (Figure 2a, II:7). The pregnancy 
was complicated by a polyhydramnios.  
At 4 months of age, he was hospitalized due to tremulous movements in his 
arms and legs. His occipitofrontal circumference was 44 cm (+3 SD), weight 
6.4 kg (+1 SD), and length 62 cm (+0.5 SD) with mild dysmorphic features 
(Figure 2b). Eye movements were dysconjugated with occasional episodes of 
nystagmus and no eye contact. He was markedly hypotonic, lacked deep tendon 
reflexes and a negative Babinski sign; had no head control and almost no 
spontaneous movements. The electroencephalogram (EEG) was abnormal with 
a high-voltaged up to 300 microV asymmetrical slow 2–3 Hz background 
activity accompanied by multifocal sharp waves and spike-wave complexes; 
there was no difference between the awake and sleep state. The brain MRI 
showed an optic nerve atrophy, small corpus callosum, dilatation of the frontal 
horns of the lateral ventricles and diffuse hypomyelination. The magnetic 
resonance spectroscopy (MRS) was normal.  
At 3 year of age, his EEG showed frontal diphasic waves and the brain MRS 
indicated a decreased N-acetylaspartic acid to creatine ratio (1.53) and slightly 
increased myo-inositol (1.1). The last MRI at the age of 4 years showed 
cerebellar atrophy and moderate cerebral atrophy (Figure 2c). In the occipital 
and parietal regions, a hyperintense white matter signal on T2 images with 
concomitant decreased volume was present (Figure 2d).  
At the age of 5 years, he was blind, bedridden and had global developmental 
delay with marked muscular atrophy and rigidity as well as additional 
Friedreich-like foot deformity on his left foot. He had some overt seizures (tonic 
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spasms) with high voltage continuous irregular epileptiform discharges and did 
not display an age-appropriate sleep pattern on EEG. He was able to recognize 
the voices of his family members; he could roll himself onto his side; also, he 
had to be fed, but he was able to swallow. 
Family history: the third child in this family, a girl (Figure 2a, II:4) died at 
the age of 5 years due to epileptic encephalopathy. The first hospitalization took 
place at the age of 4 month due to seizures and at that point, her development 
corresponded to the age of 1 month with no emotional contact and extreme 
muscular hypotonia. Her phenotype, clinical course and MRI findings including 
optic nerve atrophy, were very similar to our patient. Her EEG was abnormal 
with multifocal interictal epileptiform discharges and ictal electric discharges.  
The oldest daughter (Figure 2a, II:3) in the family had mild ID diagnosed by 
the Wechsler Intelligence Scale for Children III (WISC-III) testing. Occasio-
nally, she complained about the migraine and since the age of 13, she had 
exercise-induced vertigo attacks. About a year later, she experienced the first 
episode of aggression and self-injury necessitating isolation to the acute unit of 
psychiatric department. The most recent brain MRI study was done at the age of 
14 and showed no abnormalities. 
The third daughter (Figure 2a, II:5) had also mild ID (full scale intelligence 
quotient (IQ) was 62 by WISC-III) with impaired fine motor skills. She was 
seizure-free, but had generalized epileptiform (spike and slow wave complexes) 
discharges on EEG during photostimulation and in shallow sleep. Brain MRI, 
done at the age of 11 years, was normal. 
The youngest daughter (Figure 2a, II:6) had normal intellectual develop-
ment. There was no clinical information of the mother’s two elder sons (Figure 
2a, II:1 and II:2).  
Both parents had mild ID (performance IQ 73 in the father and 63 in the 
mother by the Wechsler Adult Intelligence Scale III) and poor social adjust-
ment. Two years before our patient was born, his mother (Figure 2a, I:2,) was 
diagnosed with probable alcohol-induced cerebellar ataxia: intention tremor of 
the hands, poor balance, and wide-based gate with horizontal nystagmus. Her 
brain MRI images showed cerebellar atrophy predominately affecting the 
vermis. The father (Figure 2a, I:3,) had no ataxia, migraines, or seizures. He had 
only modest complaints of rare headaches (without hemiplegia) and impairment 
of short-term and working memory. Brain MRI images were normal.  
WES identified two previously unreported heterozygous mutations in our 
patient’s CACNA1A gene: c.4315T>A p. (Trp1439Arg) in exon 27, and 
c.472_478delGCCTTCC p. (Ala158Thrfs_6) in exon 3 (RefSeq NM_023035.2). 
Confirmation of the CACNA1A mutations was performed by Sanger sequencing.  
The missense mutation c.4315T>A is predicted pathogenic by all tested 
software tools such as PolyPhen-2 [Adzhubei et al.2010] (HumDiv score 1), 
SIFT [Kumar et al., 2009] (score 0), and CADD [Kircher et al., 2014] (phred 
score 27.1). The amino acid position Trp1439 is conserved across species with 
tryptophan residue being present to C. elegans (PhyloP score 4.48), and is 
located in ion transport domain (InterPro IPR005821). The frameshift deletion 
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is predicted to cause a truncation of the protein in the exon three and therefore is 
apparently a loss-of-function mutation. Neither variant was present in ExAC 
(Exome Aggregation Consortium) database of 60,706 individuals, our in-house 
next generation sequencing database of 339 individuals, HGMD professional, or 
ClinVar. The missense mutation can be classified as likely pathogenic (class 4) 
and the frameshift mutation as pathogenic (class 5) according to guidelines by 
the American College of Medical Genetics and Genomics [Richards et al., 2015]. 
Both mutations were discovered also in the deceased sister (Figure 2a, II:4). 
Their mother (Figure 2a, I:2) and the eldest sister (Figure 2a, II:3) were 
heterozygous for c.4315T>A, and the father (Figure 2a, I:3) together with the 
second living sister (Figure 2a, II:5) were heterozygous for 
c.472_478delGCCTTCC. The youngest healthy sister (Figure 2a, II:6) has 
neither of the mutations. 
Expression of the CACNA1A is particularly high in Purkinje and granule 
cells [Pietrobon 2010; Volsen et al. 1995]. Mice that completely lack this 
neuronal calcium channel are born alive but have a severe phenotype of chronic 
dystonia and die soon after birth [Hoffman 2001]. Studies with knockout (KO) 
mice showed that the loss of Cav2.1 channel upregulates other voltage-gated 
calcium channels like Cav2.2 and Cav1.2 at most central synapses, although with 
different efficiency, resulting in synaptic dysfunction [Damaj et al. 2015], 
which may explain very variable phenotypes caused by the same mutation. 
Additionally, studies with KO mice demonstrate profound neuronal loss 
throughout the cerebellum [Rose et al. 2014], because in cerebellar networks, 
Cav2.1 channels regulate the whole-cell calcium current density and the intrinsic 
excitability of Purkinje cells and granule cells. This leads to altered cerebellar 
output by respectively decreasing the excitatory drive on Purkinje cells or their 
ability to release neurotransmitters, causing ataxia and dyskinesia in mice 
[Damaj et al. 2015]. Therefore, we can assume that this phenomenon has taken 
place in our described patients too. The most remarkable is cerebellar atrophy in 
our cases (Figure 2c). 
Additionally, from a clinical aspect, there is no previous highlight on 
progressive optic nerve atrophy, which was observed in the children carrying 
compound heterozygous mutations in the CACNA1A gene. To our knowledge, 
optic nerve has not investigated in previously published studies with mice 
[Damaj et al. 2015; Jen 1999; Mallmann et al. 2013; Pietrobon 2010; Rose et al. 
2014] also.  
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Figure 2. (a) Pedigree. The family with seven affected individuals from two genera-
tions. (b) Picture of our patient at the age of 5 years. Dysmorphic features include 
dolichocephaly, a high and narrow forehead, widely spaced eyes, broad eyebrows, long 
eyelashes, a wide nasal bridge, a short nose, anteverted nares, a smooth philtrum, and a 
tented vermillion of the upper lip. An MRI at the age of 4 years: (c) a sagittal section of 
a T1-weighted image shows pronounced atrophy of cerebellum and a small corpus 
callosum; (d) an axial section of a T2-weighted image showing mild cerebral atrophy 
with enlargement of ventricles. 
 
Because of striking muscular hypotonia, a muscle biopsy was done to our 
patient. The study exhibited lipid deposits in otherwise normal muscle fibres 
(Figure 3a, b). It is difficult to explain this finding as there is very little known 
about changes taking place in the muscles of patients with biallelic mutations in 
the CACNA1A gene. Considering the fact that the patient was on treatment with 
a steroid and valproic acid, we cannot declare it as a disease-specific change. 
The muscle biopsy was not performed on the deceased sister (Figure 2a, II:4), 
so further studies of other patients with biallelic CACNA1A mutations are 
necessary, to make reliable conclusions. 
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Figure 3. Muscle histopathology and electron microscopy in patient with two 
previously unreported heterozygous mutations in the CACNA1A gene. (a) Oil Red O 
staining of lipids. 40x objective (Ob); (b) Electron micrograph of muscle biopsy cells. 
Lipid (L) deposits were in close connection with mitochondria (M) membranes. 
Ob.27000x 
When comparing the clinical picture between our other family members, we 
can see some similarities but also differences. The mother (Figure 2a, I:2) 
carries a novel mutation in the CACNA1A gene – c.4315T>A that causes an 
adult onset cerebellar ataxia and atrophy. Her eldest daughter (Figure 2a, II:3) 
has the exact same mutation but the clinical picture varies in many ways. The 
mother’s problems with ataxia started in adulthood but the daughter (Figure 2a, 
II:3) experienced first signs of clumsiness and ataxic movements at the age of 
thirteen with no visual changes in brain MRI. At the age of sixteen, the main 
problem for her (Figure 2a, II:3) is uncontrollable episodes of aggression and 
self-injury requiring psychiatric admission. Psychiatric disorders with social 
phobia and anxiety are frequent findings in EA2 cohorts, these symptoms have 
been noticed especially when the disease started early in life [Nachbauer et al. 
2014]. The mother (Figure 2a, I:2) has never had psychiatric problems although 
she has a history of chronic alcohol abuse. It is stated that families including 
individuals with both early and late disease onset show a tendency to decrease 
It is previously known that mutations in the CACNA1A gene cause three allelic 
autosomal dominant conditions – EA2, SCA6, and FHM1. Damaj et al., [Damaj 
et al. 2015] recently stated that CACNA1A haploinsufficency may also cause 
cognitive impairment, autism and epileptic encephalopathy with mild cerebellar 
symptoms. These conditions occasionally overlap, since approximately 20% of 
the patients with FHM1 have cerebellar signs ranging from nystagmus to 
progressive, usually late-onset, mild ataxia [Ducros et al. 2001; Garcia-Baro-
Huarte et al. 2014; Terwindt et al. 1996] and 33% of patients with SCA6 
display episodic features which are characteristic for EA2 [Mantuano et al. 
2010]. About half of the EA2 patients report migraine headaches during the 
attacks [Jen et al. 2004], and a minority has episodes of hemiplegia [Jen 1999]. 
Only rare cases of the CACNA1A gene mutations have been associated with 
epileptic encephalopathy [Epi et al. 2013; Hino-Fukuyo et al. 2015; Ohmori et 
al. 2013].  
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in age of onset in next generations [Choi et al. 2013; Cleves et al. 2010; 
Krishnan et al. 2008].  
The father (Figure 2a, I:3) has also a novel mutation in the CACNA1A gene – 
c.472_478delGCCTTCC presumably causing a translational frameshift. He 
shares the same mutation with one of his living daughters (Figure 2a, II:5), they 
both have mild ID and no pathologic findings on brain MRI. Surprisingly, this 
daughter (Figure 2a, II:5) has generalized epileptic activity seen in an EEG at 
the age of eleven, but no overt seizures. Unfortunately, we do not have 
information about the father’s EEG study. 
None of our described family members has experienced episodic coma with 
or without cerebral oedema like described by Blumkin et al.[Blumkin et al. 
2010]. Furthermore, none of our family members has received specific treat-
ment for etiological disease.  
This is the first description of patients with biallelic mutations in the 
CACNA1A gene, which we believe to cause a unique clinical presentation – 
early onset epileptic encephalopathy, progressive cerebral, cerebellar and optic 
nerve atrophy with global developmental delay, severe muscular hypotonia and 
markedly reduced lifespan. Therefore, we are convinced that our case gives a 
novel insight into the mutations in the CACNA1A gene and expands the 
CACNA1A-related phenotype.  
 
 
5.5 Clinical description of child with a novel mutation, 
causing a third distinct phenotypic group associated  
with SLC25A4 gene (Paper IV) 
This female (Table 7, Pt. No 1) infant was born at term weighing 3,520g (0 SD), 
and she was the second child of healthy non-consanguineous Estonian parents. 
She was floppy at birth with paucity of limb movements and hyporeflexia. She 
required low-level supplemental oxygen in the immediate postnatal period, but 
was breathing air from 5 to 48 hour of age, at which point she deteriorated with 
a decrease in conscious level, feeding difficulties, and respiratory impairment. 
She was intubated and mechanically ventilated. Elevated lactate was noted in 
blood (9.7 mmol/L, normal < 2.2 mmol/L) as well as CSF (4.8 mmol/L, normal 
range 1.1–2.4 mmol/L). The urine analysis revealed increased excretion of 
lactate, 2-hydroxybutyric acid, fumarate, ketoglutarate, ethylmalonate, and 4-
hydroxyphenyl lactate. Echocardiography (echoCG) showed a mildly enlarged 
apex of the left ventricle. At day 7, despite treatment with coenzyme Q10 
(20 mg/kg/day), riboflavin (100 mg/kg/day), creatine (200 mg/kg/day), and  
L-carnitine (100 mg/kg/day), she developed persistent generalized clonic 
seizures without EEG abnormalities. Serial MRIs initially demonstrated 
communicating hydrocephalus and subsequently progressive cerebral white 
matter atrophy. Presently, at 6 years, she has a tracheostomy, is unable to speak, 
and can breathe independently for less than one hour. She is reliant on a 
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wheelchair due to proximal muscle weakness, but can walk briefly with a 
frame. Communication is by pointing or pictogram. 
Our patient had the diagnostic muscle biopsy done for the evaluation of 
suspected mitochondrial disease using a range of histopathological and bio-
chemical assays. The assessment of mitochondrial respiratory chain complex 
activities showed low complex I and IV activities in muscle, while the 
combined measurement of complexes II+III (succinate: cytochrome c reductase 
activity) was within the normal range (Table 8).  
 
Table 8. Result of the biochemical examination of the patient’s frozen muscle tissue. 
These data were previously published as a part of a diagnostic algorithm for 
mitochondrial disorders in Estonian children (Case 2) [Joost et al. 2012b]. 
mU/UCS = milliunits per unit of citrate synthase 
Enzyme activities Activity Control range 
Complex I 28 units/UCS 84–559 
Complex II + III 51 mU/UCS 37–285 
Complex IV 58 mU/UCS 520–2080 
Citrate synthase 118 mU/mg protein 45–187 
 
Histopathological assessment of the muscle biopsy revealed small and rounded 
muscle fibers with little variation in fiber size and without evidence of atrophy, 
necrosis, fibrosis, or inflammatory changes; Oil Red O staining showed lipid 
deposition and modified Gomori trichrome staining disclosed abnormal staining 
around the subsarcolemmal region of some fibers; unfortunately, histochemical 
assessment of oxidative enzyme activities was not undertaken. Electron 
microscopy investigation confirmed the accumulation of both lipid and 
glycogen, revealing numerous mitochondria with disorganized cristae, although 
paracrystalline inclusions were not detected (Figure 4). 
Despite the serious clinical problems, this girl was for a long time without 
etiologic diagnosis. Her thorough investigation began already at the age of 
newborn, when she was suspected to have MD, which was also indicated by the 
muscular biopsy; therefore, the mutations in POLG and TK2 were excluded 
after the chromosomal microarray analysis revealed no abnormalities. At that 
time, a predominantly traditional approach was used and details about this are 
described elsewhere [Joost et al. 2012b]. 
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Figure 4. Muscle histopathology and electron microscopy in patient with de novo 
heterozygous c.239G>A, p.(Arg80His) SLC25A4 mutation 
(a) ATPase at pH 10.2 shows numerous vacuoles in type 1 fibers; (b) Oil Red O staining 
highlights the lipid content of the vacuoles; (c) 1 μm sections stained with methylene 
blue-azure II-basic fuchsin staining reveals glycogen in the periphery of fibers; (d) An 
electron micrograph shows abnormal mitochondria (M) with circularly arranged cristae 
and lipid droplets (L). 
 
Eventually, we had the chance to perform WES and DNA was extracted by 
standard methods from the muscle biopsy. The genomic DNA fragments were 
enriched for exome sequences using the Agilent SureSelectXT Human All Exon 
50Mb Kit (Agilent Technologies, Santa Clara, CA, USA). WES was carried out 
on an Illumina HiSeq 2000TM platform. A novel heterozygous 
NM_001151.3:c.239G>A p.(Arg80His) mutation was detected in the SLC25A4 
gene. Software tools PolyPhen-2 (HumDiv score 0.966) [Adzhubei et al. 2010], 
SIFT (score 0) [Kumar et al. 2009], and CADD (phred score 34) [Kircher et al. 
2014] predicted the variant to be pathogenic. The amino acid position is highly 
conserved across different species (PhyloP score 6.072). The variant was not 
present in ExAC database of 60,706 individuals and this finding was confirmed 
by Sanger sequencing. Both of her parents were also tested for this mutation by 
Sanger sequencing and found out not to carry this mutation suggesting a de 
novo origin.  
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In addition, the mtDNA/nDNA ratio was determined in the frozen muscle 
biopsy using the real-time quantitative PCR to perform an mtDNA depletion 
test. The details of this method have been described previously [Dimmock et al. 
2010]. This revealed an mtDNA/nDNA ration of 436 (the average mtDNA/ 
nDNA ratio in the age-matched reference group is 1288). The percentage of the 
mtDNA/nDNA ratio compared to the average on the reference group is 34%. 
The lowest reference value corresponds to 60% of the average mtDNA/nDNA 
ration, as observed in muscle tissue of healthy controls [Dimmock et al. 2010]. 
This result confirms the mitochondrial depletion syndrome in our patient.  
Our patient was one of the seven patients with de novo, heterozygous, 
single-nucleotide substitutions in SLC25A4. Four of the seven patients 
presented an identical c.239G>A, p.(Arg80His) mutation and the other 3 cases 
harbored c.703C>G, p.(Arg235Gly) mutation. All these affected individuals 
presented with severe congenital hypotonia and profound muscle weakness 
necessitating artificial ventilation, and several died in early infancy. Our patient 
is the oldest living patient in this group. Available muscle biopsies from 
affected individuals revealed histopathological evidence of mitochondrial 
myopathy and a severe combined respiratory chain defect as a consequence of 
marked depletion of mtDNA copy number. These two variants affect highly 
conserved and functionally important amino acid residues, associated with the 
loss of steady-state AAC1 levels in patients’ skeletal muscle and diminished 
ATP transport activity in vitro. 
Mutations in SLC25A4 are well-recognized causes of mitochondrial disease; 
dominantly inherited SLC25A4 mutations have been documented in cases of 
adPEO, a adulthood-onset MD characterized by ptosis, restriction of eye 
movements, and the accumulation of clonally expanded mtDNA deletions in 
post-mitotic tissues on account of disordered mtDNA maintenance [Deschauer 
et al. 2005; Kaukonen et al. 2000; Siciliano et al. 2003]. Additionally, 
recessively inherited SLC25A4 mutations are known to cause childhood or early 
adulthood-onset mitochondrial myopathy and cardiomyopathy phenotype with 
lactic acidosis and proximal muscle weakness [Echaniz-Laguna et al. 2012; 
Korver-Keularts et al. 2015; Palmieri et al. 2005; Strauss et al. 2013]. The cases 
we present here, with de novo dominant mutations, can be considered to show a 
third distinct clinical phenotype associated with mutations in SLC25A4, which 
is more severe in its clinical presentation than those previously described. 
Despite the findings of SLC25A4 mutations in adPEO with multiple mtDNA 
deletions [Kaukonen et al. 2000], the mechanism of how an ADP/ATP carrier 
causes mtDNA instability is unknown. The current finding of mtDNA depletion 
in early-onset cases with SLC25A4 mutations links this gene to the causes of 
typical mtDNA maintenance disorders and strongly suggests that the transporter 
dysfunction causes insufficient adenine nucleotide availability for dATP 
synthesis and consequent imbalanced dNTP pools, leading to mtDNA depletion. 
Reports of recessive SLC25A4 mutations do not fit with correlation of AAC1 
transport ability and clinical severity, since the mutations, including nonsense 
[Korver-Keularts et al. 2015; Strauss et al. 2013], splicing [Echaniz-Laguna et 
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al. 2012], and missense [Korver-Keularts et al. 2015; Palmieri et al. 2005]) are 
completely null but have a much milder clinical phenotype than the case 
presented here. Knockout mouse studies have also shown that loss of AAC1 
produces a similar myopathy and cardiomyopathy phenotype to individuals with 
recessive SLC25A4 mutations [Esposito et al. 1999; Graham et al. 1997]. We, 
therefore, postulate that the complete lack of functional AAC1 triggers a 
compensatory mechanism to upregulate expression of other isoforms of the 
ADP/ATP carrier in cases of recessive disease. There are four different AAC 
isoforms and at least another three isoforms of the ATP-Mg/Pi carrier, which 
can also transport ADP and ATP [Fiermonte et al. 2004].  
The detailed explanation of possible causes of mtDNA depletion with an 
attempt to explain the differences in clinical presentation by analyzing the 
positions of affected amino acid residues within the structure of AAC1 are 
described by Thompson et al.[Thompson et al. 2016] in cooperation with us. 
Reaching the results described above and confirming the pathogenicity of 
this de novo mutation has immense implications for the application of WES and 
international collaboration by analyzing the data of a larger group of patients. 
This is an ideal example of how the previous approach is time consuming and 
sometimes does not end up with conclusive result, whereas WES along with a 
biochemical and functional studies can provide excellent final solution.  
 
 
5.6 Diverse phenotype in patients with complex I 
deficiency due to mutations in NDUFB11 (Paper V) 
This male infant (Table 7, Pt. No 7 and Table 9, Pt. No 1) was born from 
healthy non-consanguineous Estonian Russian parents at full term (Figure 5). 
During the delivery, fetal bradycardia was noticed and childbirth was ended by 
vacuum-assisted vaginal delivery. His birthweight was 3218g (–1 SD) and 
Apgar scores were 81 and 95. Soon after birth, he became hypotonic and 
bradycardia was noticed. The first blood gases analysis revealed profound lactic 
acidosis – 9.2 mmol/L (normal <2.2 mmol/L), peak value was 20mmol/L. At 
the age of 11 hours, he required intubation and mechanical ventilation with 
dopamine infusion for hypotension treatment. 
The first echoCG was done on the first day of life and it revealed pulmonary 
hypertension greater than 69 mmHg at rest, with significant tricuspid valve 
insufficiency, maximum velocity >4 m/s. Right ventricle was moderately 
trabecular and left ventricular contractile function was impaired. Abdominal 
ultrasound showed mild renal pelvis dilatation. 
EEG was also abnormal, revealing constant background activity depression, 
but no epileptic activity recognized. Periventricular cystic lesions were noticed 
on cranial MRI but no basal ganglia hyperintensity. 
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The clinical picture and the phenomenon where the lactic acidosis worsened 
during the high glucose infusion led us to suspect a high energy demanding 
IEM. 
The measurement of serum acylcarnitines profile by tandem MS revealed no 
pathology. The lactate and pyruvate ratio in blood was mildly elevated – 25 
(normal <20). Within the days after the vitamin-based and cofactor-based 
mitochondrial therapy was applied – thiamine, L-carnitine, coenzyme Q10 and 
riboflavin – lactic acidosis declined and lactate remained 2.5–5 mmol/L.  
He had mild normocytic anemia at the age of two months, during the stay in 
the intensive care unit; he recovered by additional iron administration and after 
that episode, there has been no indication for anemia and the peripheral smear, 
done twice, showed no abnormalities. 
At the age of 3.5 years, his psychomotor development is age appropriate, the 
length is 98cm (0 SD), weight 14kg (–1 SD) and head circumference 51cm 
(0 SD). He continues to have treatment with riboflavin, L-carnitine and 
coenzyme Q10 that keeps the blood lactate persistently below 3mmol/L. His 
thyroid function is normal, the brain MRI revealed no pathology, but echoCG 
shows hypertrophic cardiomyopathy (CM) with slightly decreased contractile 
function and mild pulmonary hypertension. This cardiac condition is achieved 
by sildenafil and digoxin treatment.  
Mitochondrial respiratory chain complex activities were measured spectro-
photometrically in cultured fibroblasts and revealed a reduced activity of the 
mitochondrial enzyme-complex I, while the activity of the other respiratory 
chain enzymes and complex V were normal (Table 9).  
 
Table 9. Spectrophotometrically measured mitochondrial respiratory chain complex 
activities in cultured fibroblasts. 
*The German patient, published with us in paper V. 
mU/UCS = milliunits per unit of citrate synthase 
  Patient 1 (our case) Patient 2* Ref. range 
Complex I 60 83 163–599 mU/UCS 
Complex II 445 515 335–888 mU/UCS 
Complex III 784 793 570–1383 mU/UCS 
Complex IV 532 560 288–954 mU/UCS 
Complex V 651 643 193–819 mU/UCS 
Citrate synthase 363 416 151–449 U/mg protein 
 
WES was carried out with a search for rare compound heterozygous, homozygous 
or hemizygous variants in genes that have been previously associated with 
mitochondrial dysfunction prioritized the following NDUFB11 (RefSeq 
NM_019056.6) mutation in a hemizygous state: c.328C>T, p.(Pro110Ser).  
Our study also included one German patient (Table 9, Patient 2), to whom 
WES was also performed and c.286T>C, p.(Ser96Pro) mutation in a hemizygous 
state was found in the NDUFB11 gene. Both these missense mutations were 
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located in the second exon and within the NADH domain (Figure 5B). These 
variants were validated by Sanger sequencing and carrier testing confirmed 
their de novo origin. These mutations had not been previously reported in public 
(dbSNP, ExAC) and in-house databases. 
Figure 5. A. Pedigrees; B. NDUFB11 gene. Two new variants from this study are 
shown above the gene and are located in the second exon, within the NADH domain. 
Previously published variants are written below it. 
 
Western blotting of mitochondrial extracts from fibroblasts showed that the 
expression levels of the NDUFB11 protein was decreased in both patients’ cells 
(Figure 6A and D). In addition, we observed clearly reduced levels of intact CI 
by BN-PAGE Western blot experiments (Figure 6B), which are compatible with 
the results of reduced CI enzyme activities (Table 9). 
To demonstrate that the NDUFB11 defect was responsible for the observed 
CI deficiency in both patients (our case and the German patient), we performed 
a lentiviral complementation experiment in which we introduced the wild type 
NDUFB11 gene in the patient cells and in two control cell lines. As a control 
experiment, we introduced the green fluorescent protein (GFP). Western blots 
confirmed the expression of the transgenes (Figure 6C). The respiratory chain 
enzyme activity measurements in different transduced cell lines showed that the 
introduction of wild type NDUFB11 restored the CI enzyme activity in both 
patient cell lines, while the control experiment with GFP-transduction had little 
or no effect in comparison to the activities in non-transduced cells, as shown in 
Table 9. In control cells, there was no significant change in CI activity. The 
effects on CI in the patient cells are specific for this enzyme, as there was little 
or no effect on the activities of the other respiratory chain enzymes (Figure 7B). 
In conclusion, the results of the functional data obtained in this experiment 
support the notion that the CI deficiency in the two patients is caused by 
NDUFB11 genetic defects.  
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Figure 6. Analysis of NDUFB11 protein expression in patient fibroblasts. 
(A) A western blot analysis using anti-NDUFB11 antibodies (Ab183716, Abcam) 
showed that NDUFB11 expression was clearly reduced in fibroblasts of patient 1 
in comparison to fibroblasts from four different control subjects.  
(B) A blue native PAGE/Western blot experiment shows a reduced amount of holo-
complex I in both patients’ fibroblasts in comparison to three controls, as detected 
by NDUFB11 and NDUFA9 (ab14713, Abcam) antibodies (left and right panel, 
respectively). 
(C) Lentiviral transduction of fibroblasts from both patients with NDUFB11-V5 and 
GFP-V5 fusion constructs shows expression of the transgenic proteins in both 
patients and in controls, as detected by an anti-V5 antibody (R960-25, Invitrogen) 
using SDS-PAGE/Western blotting. 
(D) SDS-PAGE/western blot analysis showing that patient 2 has a reduced expression 
level of endogenous NDUFB11 protein, whereas transduction of the cells by either 
NDUFB11-V5 or NDUFB11 without a tag (NDUFB11-stop; 1 and 2 indicate two 
different lentiviral preparations) rescues NDUFB11 expression. Note that the 
NDUFB11-V5 fusion protein has a slightly slower mobility than the endogenous 
NDUFB11 in the control fibroblasts and the transgenic NDUFB11 protein 
(without tag) in both control and patient fibroblasts 
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Figure 7. Transgenic expression of wild type NDUFB11 (Refseq NM_019056) in 
fibroblasts of the two patients specifically rescues complex I activity. The NDUFB11 
cDNA was cloned into the pLenti6.2⁄V5-DEST vector by Gateway cloning (Invitrogen). 
HEK293FT cells were transfected to produce lentivirus according to the manufacturer’s 
protocol (Invitrogen). Viral particles were harvested and used to transfect patient and 
control fibroblasts. Blasticidin selection was used to obtain stably transfected cells 
expressing the transgene. In this way, stable cell lines expressing either a NDUFB11-V5 
fusion or a GFP-V5 fusion (as negative control) were obtained. 
(A) The respiratory chain enzyme activities, as measured spectrophotometrically, 
showed a specific and significant rescue of complex I activity by NDUFB11 in the 
both patients’ cells to levels that were near the mean control level, indicated by a 
dotted line in the bottom graph (p-value <0.01). The dashed line indicates the 
lowest reference value for complex I.  
(B) The effect was specific for complex I, as the other respiratory chain enzymes 
showed little or no response to the NDUFB11-V5 transduction, compared to the 
activities measured in the control transduction experiments with GFP-V5 (top 
figure). The results shown for NDUFB11 are those obtained with a NDUFB11-V5 
fusion construct. For patient 2, we also performed a rescue experiment with 
NDUFB11 without a V5 tag, which gave very similar results (data not shown). 
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Therefore, biochemical, functional and molecular studies confirmed that 
mutations found in the NDUFB11 gene gave rise to the above described 
phenotypic features in our two new cases.  
In addition, over the past few years 13 affected patients with four 
asymptomatic family members have previously been described, and we can 
conclude that different mutations in the NDUFB11 gene can cause broad 
phenotypic divergence. Nevertheless, even the genotypic homogeneity in some 
previously described patients (Table 10) give a great deal of phenotypic 
heterogeneity. However, our findings indicate also a clinical distinction of 
NDUFB11-related manifestation from other CI deficiencies. 
Most reported cases harboring mutations in the NDUFB11 gene tend to have 
some kind of cardiac muscle impairment (10/15 cases, 67%), while in patients 
who are CI deficient, it occurs in 20% of cases [Koene et al. 2012]. Every 
affected female with a NDUFB11 mutation had cardiomyopathy – four with 
histiocytoid cardiomyopathy (HCM) [Rea et al. 2017; Shehata et al. 2015; van 
Rahden et al. 2015], one with dilated CM and one, who was investigated as a 
fetus, had thickened myocardium and pericardial effusion [van Rahden et al. 
2015]. There were also four male patients with cardiac involvement and it is 
noteworthy that one boy’s fetal cardiac ventricular hypertrophy was 
spontaneously resolved (Table 10, Pt. No 4) [Torraco et al. 2016]. However, it 
is important to point out that it is often difficult to diagnose HCM and the vast 
majority of cases of HCM are identified postmortem or on examination of the 
native explanted heart during cardiac transplantation [Bird et al. 1994]; 
therefore, it is possible that some cases of HCM remain undetected, and are 
considered as some other type of CM. 
Hematological manifestations in mitochondrial disorders, including CI 
deficiency, are aplastic, macrocytic, or sideroblastic anemia, leukopenia, 
neutropenia, thrombocytopenia or pancytopenia [Finsterer and Frank 2015]. In 
NDUFB11 defects, it is essential to highlight that almost half of the previously 
described patients (all boys) had congenital sideroblastic anemia (7/15, 47%) 
[Lichtenstein et al. 2016; Torraco et al. 2016] with no other hematological 
manifestation. To determine the potential role of the NDUFB11 gene in 
erythropoiesis, Lichtenstein et al. examined the phenotype of zebrafish ndufb11 
morphant embryos and found that partial knockdown of ndufb11 resulted in a 
decrease in the number of erythroid cells and diminished hemoglobin, which 
indicates that the NDUFB11 could have a phylogenetically conserved role in 
erythropoiesis [Lichtenstein et al. 2016]. This explains seven male patients’ 
phenotype. Concurrently, there are no other abnormalities in erythropoiesis 
described in affected patients and no female patient has had congenital 
sideroblastic anemia. 
 
Table 10. Detailed comparison of the clinical features associated with mutations in the NDUFB11 gene. 
CSF – cerebrospinal fluid; congen. – congenital; EEG – electroencephalogram; h – hour; hem – hemizygous; het – heterozygous; mo – month; N – normal; n.a. – not available; y – year; † – patients 7 and 8 are siblings; ††– two cases are from a single pedigree and 
they also have a heterozygous deletion of at least 70 kb at 2p16.3, containing part of the NRXN1 gene, which may have influenced the phenotype. Intragenic mutations and deletions in the NRXN1 are enriched in cohorts with neurodevelopmental and autistic 
spectrum disorders 
No. Sex 
cDNA  
(NM_019056.6) Protein change 
Inheri-
tance 
Age at 
last 
exami-
nation 
Age of 
onset 
Skeletal 
muscle Skin MRT Epileps 
Develop-
mental 
delay/intel-
lectual 
disability Eyes Growth 
Congen. 
sidero-
blastic 
anemia Lactic acidosis 
Cardiac 
abnormality Other anomalies   
1. F c.254G>A (het) p.(Trp85*) de novo n.a. n.a n.a n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
histiocytoid 
cardio-
myopathy   Shehata et al. 
2. F c.262C>T (het) p.(Arg88*) de novo 6 mo 
after 
birth 
axial 
hypotonia 
linear 
skin 
defect n.a. n.a. n.a. 
lacrimal-
duct atresia 
failure to 
thrive no no 
histiocytoid 
cardio-
myopathy 
died at the age of 6 
mo. Autopsy 
revealed thyroid 
abnormalities 
(large and multiple 
sites of oncocytic 
metaplasia) 
van Rahden 
et al. 
3. F c.262C>T (het) p.(Arg88*) de novo 13 mo fetal 
mild-to-
moderate 
bulbar 
palsy N 
focal histiocytoid 
change in the 
choroid plexus of 
the brain no n.a. 
Intermittent
squint n.a. no n.a. 
histiocytoid 
cardio-
myopathy 
focal histiocytoid 
change in the 
thyroid and lungs. Rea et al. 
4. M 
c.276_278delCTT 
(hem) p.(Phe93del) de novo 9 y fetal N N N no no n.a. N yes 4.2–8.2 mmol/L 
fetal tachycardia 
and hypertrophy 
of the 
ventricular walls 
with moderate 
trabeculature of 
the right 
ventricle 
dysmorphic 
features:  
hypertelorism, 
saddle nose, low 
set ears. 
Hepatospleno-
megaly and 
hydrocele. Torraco et al. 
5. M 
c.276_278delCTT 
(hem) p.(Phe93del) de novo 2 y 
after 
birth n.a N n.a. no no N 
short 
stature yes no no   
Lichtenstein 
et al. 
6. M 
c.276_278delCTT 
(hem) p.(Phe93del) 
from 
healthy 
mother 23 y n.a. myopathy N n.a. no no N N yes yes no   
Lichtenstein 
et al. 
7. M 
c.276_278delCTT 
(hem) p.(Phe93del) 
from 
healthy 
mother † 20 y fetal n.a. N n.a. no yes 
congen. 
optic 
atrophy 
short 
stature yes no no   
Lichtenstein 
et al. 
8. M 
c.276_278delCTT 
(hem) p.(Phe93del) 
from 
healthy 
mother † 16 y fetal n.a. N n.a. no yes 
congen. 
optic 
atrophy 
short 
stature yes no no   
Lichtenstein 
et al. 
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No. Sex 
cDNA  
(NM_019056.6) Protein change 
Inheri-
tance 
Age at 
last 
exami-
nation 
Age of 
onset 
Skeletal 
muscle Skin MRT Epileps 
Develop-
mental 
delay/intel-
lectual 
disability Eyes Growth 
Congen. 
sidero-
blastic 
anemia Lactic acidosis 
Cardiac 
abnormality Other anomalies   
9. M 
c.276_278delCTT 
(hem) p.(Phe93del) 
un-
known 8 y fetal myopathy N n.a. yes no N N yes no no 
single kidney, 
pulmonary 
stenosis, congenial 
inguinal hernia 
Lichtenstein 
et al. 
10. M c.286T>C (hem) p.(Ser96Pro) de novo 16 y 3-4 y N N 
mild cerebral 
atrophy no  yes 
optic 
atrophy 
short 
stature yes 
CSF lactate  
3.1 mmol/L 
(normal  
<2.1 mmol/L) 
hypertrophic 
cardio-
myopathy 
joint contractures,
 non-progressive 
mild hearing 
impairment. Patient 2 
11. F c.324T>G (het) p.(Tyr108*) de novo child n.a n.a n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
histiocytoid 
cardio-
myopathy   Shehata et al. 
12. M c.328C>T (hem) p.(Pro110Ser) de novo 3,5 y 
after 
birth N N N 
no; EEG – 
mild back-
ground 
activity 
depres-sion no N N no 
Serum lactate 
 2-20 mmol/L 
hypertrophic 
cardio-
myopathy   Patient 1 
13. M c.361G>A (hem) p.(Glu131Lys) de novo 55 h fetal n.a. 
redun-
dant 
skin n.a. n.a. n.a. n.a. 
intraute 
rine growth 
restriction n.a. n.a. heart failure 
died at the age of 
55 hours Kohda et al. 
14. F c.402delG (het) p.(Arg134Serfs*3) 
from 
healthy 
mother  
†† 4,5 y n.a. n.a. 
linear 
skin 
defect 
corpus-callosum 
agenesis and dilated 
lateral ventricles yes  
severe global 
development
al delay 
myopia, 
nystagmus, 
strabismus 
failure to 
thrive no no 
dilated cardio-
myopathy   
van Rahden 
et al. 
15. F c.402delG (het) p.(Arg134Serfs*3) 
from 
healthy 
mother  
†† 
pregnancy 
was 
terminated 
 at the 24th 
week fetal n.a. n.a. 
corpus-callosum 
dysgenesis, 
connected lateral 
ventricles, a small 
cerebellum and the 
cavum septum 
pellucidum n.a. n.a. n.a. 
intrauterine 
growth 
restriction n.a. n.a. 
thickened 
myocardium 
and pericardial 
effusion   
van Rahden 
et al. 
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The neurological symptoms in patients with CI deficiency are observed to be 
variable, whereas muscle hypotonia is seen in 60% of patients and no other 
single sign is present in more than 35% of patients [Koene et al. 2012]. In those 
with NDUFB11 mutations, only two previously described patients (2/15, 13%) 
have myopathy (one adult and one 8-year-old boy [Lichtenstein et al. 2016]); 
one infant had axial hypotonia (died at the age of six months [van Rahden et al. 
2015]) and one with mild to moderate bulbar palsy [Rea et al. 2017]. 
Importantly, there are some less specific phenotypical features shared by most 
CI deficient patients such as brain MRI abnormalities, particularly signs of 
Leigh syndrome, which have been noted for more than 80% of CI-deficient 
patients [Fassone and Rahman 2012; Koene et al. 2012]. None of the previously 
described affected patients or carriers of mutation in the NDUFB11 gene has 
been described with Leigh syndrome. MRI findings were described only in 4/15 
cases with NDUFB11 defects, and are rather rare containing histiocytoid change 
in the choroid plexus of the brain, mild cerebral atrophy and developmental 
malformation (including corpus callosum) [Rea et al. 2017; van Rahden et al. 
2015]. 
The failure to thrive or short stature was described in 7/15 (47%) affected 
patients with NDUFB11 defect (three females and four males), which is also a 
quite commonly (34%) reported clinical symptom in patients with nuclear-
encoded CI deficiency [Koene et al. 2012]. Developmental delay or ID was 
described in analyzed cohort in three boys and one girl (4/15, 27%); epilepsy 
was even less common – one male and one female (2/15, 13%). 
In the group of NDUFB11 patients, only two patients died at an early age: 
one female (age six months [van Rahden et al. 2015]) and one male (age 55 
hours [Kohda et al. 2016]); however, one pregnancy was also terminated at the 
24th gestational week, due to multiple developmental malformations [van 
Rahden et al. 2015]. This data do not correspond with the CI deficiency, which 
often results in a fatal phenotype: approximately 75% of the patients die before 
the age of ten years, and nearly 50% of them before the age of two years [Koene 
et al. 2012]. 
It is widely known that mitochondrial diseases show a broad spectrum of 
clinical symptoms and we still cannot explain why identical mutations in the 
same gene can cause such phenotypic divergence (Table 10). Most of the 
affected NDUFB11 males with sideroblastic anemia had several coexisting 
complaints such as myopathy, lactic acidosis, or short stature, with other neuro-
developmental or organ dysgenesis. Similar considerable clinical overlap is 
seen in patients with HCM. Therefore, it should be recognized that patients with 
NDUFB11 mutations can give rise to a variable clinical phenotype. 
Gurok et al. noted that the NDUFB11 gene is highly expressed in mice heart 
tissue [Gurok et al. 2007]. A higher expression level was also in kidney and 
skeletal muscle, which were rarely impaired in affected humans. Medium 
expression was found in the brain, whereas in all other organs it was weakly 
expressed. During mouse development, the transcript was detected at all stages, 
including embryonic development, with the highest expression at early age 
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[Gurok et al. 2007]. These results demonstrate serious disturbance in fetal 
development [van Rahden et al. 2015] and may also give a partial explanation 
of disappearance of some clinical manifestations (Table 10, Pt. No 4 [Torraco et 
al. 2016]).  
There are different potential explanations for the wide phenotypic mani-
festation and one is somatic mosaicism [Rea et al. 2017; van Rahden et al. 2015]. 
Several studies have demonstrated X-inactivation in peripheral blood leuko-
cytes, demonstrating the skewing toward the unaffected X chromosome 
[Lichtenstein et al. 2016; van Rahden et al. 2015]. This phenomenon could help 
to explain why healthy mothers and sister carry the same mutation as affected 
family members. Furthermore, phenotypic variability may reflect different 
abilities of developing tissues and organs in embryonic cells to handle a defective 
mitochondrial respiratory chain system; the phenotype can be influenced by the 
presence of additional variants, and environmental or epigenetic factors [van 
Rahden et al. 2015]. 
In conclusion, the mutations in the NDUFB11 are the cause of isolated CI 
deficiency and similar to various other genes, which are affecting mitochondrial 
CI, there is a relative wide variation in clinical symptoms of affected patients. 
However, our findings present clinical distinctions of NDUFB11-related mani-
festation from other CI deficiencies, and highlight that histiocytoid cardio-
myopathy and/or congenital sideroblastic anemia could be indicative of 
NDUFB11 gene defects. 
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6. CONCLUSION 
1. Based on our four-year study period, we can conclude that the choice of 
screening methodology and structure of our expanded newborn screening 
program has been justified in Estonia (Paper I and VI). 
a. We have screened 54,899 newborns and confirmed the diagnosis of 29 
children, therefore the overall prevalence of congenital metabolic dis-
orders identified with newborn screening in Estonia is 1:1,893 newborns.  
b. Unexpectedly, the most common disorder, which was identified with 
NBS, was congenital acquired vitamin B12 deficiency. The prevalence of 
this diagnosis, calculated for three years, is 1:2,959. 
c. The second most common detected group of disorders were HPA, as was 
assumed earlier. 
d. Based on the four-year NBS screening experience, we can affirm that the 
incidence of MCADD in Estonia remains rare, as was previously 
presumed. During that period, we did not diagnose any newborn with this 
condition.  
e. Over the four years, the FPR has remained to 0.1% and the PPV has risen 
to 36.7%. In the last (fourth) year, the FPR was 0.07% and the PPV was 
52.6%. The overall specificity is 99.9% and since we still have not 
diagnosed any false negative case, the overall sensitivity of tandem MS 
screening remains 100%.  
 
2. Based on our study results and previously published literature, we can conc-
lude that, the WES analysis in clinical practice in patients with suspicion of 
childhood-onset MDs is providing very high effectiveness (Paper II). 
a. We found disease-causing gene variants in 17 out of 28 patients, there-
fore, the effectiveness of WES in patients with suspected MD in an onset 
of early childhood was high – 61%.  
b. An MD was found in only 14% (4/28) of the patients in nuclear DNA. 
Other variants found were associated with a neuromuscular disease, a 
neurodegenerative disorder, a multisystemic disease, and in one case with 
an isolated cardiomyopathy-causing gene. 
c. We have also successfully developed and conducted the analysis of 
mtDNA from standard WES reads and diagnosed one patient with 
mtDNA mutation (a point mutation in the MT-ATP6 gene). This provides 
evidence that this method can be routinely used in clinical practice. 
d. Based on our results, we recommend the WES analysis as a first-tier 
method in clinical practice for children with any multisystem, neurologi-
cal and/or neuromuscular problems as nuclear DNA variants are more 
common in children with MD. 
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3. Clinical and molecular investigations of two severely affected siblings 
revealed biallelic mutations in the CACNA1A gene, expanding the genotypic 
and phenotypic spectra of CACNA1A-related disorders (Paper III). 
a. Our study group presented for the first time two siblings with compound 
heterozygous mutations in the CACNA1A gene. All other variants, 
reported before, were only heterozygous state.  
b. Whole exome sequencing identified two previously unreported hetero-
zygous mutations in our patient’s CACNA1A gene: c.4315T>A  
p.(Trp1439Arg) in exon 27, and c.472_478delGCCTTCC p. 
(Ala158Thrfs_6) in exon 3. 
c. These semidominantly inherited mutations in the CACNA1A gene are 
likely to cause early onset epileptic encephalopathy, progressive cerebral, 
cerebellar, and optic nerve atrophy with severe muscular hypotonia and 
reduced lifespan. 
 
4. Clinical, molecular and functional investigations revealed a novel de novo 
mutation in the SLC25A4 gene, which causes a third distinct clinical 
phenotype associated with this gene (Paper IV). 
a. As a result of international cooperation, we evaluated the functional and 
clinical effect of a novel de novo heterozygous, single-nucleotide substi-
tutions in the SLC25A4 gene in seven patients. 
b. Four patients harbored a c.239G>A (p.Arg80His) mutation and three 
patients had a c.703C>G (p.Arg235Gly) mutation. Both mutations 
affected highly conserved and functionally important amino acid 
residues, associated with the loss of steady-state AAC1 levels in patients’ 
skeletal muscle and diminished ATP transport activity in vitro. 
c. The phenotypes of all the affected individuals were very similar, pre-
senting severe congenital hypotonia and profound muscle weakness, 
necessitating artificial ventilation, and causing frequent deaths in early 
infancy. 
d. Available muscle biopsies from the affected individuals revealed histo-
pathological evidence of mitochondrial myopathy and a severe combined 
respiratory chain defect as a consequence of marked depletion of the 
mtDNA copy number. 
 
5. Clinical, molecular, and functional investigations from two patients revealed 
two novel de novo mutations in the NDUFB11 gene that cause mitochondrial 
CI deficiency. Our findings together with the review of the 13 previously 
described patients demonstrate a wide spectrum of clinical features 
associated with the NDUFB11-related CI deficiency (Paper V). 
a. Both patients had lactic acidosis, hypertrophic cardiomyopathy and 
isolated CI deficiency due to de novo hemizygous mutations (c.286C>T 
and c.328C>T) in the NDUFB11 gene.  
b. The expression levels of the NDUFB11 protein was decreased in both 
patients’ cells and a lentiviral complementation experiment demonstrated 
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that the CI deficiency in the two patients was caused by NDUFB11 
genetic defects.  
c. All patients with the mutation in the NDUFB11 gene (including pre-
viously described patients) present broad phenotypic divergence, which 
distinguishes it  from other CI deficiencies. However, histiocytoid cardio-
myopathy and/or congenital sideroblastic anemia could be indicative for 
mutation in the NDUFB11 gene.  
 
  
76 
7. REFERENCES 
Adam BW, Hall EM, Sternberg M, Lim TH, Flores SR, O’Brien S, Simms D, Li LX, 
De Jesus VR, Hannon WH. 2011. The stability of markers in dried-blood spots for 
recommended newborn screening disorders in the United States. Clinical 
biochemistry 44(17–18):1445–1450. 
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging 
missense mutations. Nat Methods 7(4):248–249. 
Allen LH. 2008. Causes of vitamin B12 and folate deficiency. Food and nutrition 
bulletin 29(2 Suppl):S20–34; discussion S35–27. 
Allen LH. 2009. How common is vitamin B-12 deficiency? Am J Clin Nutr 89(2):693s–
696s. 
Allen LH, Rosado JL, Casterline JE, Martinez H, Lopez P, Munoz E, Black AK. 1995. 
Vitamin B-12 deficiency and malabsorption are highly prevalent in rural Mexican 
communities. The American journal of clinical nutrition 62(5):1013–1019. 
Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. 2017. The genetics and 
pathology of mitochondrial disease. J Pathol 241(2):236–250. 
Armour CM, Brebner A, Watkins D, Geraghty MT, Chan A, Rosenblatt DS. 2013. A 
patient with an inborn error of vitamin B12 metabolism (cblF) detected by newborn 
screening. Pediatrics 132(1):e257–261. 
Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, Shendure J. 
2011. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev 
Genet 12(11):745–755. 
Berg JS, Agrawal PB, Bailey DB, Jr., Beggs AH, Brenner SE, Brower AM, Cakici JA, 
Ceyhan-Birsoy O, Chan K, Chen F, Currier RJ, Dukhovny D, Green RC, Harris-
Wai J, Holm IA, Iglesias B, Joseph G, Kingsmore SF, Koenig BA, Kwok PY, 
Lantos J, Leeder SJ, Lewis MA, McGuire AL, Milko LV, Mooney SD, Parad RB, 
Pereira S, Petrikin J, Powell BC, Powell CM, Puck JM, Rehm HL, Risch N, Roche 
M, Shieh JT, Veeraraghavan N, Watson MS, Willig L, Yu TW, Urv T, Wise AL. 
2017. Newborn Sequencing in Genomic Medicine and Public Health. Pediatrics 
139(2). 
Bhate V, Deshpande S, Bhat D, Joshi N, Ladkat R, Watve S, Fall C, de Jager CA, 
Refsum H, Yajnik C. 2008. Vitamin B12 status of pregnant Indian women and 
cognitive function in their 9-year-old children. Food and nutrition bulletin 
29(4):249–254. 
Bird LM, Krous HF, Eichenfield LF, Swalwell CI, Jones MC. 1994. Female infant with 
oncocytic cardiomyopathy and microphthalmia with linear skin defects (MLS): a 
clue to the pathogenesis of oncocytic cardiomyopathy? Am J Med Genet 
53(2):141–148. 
Black MM. 2008. Effects of vitamin B12 and folate deficiency on brain development in 
children. Food and nutrition bulletin 29(2 Suppl):S126–131. 
Blumkin L, Michelson M, Leshinsky-Silver E, Kivity S, Lev D, Lerman-Sagie T. 2010. 
Congenital ataxia, mental retardation, and dyskinesia associated with a novel 
CACNA1A mutation. J Child Neurol 25(7):892–897. 
Bodamer OA, Hoffmann GF, Lindner M. 2007. Expanded newborn screening in Europe 
2007. J Inherit Metab Dis 30(4):439–444. 
Bonham JR. 2014. Expanded newborn screening – progress into practice. Clinical 
biochemistry 47(9):697–698. 
77 
Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich SS, Loeber JG, Taruscio 
D, Vittozzi L, Cornel MC, Hoffmann GF. 2012. Newborn screening programmes in 
Europe; arguments and efforts regarding harmonization. Part 2. From screening 
laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis 
35(4):613–625. 
Burlina AB, Corsello G. 2015. Survey of Italian pediatricians’ perspectives and 
knowledge about neonatal screening. Italian journal of pediatrics 41:41. 
Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, Laskowski A, 
Garone C, Liu S, Jaffe DB, Christodoulou J, Fletcher JM, Bruno DL, Goldblatt J, 
Dimauro S, Thorburn DR, Mootha VK. 2012. Molecular diagnosis of infantile 
mitochondrial disease with targeted next-generation sequencing. Science 
translational medicine 4(118):118ra110. 
Campbell CD, Ganesh J, Ficicioglu C. 2005. Two newborns with nutritional vitamin 
B12 deficiency: challenges in newborn screening for vitamin B12 deficiency. 
Haematologica 90(12 Suppl):ECR45. 
Carmel R. 2000. Current concepts in cobalamin deficiency. Annu Rev Med 51:357–
375. 
Carmel R. 2011. Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic 
setting: a critical overview of context, applications, and performance characteristics 
of cobalamin, methylmalonic acid, and holotranscobalamin II. The American 
journal of clinical nutrition 94(1):348S–358S. 
Carmel R. 2012. Subclinical cobalamin deficiency. Current opinion in gastroenterology 
28(2):151–158. 
Carmel R. 2013. Diagnosis and management of clinical and subclinical cobalamin 
deficiencies: why controversies persist in the age of sensitive metabolic testing. 
Biochimie 95(5):1047–1055. 
Carroll J, Shannon RJ, Fearnley IM, Walker JE, Hirst J. 2002. Definition of the nuclear 
encoded protein composition of bovine heart mitochondrial complex I. 
Identification of two new subunits. The Journal of biological chemistry 
277(52):50311–50317. 
Celiker MY, Chawla A. 2009. Congenital B12 deficiency following maternal gastric 
bypass. Journal of perinatology : official journal of the California Perinatal 
Association 29(9):640–642. 
Chace D.H. KTA. 2005. A biochemical perspective on the use of tandem mass 
spectrometry for newborn screening and clinical testing. Clin Biochem 38:296–
309. 
Choi KD, Yook JW, Kim MJ, Kim HS, Park YE, Kim JS, Choi JH, Shin JH, Kim DS. 
2013. Possible anticipation associated with a novel splice site mutation in episodic 
ataxia type 2. Neurological sciences : official journal of the Italian Neurological 
Society and of the Italian Society of Clinical Neurophysiology 34(9):1629–1632. 
Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, Ruden DM, Lu X. 2012. Using 
Drosophila melanogaster as a model for genotoxic chemical mutational studies 
with a new program, SnpSift. Frontiers in genetics 3:35. 
Clemencon B, Babot M, Trezeguet V. 2013. The mitochondrial ADP/ATP carrier 
(SLC25 family): pathological implications of its dysfunction. Molecular aspects of 
medicine 34(2–3):485–493. 
Cleves C, Parikh S, Rothner AD, Tepper SJ. 2010. Link between confusional migraine, 
hemiplegic migraine and episodic ataxia type 2: Hypothesis, family genealogy, 
gene typing and classification. Cephalalgia 30(6):740–743. 
78 
Clynes D, Gibbons RJ. 2013. ATRX and the replication of structured DNA. Curr Opin 
Genet Dev 23(3):289–294. 
Couce ML, Castineiras DE, Boveda MD, Bana A, Cocho JA, Iglesias AJ, Colon C, 
Alonso-Fernandez JR, Fraga JM. 2011. Evaluation and long-term follow-up of 
infants with inborn errors of metabolism identified in an expanded screening 
programme. Mol Genet Metab 104(4):470–475. 
Cullup T, Kho AL, Dionisi-Vici C, Brandmeier B, Smith F, Urry Z, Simpson MA, Yau 
S, Bertini E, McClelland V, Al-Owain M, Koelker S, Koerner C, Hoffmann GF, 
Wijburg FA, ten Hoedt AE, Rogers RC, Manchester D, Miyata R, Hayashi M, Said 
E, Soler D, Kroisel PM, Windpassinger C, Filloux FM, Al-Kaabi S, Hertecant J, 
Del Campo M, Buk S, Bodi I, Goebel HH, Sewry CA, Abbs S, Mohammed S, 
Josifova D, Gautel M, Jungbluth H. 2013. Recessive mutations in EPG5 cause Vici 
syndrome, a multisystem disorder with defective autophagy. Nature genetics 
45(1):83–87. 
Curtain RP, Smith RL, Ovcaric M, Griffiths LR. 2006. Minor head trauma-induced 
sporadic hemiplegic migraine coma. Pediatr Neurol 34(4):329–332. 
D’Amico A, Fattori F, Bellacchio E, Catteruccia M, Servidei S, Bertini E. 2013. A new 
de novo missense mutation in MYH2 expands clinical and genetic findings in 
hereditary myosin myopathies. Neuromuscul Disord 23(5):437–440. 
Damaj L, Lupien-Meilleur A, Lortie A, Riou E, Ospina LH, Gagnon L, Vanasse C, 
Rossignol E. 2015. CACNA1A haploinsufficiency causes cognitive impairment, 
autism and epileptic encephalopathy with mild cerebellar symptoms. European 
journal of human genetics : EJHG. 
Danhauser K, Iuso A, Haack TB, Freisinger P, Brockmann K, Mayr JA, Meitinger T, 
Prokisch H. 2011. Cellular rescue-assay aids verification of causative DNA-
variants in mitochondrial complex I deficiency. Mol Genet Metab 103(2):161–166. 
Deegan KL, Jones KM, Zuleta C, Ramirez-Zea M, Lildballe DL, Nexo E, Allen LH. 
2012. Breast milk vitamin B-12 concentrations in Guatemalan women are 
correlated with maternal but not infant vitamin B-12 status at 12 months 
postpartum. The Journal of nutrition 142(1):112–116. 
DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, 
del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, 
Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. 2011. A 
framework for variation discovery and genotyping using next-generation DNA 
sequencing data. Nature genetics 43(5):491–498. 
Deschauer M, Hudson G, Muller T, Taylor RW, Chinnery PF, Zierz S. 2005. A novel 
ANT1 gene mutation with probable germline mosaicism in autosomal dominant 
progressive external ophthalmoplegia. Neuromuscul Disord 15(4):311–315. 
Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in H. 2014. 
Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J 
Haematol 166(4):496–513. 
Dhondt JL. 2007. Neonatal screening: from the ‘Guthrie age’ to the ‘genetic age’. J 
Inherit Metab Dis 30(4):418–422. 
Dhondt JL. 2010. Expanded newborn screening: social and ethical issues. J Inherit 
Metab Dis 33(Suppl 2):S211–217. 
Dimmock D, Tang LY, Schmitt ES, Wong LJ. 2010. Quantitative evaluation of the 
mitochondrial DNA depletion syndrome. Clin Chem 56(7):1119–1127. 
Dinwiddie DL, Smith LD, Miller NA, Atherton AM, Farrow EG, Strenk ME, Soden SE, 
Saunders CJ, Kingsmore SF. 2013. Diagnosis of mitochondrial disorders by 
79 
concomitant next-generation sequencing of the exome and mitochondrial genome. 
Genomics 102(3):148–156. 
Dolce V, Scarcia P, Iacopetta D, Palmieri F. 2005. A fourth ADP/ATP carrier isoform 
in man: identification, bacterial expression, functional characterization and tissue 
distribution. FEBS letters 579(3):633–637. 
Dror DK, Allen LH. 2008. Effect of vitamin B12 deficiency on neurodevelopment in 
infants: current knowledge and possible mechanisms. Nutr Rev 66(5):250–255. 
Ducros A, Denier C, Joutel A, Cecillon M, Lescoat C, Vahedi K, Darcel F, Vicaut E, 
Bousser MG, Tournier-Lasserve E. 2001. The clinical spectrum of familial 
hemiplegic migraine associated with mutations in a neuronal calcium channel. N 
Engl J Med 345(1):17–24. 
Duggan C, Srinivasan K, Thomas T, Samuel T, Rajendran R, Muthayya S, Finkelstein 
JL, Lukose A, Fawzi W, Allen LH, Bosch RJ, Kurpad AV. 2014. Vitamin B-12 
supplementation during pregnancy and early lactation increases maternal, breast 
milk, and infant measures of vitamin B-12 status. The Journal of nutrition 
144(5):758–764. 
Echaniz-Laguna A, Chassagne M, Ceresuela J, Rouvet I, Padet S, Acquaviva C, Nataf 
S, Vinzio S, Bozon D, Mousson de Camaret B. 2012. Complete loss of expression 
of the ANT1 gene causing cardiomyopathy and myopathy. Journal of medical 
genetics 49(2):146–150. 
Epi KC, Epilepsy Phenome/Genome P, Allen AS, Berkovic SF, Cossette P, Delanty N, 
Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, Heinzen EL, 
Hitomi Y, Howell KB, Johnson MR, Kuzniecky R, Lowenstein DH, Lu YF, Madou 
MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O’Brien TJ, Ottman R, Petrovski 
S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil B, 
Alldredge BK, Bautista JF, Berkovic SF, Boro A, Cascino GD, Consalvo D, 
Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, 
Friedman D, Geller EB, Glauser T, Glynn S, Haut SR, Hayward J, Helmers SL, 
Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, 
Kuzniecky R, Lowenstein DH, McGuire SM, Motika PV, Novotny EJ, Ottman R, 
Paolicchi JM, Parent JM, Park K, Poduri A, Scheffer IE, Shellhaas RA, Sherr EH, 
Shih JJ, Singh R, Sirven J, Smith MC, Sullivan J, Lin Thio L, Venkat A, Vining 
EP, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR. 2013. De 
novo mutations in epileptic encephalopathies. Nature 501(7466):217–221. 
Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC. 1999. Mitochondrial disease 
in mouse results in increased oxidative stress. Proceedings of the National 
Academy of Sciences of the United States of America 96(9):4820–4825. 
Estrella J, Wilcken B, Carpenter K, Bhattacharya K, Tchan M, Wiley V. 2014. 
Expanded newborn screening in New South Wales: missed cases. J Inherit Metab 
Dis 37(6):881–887. 
Fassone E, Rahman S. 2012. Complex I deficiency: clinical features, biochemistry and 
molecular genetics. Journal of medical genetics 49(9):578–590. 
Fenech M. 2012. Folate (vitamin B9) and vitamin B12 and their function in the 
maintenance of nuclear and mitochondrial genome integrity. Mutat Res-Fund Mol 
M 733(1–2):21–33. 
Fernhoff PM. 2009. Newborn screening for genetic disorders. Pediatr Clin North Am 
56(3):505–513, Table of Contents. 
Ficicioglu C. 2017. New tools and approaches to newborn screening: ready to open 
Pandora’s box? Cold Spring Harbor molecular case studies 3(3):a001842. 
80 
Ficicioglu C, Payan I. 2006. 3-Methylcrotonyl-CoA carboxylase deficiency: metabolic 
decompensation in a noncompliant child detected through newborn screening. 
Pediatrics 118(6):2555–2556. 
Fiermonte G, De Leonardis F, Todisco S, Palmieri L, Lasorsa FM, Palmieri F. 2004. 
Identification of the mitochondrial ATP-Mg/Pi transporter. Bacterial expression, 
reconstitution, functional characterization, and tissue distribution. The Journal of 
biological chemistry 279(29):30722–30730. 
Finkelstein J, Kurpad A, Thomas T, Bose B, Samuel T, Srinivasan K, Duggan C. 2014. 
Vitamin B12 status in pregnant women and their children in India. FASEB J 28(1). 
Finsterer J, Frank M. 2015. Haematological abnormalities in mitochondrial disorders. 
Singapore Med J 56(7):412–419. 
Fiore C, Trezeguet V, Le Saux A, Roux P, Schwimmer C, Dianoux AC, Noel F, 
Lauquin GJ, Brandolin G, Vignais PV. 1998. The mitochondrial ADP/ATP carrier: 
structural, physiological and pathological aspects. Biochimie 80(2):137–150. 
Fisher DZ, Chaudhary N, Blobel G. 1986. cDNA sequencing of nuclear lamins A and C 
reveals primary and secondary structural homology to intermediate filament 
proteins. Proceedings of the National Academy of Sciences of the United States of 
America 83(17):6450–6454. 
Fokstuen S, Makrythanasis P, Hammar E, Guipponi M, Ranza E, Varvagiannis K, 
Santoni FA, Albarca-Aguilera M, Poleggi ME, Couchepin F, Brockmann C, 
Mauron A, Hurst SA, Moret C, Gehrig C, Vannier A, Bevillard J, Araud T, Gimelli 
S, Stathaki E, Paoloni-Giacobino A, Bottani A, Sloan-Bena F, Sizonenko LD, 
Mostafavi M, Hamamy H, Nouspikel T, Blouin JL, Antonarakis SE. 2016. 
Experience of a multidisciplinary task force with exome sequencing for Mendelian 
disorders. Human genomics 10(1):24. 
Freilinger T, Bohe M, Wegener B, Muller-Myhsok B, Dichgans M, Knoblauch H. 2008. 
Expansion of the phenotypic spectrum of the CACNA1A T666M mutation: a 
family with familial hemiplegic migraine type 1, cerebellar atrophy and mental 
retardation. Cephalalgia 28(4):403–407. 
Galmiche L, Serre V, Beinat M, Assouline Z, Lebre AS, Chretien D, Nietschke P, 
Benes V, Boddaert N, Sidi D, Brunelle F, Rio M, Munnich A, Rotig A. 2011. 
Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. 
Hum Mutat 32(11):1225–1231. 
Garcia-Baro-Huarte M, Iglesias-Mohedano AM, Slocker-Barrio M, Vazquez-Lopez M, 
Garcia-Morin M, Miranda-Herrero MC, Castro-Castro P. 2014. Phenotypic 
variability in a four generation family with a p.Thr666Met CACNA1A gene 
mutation. Pediatr Neurol 51(4):557–559. 
Garcia CD, Torres-Sanchez L, Chen J, Schnaas L, Hernandez C, Osorio E, Portillo MG, 
Lopez-Carrillo L. 2009. Maternal MTHFR 677C > T genotype and dietary intake of 
folate and vitamin B-12: their impact on child neurodevelopment. Nutr Neurosci 
12(1):13–20. 
Garg U, Dasouki M. 2006. Expanded newborn screening of inherited metabolic 
disorders by tandem mass spectrometry: clinical and laboratory aspects. Clinical 
biochemistry 39(4):315–332. 
Germain DP. 2017. Pseudoxanthoma elasticum. Orphanet J Rare Dis 12(1):85. 
Giles RE, Blanc H, Cann HM, Wallace DC. 1980. Maternal inheritance of human 
mitochondrial DNA. Proceedings of the National Academy of Sciences of the 
United States of America 77(11):6715–6719. 
81 
Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, Wallace DC. 1997. 
A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a 
deficiency in the heart/muscle isoform of the adenine nucleotide translocator. 
Nature genetics 16(3):226–234. 
Graham SM, Arvela OM, Wise GA. 1992. Long-term neurologic consequences of 
nutritional vitamin B12 deficiency in infants. J Pediatr 121(5 Pt 1):710–714. 
Gramer G, Abdoh G, Ben-Omran T, Shahbeck N, Ali R, Mahmoud L, Fang-Hoffmann 
J, Hoffmann GF, Al Rifai H, Okun JG. 2017. Newborn screening for remethylation 
disorders and vitamin B12 deficiency-evaluation of new strategies in cohorts from 
Qatar and Germany. World journal of pediatrics : WJP 13(2):136–143. 
Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, 
Nussbaum RL, O’Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, 
Biesecker LG, American College of Medical G, Genomics. 2013. ACMG 
recommendations for reporting of incidental findings in clinical exome and genome 
sequencing. Genetics in medicine : official journal of the American College of 
Medical Genetics 15(7):565–574. 
Grunert SC, Stucki M, Morscher RJ, Suormala T, Burer C, Burda P, Christensen E, 
Ficicioglu C, Herwig J, Kolker S, Moslinger D, Pasquini E, Santer R, Schwab KO, 
Wilcken B, Fowler B, Yue WW, Baumgartner MR. 2012. 3-methylcrotonyl-CoA 
carboxylase deficiency: clinical, biochemical, enzymatic and molecular studies in 
88 individuals. Orphanet J Rare Dis 7:31. 
Gurok U, Bork K, Nuber U, Sporle R, Nohring S, Horstkorte R. 2007. Expression of 
Ndufb11 encoding the neuronal protein 15.6 during neurite outgrowth and 
development. Gene expression patterns : GEP 7(3):370–374. 
Guthrie R, Susi A. 1963. A Simple Phenylalanine Method for Detecting Phenyl-
ketonuria in Large Populations of Newborn Infants. Pediatrics 32:338–343. 
Haack TB, Gorza M, Danhauser K, Mayr JA, Haberberger B, Wieland T, Kremer L, 
Strecker V, Graf E, Memari Y, Ahting U, Kopajtich R, Wortmann SB, Rodenburg 
RJ, Kotzaeridou U, Hoffmann GF, Sperl W, Wittig I, Wilichowski E, Schottmann 
G, Schuelke M, Plecko B, Stephani U, Strom TM, Meitinger T, Prokisch H, 
Freisinger P. 2014. Phenotypic spectrum of eleven patients and five novel MTFMT 
mutations identified by exome sequencing and candidate gene screening. Mol 
Genet Metab 111(3):342–352. 
Haack TB, Haberberger B, Frisch EM, Wieland T, Iuso A, Gorza M, Strecker V, Graf 
E, Mayr JA, Herberg U, Hennermann JB, Klopstock T, Kuhn KA, Ahting U, Sperl 
W, Wilichowski E, Hoffmann GF, Tesarova M, Hansikova H, Zeman J, Plecko B, 
Zeviani M, Wittig I, Strom TM, Schuelke M, Freisinger P, Meitinger T, 
Prokisch H. 2012. Molecular diagnosis in mitochondrial complex I deficiency using 
exome sequencing. Journal of medical genetics 49(4):277–283. 
Haan J, Terwindt GM, van den Maagdenberg AM, Stam AH, Ferrari MD. 2008. A 
review of the genetic relation between migraine and epilepsy. Cephalalgia 
28(2):105–113. 
Hadano S, Benn SC, Kakuta S, Otomo A, Sudo K, Kunita R, Suzuki-Utsunomiya K, 
Mizumura H, Shefner JM, Cox GA, Iwakura Y, Brown RH, Jr., Ikeda JE. 2006. 
Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit 
age-dependent neurological deficits and altered endosome trafficking. Hum Mol 
Genet 15(2):233–250. 
82 
Hannibal L, Kim J, Brasch NE, Wang S, Rosenblatt DS, Banerjee R, Jacobsen DW. 
2009. Processing of alkylcobalamins in mammalian cells: A role for the MMACHC 
(cblC) gene product. Mol Genet Metab 97(4):260–266. 
Hannibal L, Lysne V, Bjorke-Monsen AL, Behringer S, Grunert SC, Spiekerkoetter U, 
Jacobsen DW, Blom HJ. 2016. Biomarkers and Algorithms for the Diagnosis of 
Vitamin B12 Deficiency. Frontiers in molecular biosciences 3:27. 
Harms E, Olgemoller B. 2011. Neonatal screening for metabolic and endocrine 
disorders. Deutsches Arzteblatt international 108(1–2):11–21; quiz 22. 
Hayashida T, Saito Y, Ishii A, Yamada H, Itakura A, Minato T, Fukuyama T, 
Maegaki Y, Hirose S. 2017. CACNA1A-related early-onset encephalopathy with 
myoclonic epilepsy: A case report. Brain Dev. 
Hikmat O, Eichele T, Tzoulis C, Bindoff LA. 2017. Understanding the Epilepsy in 
POLG Related Disease. International journal of molecular sciences 18(9). 
Hino-Fukuyo N, Kikuchi A, Arai-Ichinoi N, Niihori T, Sato R, Suzuki T, Kudo H, 
Sato Y, Nakayama T, Kakisaka Y, Kubota Y, Kobayashi T, Funayama R, Naka-
yama K, Uematsu M, Aoki Y, Haginoya K, Kure S. 2015. Genomic analysis 
identifies candidate pathogenic variants in 9 of 18 patients with unexplained West 
syndrome. Hum Genet 134(6):649–658. 
Hinton CF, Ojodu JA, Fernhoff PM, Rasmussen SA, Scanlon KS, Hannon WH. 2010. 
Maternal and Neonatal Vitamin B12 Deficiency Detected through Expanded 
Newborn Screening-United States, 2003–2007. J Pediatr 157(1):162–163. 
Hoefs SJ, Rodenburg RJ, Smeitink JA, van den Heuvel LP. 2012. Molecular base of 
biochemical complex I deficiency. Mitochondrion 12(5):520–532. 
Hoffman EP. 2001. Hemiplegic migraine–downstream of a single-base change. N Engl 
J Med 345(1):57–59. 
Hoffmann GF, Lindner M, Loeber JG. 2014. 50 years of newborn screening. J Inherit 
Metab Dis 37(2):163–164. 
Holtmann M, Opp J, Tokarzewski M, Korn-Merker E. 2002. Human epilepsy, episodic 
ataxia type 2, and migraine. Lancet 359(9301):170–171. 
Honzik T, Tesarova M, Magner M, Mayr J, Jesina P, Vesela K, Wenchich L, Szenti-
vanyi K, Hansikova H, Sperl W, Zeman J. 2012. Neonatal onset of mitochondrial 
disorders in 129 patients: clinical and laboratory characteristics and a new approach 
to diagnosis. J Inherit Metab Dis 35(5):749–759. 
Huigsloot M, Nijtmans LG, Szklarczyk R, Baars MJ, van den Brand MA, Hendriks-
franssen MG, van den Heuvel LP, Smeitink JA, Huynen MA, Rodenburg RJ. 2011. 
A mutation in C2orf64 causes impaired cytochrome c oxidase assembly and 
mitochondrial cardiomyopathy. Am J Hum Genet 88(4):488–493. 
Hure AJ, Collins CE, Smith R. 2012. A longitudinal study of maternal folate and 
vitamin B12 status in pregnancy and postpartum, with the same infant markers at 6 
months of age. Maternal and child health journal 16(4):792–801. 
Irevall T, Axelsson I, Naumburg E. 2017. B12 deficiency is common in infants and is 
accompanied by serious neurological symptoms. Acta paediatrica 106(1):101–104. 
Italian Society for the Study of Inborn Metabolic Diseases and Newborn Screening S. 
2015. 
Janeckova H, Hron K, Wojtowicz P, Hlidkova E, Baresova A, Friedecky D, Zidkova L, 
Hornik P, Behulova D, Prochazkova D, Vinohradska H, Peskova K, Bruheim P, 
Smolka V, Stastna S, Adam T. 2012. Targeted metabolomic analysis of plasma 
samples for the diagnosis of inherited metabolic disorders. Journal of chromato-
graphy A 1226:11–17. 
83 
Jen J. 1999. Calcium channelopathies in the central nervous system. Curr Opin 
Neurobiol 9(3):274–280. 
Jen J, Kim GW, Baloh RW. 2004. Clinical spectrum of episodic ataxia type 2. 
Neurology 62(1):17–22. 
Jen J, Wan J, Graves M, Yu H, Mock AF, Coulin CJ, Kim G, Yue Q, Papazian DM, 
Baloh RW. 2001. Loss-of-function EA2 mutations are associated with impaired 
neuromuscular transmission. Neurology 57(10):1843–1848. 
Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA, members of the 
NE, Policy Advisory B. 2018. Sequencing Newborns: A Call for Nuanced Use of 
Genomic Technologies. Hastings Cent Rep 48 Suppl 2:S2–S6. 
Jonckheere AI, Renkema GH, Bras M, van den Heuvel LP, Hoischen A, Gilissen C, 
Nabuurs SB, Huynen MA, de Vries MC, Smeitink JA, Rodenburg RJ. 2013. A 
complex V ATP5A1 defect causes fatal neonatal mitochondrial encephalopathy. 
Brain 136(Pt 5):1544–1554. 
Joost K. 2012. Selective screening of metabolic diseases in Estonia: the application of 
new diagnostic methods. Doctoral dissertation. Tartu University Press 270. 
Joost K, Ounap K, Zordania R, Uudelepp ML, Olsen RK, Kall K, Kilk K, Soomets U, 
Kahre T. 2012a. Prevalence of Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase 
Deficiency in Estonia. Jimd Rep 2:79–85. 
Joost K, Rodenburg RJ, Piirsoo A, van den Heuvel L, Zordania R, Poder H, Talvik I, 
Kilk K, Soomets U, Ounap K. 2012b. A Diagnostic Algorithm for Mitochondrial 
Disorders in Estonian Children. Mol Syndromol 3(3):113–119. 
Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, Kullmann DM, 
Hanna MG. 2001. Human epilepsy associated with dysfunction of the brain P/Q-
type calcium channel. Lancet 358(9284):801–807. 
Kaname T, Yanagi K, Naritomi K. 2014. A commentary on the promise of whole-
exome sequencing in medical genetics. J Hum Genet 59(3):117–118. 
Kasper DC, Ratschmann R, Metz TF, Mechtler TP, Moslinger D, Konstantopoulou V, 
Item CB, Pollak A, Herkner KR. 2010. The national Austrian newborn screening 
program – eight years experience with mass spectrometry. past, present, and future 
goals. Wien Klin Wochenschr 122(21–22):607–613. 
Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, Keranen S, 
Peltonen L, Suomalainen A. 2000. Role of adenine nucleotide translocator 1 in 
mtDNA maintenance. Science 289(5480):782–785. 
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. 2014. A general 
framework for estimating the relative pathogenicity of human genetic variants. 
Nature genetics 46(3):310–315. 
Kisler JE, Whittaker RG, McFarland R. 2010. Mitochondrial diseases in childhood: a 
clinical approach to investigation and management. Dev Med Child Neurol 
52(5):422–433. 
Klee GG. 2000. Cobalamin and folate evaluation: measurement of methylmalonic acid 
and homocysteine vs vitamin B(12) and folate. Clin Chem 46(8 Pt 2):1277–1283. 
Klingenberg M. 1989. Molecular aspects of the adenine nucleotide carrier from 
mitochondria. Arch Biochem Biophys 270(1):1–14. 
Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, 
Wilson RK, Ding L. 2009. VarScan: variant detection in massively parallel 
sequencing of individual and pooled samples. Bioinformatics 25(17):2283–2285. 
Koebnick C, Hoffmann I, Dagnelie PC, Heins UA, Wickramasinghe SN, Ratnayaka ID, 
Gruendel S, Lindemans J, Leitzmann C. 2004. Long-term ovo-lacto vegetarian diet 
84 
impairs vitamin B-12 status in pregnant women. The Journal of nutrition 
134(12):3319–3326. 
Koene S, Rodenburg RJ, van der Knaap MS, Willemsen MA, Sperl W, Laugel V, 
Ostergaard E, Tarnopolsky M, Martin MA, Nesbitt V, Fletcher J, Edvardson S, 
Procaccio V, Slama A, van den Heuvel LP, Smeitink JA. 2012. Natural disease 
course and genotype-phenotype correlations in Complex I deficiency caused by 
nuclear gene defects: what we learned from 130 cases. J Inherit Metab Dis 
35(5):737–747. 
Koenig MK. 2008. Presentation and diagnosis of mitochondrial disorders in children. 
Pediatr Neurol 38(5):305–313. 
Kohda M, Tokuzawa Y, Kishita Y, Nyuzuki H, Moriyama Y, Mizuno Y, Hirata T, 
Yatsuka Y, Yamashita-Sugahara Y, Nakachi Y, Kato H, Okuda A, Tamaru S, 
Borna NN, Banshoya K, Aigaki T, Sato-Miyata Y, Ohnuma K, Suzuki T, Nagao A, 
Maehata H, Matsuda F, Higasa K, Nagasaki M, Yasuda J, Yamamoto M, 
Fushimi T, Shimura M, Kaiho-Ichimoto K, Harashima H, Yamazaki T, Mori M, 
Murayama K, Ohtake A, Okazaki Y. 2016. A Comprehensive Genomic Analysis 
Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex 
Deficiencies. PLoS genetics 12(1):e1005679. 
Koopman WJ, Willems PH, Smeitink JA. 2012. Monogenic mitochondrial disorders. N 
Engl J Med 366(12):1132–1141. 
Kors EE, Haan J, Giffin NJ, Pazdera L, Schnittger C, Lennox GG, Terwindt GM, 
Vermeulen FL, Van den Maagdenberg AM, Frants RR, Ferrari MD. 2003. 
Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation: a 
description of 5 families with familial hemiplegic migraine. Arch Neurol 
60(5):684–688. 
Korver-Keularts IM, de Visser M, Bakker HD, Wanders RJ, Vansenne F, Scholte HR, 
Dorland L, Nicolaes GA, Spaapen LM, Smeets HJ, Hendrickx AT, van den Bosch 
BJ. 2015. Two Novel Mutations in the SLC25A4 Gene in a Patient with Mito-
chondrial Myopathy. Jimd Rep 22:39–45. 
Krishnan AV, Bostock H, Ip J, Hayes M, Watson S, Kiernan MC. 2008. Axonal 
function in a family with episodic ataxia type 2 due to a novel mutation. J Neurol 
255(5):750–755. 
Kucharczyk R, Ezkurdia N, Couplan E, Procaccio V, Ackerman SH, Blondel M, di 
Rago JP. 2010. Consequences of the pathogenic T9176C mutation of human 
mitochondrial DNA on yeast mitochondrial ATP synthase. Biochimica et bio-
physica acta 1797(6–7):1105–1112. 
Kuhne T, Bubl R, Baumgartner R. 1991. Maternal vegan diet causing a serious infantile 
neurological disorder due to vitamin B12 deficiency. Eur J Pediatr 150(3):205–208. 
Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous 
variants on protein function using the SIFT algorithm. Nature Protocols 4(7):1073–
1082. 
la Marca G. 2014. Mass spectrometry in clinical chemistry: the case of newborn 
screening. Journal of pharmaceutical and biomedical analysis 101:174–182. 
Landau YE, Waisbren SE, Chan LM, Levy HL. 2017. Long-term outcome of expanded 
newborn screening at Boston children’s hospital: benefits and challenges in 
defining true disease. J Inherit Metab Dis 40(2):209–218. 
Lehotay DC, Hall P, Lepage J, Eichhorst JC, Etter ML, Greenberg CR. 2011. LC-
MS/MS progress in newborn screening. Clinical biochemistry 44(1):21–31. 
85 
Levy HL. 2010. Newborn screening conditions: What we know, what we do not know, 
and how we will know it. Genetics in medicine : official journal of the American 
College of Medical Genetics 12(12 Suppl):S213–214. 
Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 25(14):1754–1760. 
Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler 
transform. Bioinformatics 26(5):589–595. 
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, 
Durbin R, Genome Project Data Processing S. 2009. The Sequence Alignment/Map 
format and SAMtools. Bioinformatics 25(16):2078–2079. 
Liao Y, Anttonen AK, Liukkonen E, Gaily E, Maljevic S, Schubert S, Bellan-Koch A, 
Petrou S, Ahonen VE, Lerche H, Lehesjoki AE. 2010. SCN2A mutation associated 
with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. Neurology 
75(16):1454–1458. 
Lichtenstein DA, Crispin AW, Sendamarai AK, Campagna DR, Schmitz-Abe K, Sousa 
CM, Kafina MD, Schmidt PJ, Niemeyer CM, Porter J, May A, Patnaik MM, 
Heeney MM, Kimmelman A, Bottomley SS, Paw BH, Markianos K, Fleming MD. 
2016. A recurring mutation in the respiratory complex 1 protein NDUFB11 is 
responsible for a novel form of X-linked sideroblastic anemia. Blood 
128(15):1913–1917. 
Lillevali H, Margus, K., Õunap, K., Metspalu, A. 2000. Mutation 985A>G in the 
MCAD gene shows low incidence in Estonian population. Hum Mutat 15 (3):293–
294. 
Lillevali H, Reinson K, Muru K, Simenson K, Murumets U, Mols T, Ounap K. 2017. 
Hyperphenylalaninaemias in Estonia: Genotype-Phenotype Correlation and 
Comparative Overview of the Patient Cohort Before and After Nation-Wide 
Neonatal Screening. Jimd Rep. 
Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, Marcell PD, 
Stabler SP, Allen RH. 1988. Neuropsychiatric disorders caused by cobalamin 
deficiency in the absence of anemia or macrocytosis. N Engl J Med 318(26):1720–
1728. 
Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, 
Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF. 2011. Efficacy 
and outcome of expanded newborn screening for metabolic diseases–report of 10 
years from South-West Germany. Orphanet J Rare Dis 6:44. 
Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, Hoffmann GF, 
Vittozzi L. 2012. Newborn screening programmes in Europe; arguments and efforts 
regarding harmonization. Part 1. From blood spot to screening result. J Inherit 
Metab Dis 35(4):603–611. 
Lorson CL, Androphy EJ. 1998. The domain encoded by exon 2 of the survival motor 
neuron protein mediates nucleic acid binding. Hum Mol Genet 7(8):1269–1275. 
Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, Procaccio V, 
Wallace DC. 2013. mtDNA Variation and Analysis Using Mitomap and Mito-
master. Current protocols in bioinformatics / editoral board, Andreas D Baxevanis 
[et al] 44:1 23 21–26. 
Lovblad K, Ramelli G, Remonda L, Nirkko AC, Ozdoba C, Schroth G. 1997. 
Retardation of myelination due to dietary vitamin B12 deficiency: cranial MRI 
findings. Pediatr Radiol 27(2):155–158. 
86 
Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Duno M, 
Skogstrand K, Olsen RK, Jensen UG, Cohen A, Larsen N, Saugmann-Jensen P, 
Gregersen N, Brandt NJ, Christensen E, Skovby F, Norgaard-Pedersen B. 2012. 
Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and 
Greenland–experience and development of a routine program for expanded 
newborn screening. Mol Genet Metab 107(3):281–293. 
Luo X, Pitkanen S, Kassovska-Bratinova S, Robinson BH, Lehotay DC. 1997. 
Excessive formation of hydroxyl radicals and aldehydic lipid peroxidation products 
in cultured skin fibroblasts from patients with complex I deficiency. J Clin Invest 
99(12):2877–2882. 
Luo X, Rosenfeld JA, Yamamoto S, Harel T, Zuo Z, Hall M, Wierenga KJ, Pastore MT, 
Bartholomew D, Delgado MR, Rotenberg J, Lewis RA, Emrick L, Bacino CA, 
Eldomery MK, Coban Akdemir Z, Xia F, Yang Y, Lalani SR, Lotze T, Lupski JR, 
Lee B, Bellen HJ, Wangler MF, Members of the UDN. 2017. Clinically severe 
CACNA1A alleles affect synaptic function and neurodegeneration differentially. 
PLoS genetics 13(7):e1006905. 
Lysne V, Strand E, Svingen GF, Bjorndal B, Pedersen ER, Midttun O, Olsen T, Ueland 
PM, Berge RK, Nygard O. 2016. Peroxisome Proliferator-Activated Receptor 
Activation is Associated with Altered Plasma One-Carbon Metabolites and B-
Vitamin Status in Rats. Nutrients 8(1). 
Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, 
Busch U, Krone N, v Kries R, Roscher AA. 2005. Population spectrum of ACADM 
genotypes correlated to biochemical phenotypes in newborn screening for medium-
chain acyl-CoA dehydrogenase deficiency. Hum Mutat 25(5):443–452. 
Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. 2011. What can 
exome sequencing do for you? J Med Genet 48(9):580–589. 
Mallmann RT, Elgueta C, Sleman F, Castonguay J, Wilmes T, van den Maagdenberg A, 
Klugbauer N. 2013. Ablation of Ca(V)2.1 voltage-gated Ca(2)(+) channels in 
mouse forebrain generates multiple cognitive impairments. PLoS One 
8(10):e78598. 
Mantuano E, Romano S, Veneziano L, Gellera C, Castellotti B, Caimi S, Testa D, 
Estienne M, Zorzi G, Bugiani M, Rajabally YA, Barcina MJ, Servidei S, Panico A, 
Frontali M, Mariotti C. 2010. Identification of novel and recurrent CACNA1A gene 
mutations in fifteen patients with episodic ataxia type 2. J Neurol Sci 291(1–2):30–
36. 
Marble M, Copeland S, Khanfar N, Rosenblatt DS. 2008. Neonatal vitamin B12 
deficiency secondary to maternal subclinical pernicious anemia: identification by 
expanded newborn screening. J Pediatr 152(5):731–733. 
McCabe LL, McCabe ER. 2008. Expanded newborn screening: implications for 
genomic medicine. Annu Rev Med 59:163–175. 
McCaddon A. 2013. Vitamin B12 in neurology and ageing; clinical and genetic aspects. 
Biochimie 95(5):1066–1076. 
McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, 
Ahlman H, Allen JJ, Antonozzi I, Archer S, Au S, Auray-Blais C, Baker M, 
Bamforth F, Beckmann K, Pino GB, Berberich SL, Binard R, Boemer F, Bonham J, 
Breen NN, Bryant SC, Caggana M, Caldwell SG, Camilot M, Campbell C, 
Carducci C, Bryant SC, Caggana M, Caldwell SG, Camilot M, Campbell C, 
Carducci C, Cariappa R, Carlisle C, Caruso U, Cassanello M, Castilla AM, Ramos 
DE, Chakraborty P, Chandrasekar R, Ramos AC, Cheillan D, Chien YH, Childs 
87 
TA, Chrastina P, Sica YC, de Juan JA, Colandre ME, Espinoza VC, Corso G, 
Currier R, Cyr D, Czuczy N, D’Apolito O, Davis T, de Sain-Van der Velden MG, 
Delgado Pecellin C, Di Gangi IM, Di Stefano CM, Dotsikas Y, Downing M, 
Downs SM, Dy B, Dymerski M, Rueda I, Elvers B, Eaton R, Eckerd BM, El 
Mougy F, Eroh S, Espada M, Evans C, Fawbush S, Fijolek KF, Fisher L, 
Franzson L, Frazier DM, Garcia LR, Bermejo MS, Gavrilov D, Gerace R, 
Giordano G, Irazabal YG, Greed LC, Grier R, Grycki E, Gu X, Gulamali-Majid F, 
Hagar AF, Han L, Hannon WH, Haslip C, Hassan FA, He M, Hietala A, 
Himstedt L, Hoffman GL, Hoffman W, Hoggatt P, Hopkins PV, Hougaard DM, 
Hughes K, Hunt PR, Hwu WL, Hynes J, Ibarra-Gonzalez I, Ingham CA, 
Ivanova M, Jacox WB, John C, Johnson JP, Jonsson JJ, Karg E, Kasper D, 
Klopper B, Katakouzinos D, Khneisser I, Knoll D, Kobayashi H, Koneski R, 
Kozich V, Kouapei R, Kohlmueller D, Kremensky I, la Marca G, Lavochkin M, 
Lee SY, Lehotay DC, Lemes A, Lepage J, Lesko B, Lewis B, Lim C, Linard S, 
Lindner M, Lloyd-Puryear MA, Lorey F, Loukas YL, Luedtke J, Maffitt N, 
Magee JF, Manning A, Manos S, Marie S, Hadachi SM, Marquardt G, Martin SJ, 
Matern D, Mayfield Gibson SK, Mayne P, McCallister TD, McCann M, McClure J, 
McGill JJ, McKeever CD, McNeilly B, Morrissey MA, Moutsatsou P, 
Mulcahy EA, Nikoloudis D, Norgaard-Pedersen B, Oglesbee D, Oltarzewski M, 
Ombrone D, Ojodu J, Papakonstantinou V, Reoyo SP, Park HD, Pasquali M, 
Pasquini E, Patel P, Pass KA, Peterson C, Pettersen RD, Pitt JJ, Poh S, Pollak A, 
Porter C, Poston PA, Price RW, Queijo C, Quesada J, Randell E, Ranieri E, 
Raymond K, Reddic JE, Reuben A, Ricciardi C, Rinaldo P, Rivera JD, Roberts A, 
Rocha H, Roche G, Greenberg CR, Mellado JM, Juan-Fita MJ, Ruiz C, 
Ruoppolo M, Rutledge SL, Ryu E, Saban C, Sahai I, Garcia-Blanco MI, Santiago-
Borrero P, Schenone A, Schoos R, Schweitzer B, Scott P, Seashore MR, 
Seeterlin MA, Sesser DE, Sevier DW, Shone SM, Sinclair G, Skrinska VA, 
Stanley EL, Strovel ET, Jones AL, Sunny S, Takats Z, Tanyalcin T, Teofoli F, 
Thompson JR, Tomashitis K, Domingos MT, Torres J, Torres R, Tortorelli S, 
Turi S, Turner K, Tzanakos N, Valiente AG, Vallance H, Vela-Amieva M, 
Vilarinho L, von Dobeln U, Vincent MF, Vorster BC, Watson MS, Webster D, 
Weiss S, Wilcken B, Wiley V, Williams SK, Willis SA, Woontner M, Wright K, 
Yahyaoui R, Yamaguchi S, Yssel M, Zakowicz WM. 2011. Clinical validation of 
cutoff target ranges in newborn screening of metabolic disorders by tandem mass 
spectrometry: a worldwide collaborative project. Genetics in medicine : official 
journal of the American College of Medical Genetics 13(3):230–254. 
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Gari-
mella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome 
Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA 
sequencing data. Genome research 20(9):1297–1303. 
Mikelsaar RV, Zordania R, Viikmaa M, Kudrjavtseva G. 1998. Neonatal screening for 
congenital hypothyroidism in Estonia. J Med Screen 5(1):20–21. 
Millington DS, Kodo N, Terada N, Roe D, Chace DH. 1991. The Analysis of 
Diagnostic Markers of Genetic-Disorders in Human Blood and Urine Using 
Tandem Mass-Spectrometry with Liquid Secondary Ion Mass-Spectrometry. Int J 
Mass Spectrom 111:211–228. 
Mimaki M, Wang X, McKenzie M, Thorburn DR, Ryan MT. 2012. Understanding 
mitochondrial complex I assembly in health and disease. Biochimica et biophysica 
acta 1817(6):851–862. 
88 
Minet JC, Bisse E, Aebischer CP, Beil A, Wieland H, Lutschg J. 2000. Assessment of 
vitamin B-12, folate, and vitamin B-6 status and relation to sulfur amino acid 
metabolism in neonates. The American journal of clinical nutrition 72(3):751–757. 
Minnet C, Koc A, Aycicek A, Kocyigit A. 2011. Vitamin B12 treatment reduces 
mononuclear DNA damage. Pediatr Int 53(6):1023–1027. 
Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. 2008. Effects of folate and 
vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. 
Food and nutrition bulletin 29(2 Suppl):S101–111; discussion S112–105. 
Monsen AL, Refsum H, Markestad T, Ueland PM. 2003. Cobalamin status and its 
biochemical markers methylmalonic acid and homocysteine in different age groups 
from 4 days to 19 years. Clin Chem 49(12):2067–2075. 
Monsen ALB, Ueland PM, Vollset SE, Guttormsen AB, Markestad T, Solheim E, 
Refsum H. 2001. Determinants of cobalamin status in newborns. Pediatrics 
108(3):624–630. 
Morava E, van den Heuvel L, Hol F, de Vries MC, Hogeveen M, Rodenburg RJ, 
Smeitink JA. 2006a. Mitochondrial disease criteria: diagnostic applications in 
children. Neurology 67(10):1823–1826. 
Morava E, van den Heuvel L, Hol F, de Vries MC, Hogeveen M, Rodenburg RJ, 
Smeitink JAM. 2006b. Mitochondrial disease criteria – Diagnostic applications in 
children. Neurology 67(10):1823–1826. 
Munnich A, Rotig A, Chretien D, Cormier V, Bourgeron T, Bonnefont JP, Saudubray 
JM, Rustin P. 1996. Clinical presentation of mitochondrial disorders in childhood. J 
Inherit Metab Dis 19(4):521–527. 
Murphy SP, Allen LH. 2003. Nutritional importance of animal source foods. The 
Journal of nutrition 133(11 Suppl 2):3932S–3935S. 
Muthayya S, Dwarkanath P, Mhaskar M, Mhaskar R, Thomas A, Duggan C, Fawzi 
WW, Bhat S, Vaz M, Kurpad A. 2006. The relationship of neonatal serum vitamin 
B12 status with birth weight. Asia Pacific journal of clinical nutrition 15(4):538–
543. 
Nachbauer W, Nocker M, Karner E, Stankovic I, Unterberger I, Eigentler A, 
Schneider R, Poewe W, Delazer M, Boesch S. 2014. Episodic ataxia type 2: 
phenotype characteristics of a novel CACNA1A mutation and review of the 
literature. J Neurol 261(5):983–991. 
Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, Wicklund M, 
Barohn RJ, Ensrud E, Griggs RC, Gronseth G, Amato AA, Guideline Development 
Subcommittee of the American Academy of N, Practice Issues Review Panel of the 
American Association of N, Electrodiagnostic M. 2014. Evidence-based guideline 
summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of 
the guideline development subcommittee of the American Academy of Neurology 
and the practice issues review panel of the American Association of Neuromuscular 
& Electrodiagnostic Medicine. Neurology 83(16):1453–1463. 
Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, Mensenkamp AR, 
Rodenburg RJ, Yntema HG, Spruijt L, Vermeer S, Rinne T, van Gassen KL, 
Bodmer D, Lugtenberg D, de Reuver R, Buijsman W, Derks RC, Wieskamp N, van 
den Heuvel B, Ligtenberg MJ, Kremer H, Koolen DA, van de Warrenburg BP, 
Cremers FP, Marcelis CL, Smeitink JA, Wortmann SB, van Zelst-Stams WA, 
Veltman JA, Brunner HG, Scheffer H, Nelen MR. 2013. A post-hoc comparison of 
the utility of sanger sequencing and exome sequencing for the diagnosis of 
heterogeneous diseases. Hum Mutat 34(12):1721–1726. 
89 
Nissenkorn A, Zeharia A, Lev D, Fatal-Valevski A, Barash V, Gutman A, Harel S, 
Lerman-Sagie T. 1999. Multiple presentation of mitochondrial disorders. Arch Dis 
Child 81(3):209–214. 
Nouws J, Nijtmans LG, Smeitink JA, Vogel RO. 2012. Assembly factors as a new class 
of disease genes for mitochondrial complex I deficiency: cause, pathology and 
treatment options. Brain 135(Pt 1):12–22. 
Obeid R, Morkbak AL, Munz W, Nexo E, Herrmann W. 2006. The cobalamin-binding 
proteins transcobalamin and haptocorrin in maternal and cord blood sera at birth. 
Clin Chem 52(2):263–269. 
Ochman H, Moran NA. 2001. Genes lost and genes found: Evolution of bacterial 
pathogenesis and symbiosis. Science 292(5519):1096–1098. 
Ohmori I, Ouchida M, Kobayashi K, Jitsumori Y, Mori A, Michiue H, Nishiki T, 
Ohtsuka Y, Matsui H. 2013. CACNA1A variants may modify the epileptic pheno-
type of Dravet syndrome. Neurobiol Dis 50:209–217. 
Ohtake A, Murayama K, Mori M, Harashima H, Yamazaki T, Tamaru S, Yamashita Y, 
Kishita Y, Nakachi Y, Kohda M, Tokuzawa Y, Mizuno Y, Moriyama Y, Kato H, 
Okazaki Y. 2014. Diagnosis and molecular basis of mitochondrial respiratory chain 
disorders: exome sequencing for disease gene identification. Biochimica et bio-
physica acta 1840(4):1355–1359. 
Ombrone D, Giocaliere E, Forni G, Malvagia S, la Marca G. 2016. Expanded newborn 
screening by mass spectrometry: New tests, future perspectives. Mass Spectrom 
Rev 35(1):71–84. 
Ounap K. 1999. Phenylketonuria in Estonia: incidence, newborn screening, diagnosis, 
clinical characterization and genotype/phenotype correlation. Doctoral dissertation. 
Tartu University Press 79. 
Ounap K, Lillevali H, Metspalu A, Lipping-Sitska M. 1998. Development of the 
phenylketonuria screening programme in Estonia. J Med Screen 5(1):22–23. 
Pagniez-Mammeri H. LS, Legrand A., Bénit P., Rustin P., Slama A. 2012. Mito-
chondrial complex I deficiency of nuclear origin I. Structural genes. Mol Genet 
Metab 105:163–172. 
Pajusalu S, Mencacci NE, Atasu B, Rein R, Puusepp S, Reinson K, Tomberg T, 
Wiethoff S, Papandreou A, Warner TT, Balint B, Bhatia KP, Gasser T, Simon-
Sanchez J, Kurian MA, Acuna K, Pak M, Lohmann E, Wood N, Õunap K. 2017. 
BZRAP1 (RIM-BP1) mutations cause a novel autosomal recessive dystonia 
syndrome. European Human Genetics Conference, 27–30052017. Copenhagen, 
Denmark: Springer Nature. 
Palmieri L, Alberio S, Pisano I, Lodi T, Meznaric-Petrusa M, Zidar J, Santoro A, 
Scarcia P, Fontanesi F, Lamantea E, Ferrero I, Zeviani M. 2005. Complete loss-of-
function of the heart/muscle-specific adenine nucleotide translocator is associated 
with mitochondrial myopathy and cardiomyopathy. Hum Mol Genet 14(20):3079–
3088. 
Phadke R. 2017. Myopathology of Adult and Paediatric Mitochondrial Diseases. J Clin 
Med 6(7). 
Picardi E, Pesole G. 2012. Mitochondrial genomes gleaned from human whole-exome 
sequencing. Nat Methods 9(6):523–524. 
Pietrobon D. 2010. CaV2.1 channelopathies. Pflugers Arch 460(2):375–393. 
Pollitt RJ. 2006. International perspectives on newborn screening. J Inherit Metab Dis 
29(2–3):390–396. 
90 
Pollitt RJ. 2007. Introducing new screens: why are we all doing different things? J 
Inherit Metab Dis 30(4):423–429. 
Previs MJ, Beck Previs S, Gulick J, Robbins J, Warshaw DM. 2012. Molecular 
mechanics of cardiac myosin-binding protein C in native thick filaments. Science 
337(6099):1215–1218. 
Puusepp S, Kovacs-Nagy R, Alhaddad B, Braunisch M, Hoffmann GF, Kotzaeridou U, 
Lichvarova L, Liiv M, Makowski C, Mandel M, Meitinger T, Pajusalu S, 
Rodenburg RJ, Safiulina D, Strom TM, Talvik I, Vaarmann A, Wilson C, 
Kaasik A, Haack TB, Ounap K. 2018. Compound heterozygous SPATA5 variants 
in four families and functional studies of SPATA5 deficiency. European journal of 
human genetics : EJHG 26(3):407–419. 
Rasmussen SA, Fernhoff PM, Scanlon KS. 2001. Vitamin B12 deficiency in children 
and adolescents. J Pediatr 138(1):10–17. 
Ray JG, Goodman J, O’Mahoney PRA, Mamdani MM, Jiang D. 2008. High rate of 
maternal vitamin B12 deficiency nearly a decade after Canadian folic acid flour 
fortification. Qjm-Int J Med 101(6):475–477. 
Rea G, Homfray T, Till J, Roses-Noguer F, Buchan RJ, Wilkinson S, Wilk A, Walsh R, 
John S, McKee S, Stewart FJ, Murday V, Taylor RW, Ashworth M, Baksi AJ, 
Daubeney P, Prasad S, Barton PJR, Cook SA, Ware JS. 2017. Histiocytoid 
cardiomyopathy and microphthalmia with linear skin defects syndrome: phenotypes 
linked by truncating variants in NDUFB11. Cold Spring Harbor molecular case 
studies 3(1):a001271. 
Refsum H, Grindflek AW, Ueland PM, Fredriksen A, Meyer K, Ulvik A, Guttormsen 
AB, Iversen OE, Schneede J, Kase BF. 2004. Screening for serum total homo-
cysteine in newborn children. Clin Chem 50(10):1769–1784. 
Reinson K, Ilo U, Künnapas K, Vals M-A, Muru K, Kriisa A, Õunap K. 2016a. 
Vastsündinute laiendatud sõeluurimise juurutamine Eestis 19 kaasasündinud 
ainevahetushaiguse suhtes: esimese 1,5 aasta tulemuste kokkuvõte. Eesti Arst 
95(8):506–514. 
Reinson K, Oiglane-Shlik E, Talvik I, Vaher U, Ounapuu A, Ennok M, Teek R, 
Pajusalu S, Murumets U, Tomberg T, Puusepp S, Piirsoo A, Reimand T, Ounap K. 
2016b. Biallelic CACNA1A mutations cause early onset epileptic encephalopathy 
with progressive cerebral, cerebellar, and optic nerve atrophy. American journal of 
medical genetics Part A 170(8):2173–2176. 
Rinaldo P, Cowan TM, Matern D. 2008. Acylcarnitine profile analysis. Genetics in 
medicine : official journal of the American College of Medical Genetics 10(2):151–
156. 
Rinaldo P, Zafari S, Tortorelli S, Matern D. 2006. Making the case for objective perfor-
mance metrics in newborn screening by tandem mass spectrometry. Mental 
retardation and developmental disabilities research reviews 12(4):255–261. 
Rodenburg RJ. 2011. Biochemical diagnosis of mitochondrial disorders. J Inherit Metab 
Dis 34(2):283–292. 
Rodenburg RJ. 2016. Mitochondrial complex I-linked disease. Biochimica et biophysica 
acta 1857(7):938–945. 
Rose SJ, Kriener LH, Heinzer AK, Fan X, Raike RS, van den Maagdenberg AM, Hess 
EJ. 2014. The first knockin mouse model of episodic ataxia type 2. Experimental 
neurology 261:553–562. 
91 
Rubio-Gozalbo ME, Sengers RCA, Trijbels JMF, Doesburg WH, Janssen AJM, 
Verbeek ALM, Smeitink JAM. 2000. A prognostic index as diagnostic strategy in 
children suspected of mitochondriocytopathy. Neuropediatrics 31(3):114–121. 
Sarafoglou K, Rodgers J, Hietala A, Matern D, Bentler K. 2011. Expanded newborn 
screening for detection of vitamin B12 deficiency. JAMA 305(12):1198–1200. 
Savage DG, Lindenbaum J, Stabler SP, Allen RH. 1994. Sensitivity of serum 
methylmalonic acid and total homocysteine determinations for diagnosing 
cobalamin and folate deficiencies. The American journal of medicine 96(3):239–
246. 
Schoen EJ, Baker JC, Colby CJ, To TT. 2002. Cost-benefit analysis of universal tandem 
mass spectrometry for newborn screening. Pediatrics 110(4):781–786. 
Schroder TH, Mattman A, Sinclair G, Vallance HD, Lamers Y. 2016. Reference 
interval of methylmalonic acid concentrations in dried blood spots of healthy, term 
newborns to facilitate neonatal screening of vitamin B12 deficiency. Clinical 
biochemistry 49(13–14):973–978. 
Schuelke M, Oien NC, Oldfors A. 2017. Myopathology in the times of modern genetics. 
Neuropathol Appl Neurobiol 43(1):44–61. 
Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. 
2003. Expanded newborn screening for inborn errors of metabolism by electrospray 
ionization-tandem mass spectrometry: results, outcome, and implications. 
Pediatrics 111(6 Pt 1):1399–1406. 
Scolamiero E, Villani GR, Ingenito L, Pecce R, Albano L, Caterino M, di Girolamo 
MG, Di Stefano C, Franzese I, Gallo G, Ruoppolo M. 2014. Maternal vitamin B12 
deficiency detected in expanded newborn screening. Clinical biochemistry 
47(18):312–317. 
Selhub J, Morris MS, Jacques PF. 2007. In vitamin B12 deficiency, higher serum folate 
is associated with increased total homocysteine and methylmalonic acid 
concentrations. Proceedings of the National Academy of Sciences of the United 
States of America 104(50):19995–20000. 
Shehata BM, Cundiff CA, Lee K, Sabharwal A, Lalwani MK, Davis AK, Agrawal V, 
Sivasubbu S, Iannucci GJ, Gibson G. 2015. Exome sequencing of patients with 
histiocytoid cardiomyopathy reveals a de novo NDUFB11 mutation that plays a 
role in the pathogenesis of histiocytoid cardiomyopathy. American journal of 
medical genetics Part A 167A(9):2114–2121. 
Siciliano G, Tessa A, Petrini S, Mancuso M, Bruno C, Grieco GS, Malandrini A, 
DeFlorio L, Martini B, Federico A, Nappi G, Santorelli FM, Murri L. 2003. 
Autosomal dominant external ophthalmoplegia and bipolar affective disorder 
associated with a mutation in the ANT1 gene. Neuromuscul Disord 13(2):162–165. 
Sim KG, Hammond J, Wilcken B. 2002. Strategies for the diagnosis of mitochondrial 
fatty acid beta-oxidation disorders. Clinica chimica acta; international journal of 
clinical chemistry 323(1–2):37–58. 
Smits P, Smeitink J, van den Heuvel L. 2010. Mitochondrial translation and beyond: 
processes implicated in combined oxidative phosphorylation deficiencies. Journal 
of biomedicine & biotechnology 2010:737385. 
Soden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, LePichon JB, 
Miller NA, Thiffault I, Dinwiddie DL, Twist G, Noll A, Heese BA, Zellmer L, 
Atherton AM, Abdelmoity AT, Safina N, Nyp SS, Zuccarelli B, Larson IA, 
Modrcin A, Herd S, Creed M, Ye Z, Yuan X, Brodsky RA, Kingsmore SF. 2014. 
92 
Effectiveness of exome and genome sequencing guided by acuity of illness for 
diagnosis of neurodevelopmental disorders. Sci Transl Med 6(265):265ra168. 
Solomon BD, Pineda-Alvarez DE, Bear KA, Mullikin JC, Evans JP, Program NCS. 
2012. Applying Genomic Analysis to Newborn Screening. Mol Syndromol 
3(2):59–67. 
Solomon LR. 2005. Cobalamin-responsive disorders in the ambulatory care setting: 
unreliability of cobalamin, methylmalonic acid, and homocysteine testing. Blood 
105(3):978–985; author reply 1137. 
Stadler SC, Polanetz R, Maier EM, Heidenreich SC, Niederer B, Mayerhofer PU, 
Lagler F, Koch HG, Santer R, Fletcher JM, Ranieri E, Das AM, Spiekerkotter U, 
Schwab KO, Potzsch S, Marquardt I, Hennermann JB, Knerr I, Mercimek-
Mahmutoglu S, Kohlschmidt N, Liebl B, Fingerhut R, Olgemoller B, Muntau AC, 
Roscher AA, Roschinger W. 2006. Newborn screening for 3-methylcrotonyl-CoA 
carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations 
and impact on risk assessment. Hum Mutat 27(8):748–759. 
Stewart JB, Chinnery PF. 2015. The dynamics of mitochondrial DNA heteroplasmy: 
implications for human health and disease. Nat Rev Genet 16(9):530–542. 
Strauss KA, DuBiner L, Simon M, Zaragoza M, Sengupta PP, Li P, Narula N, Dreike S, 
Platt J, Procaccio V, Ortiz-Gonzalez XR, Puffenberger EG, Kelley RI, Morton DH, 
Narula J, Wallace DC. 2013. Severity of cardiomyopathy associated with adenine 
nucleotide translocator-1 deficiency correlates with mtDNA haplogroup. Pro-
ceedings of the National Academy of Sciences of the United States of America 
110(9):3453–3458. 
Strupp M, Zwergal A, Brandt T. 2007. Episodic ataxia type 2. Neurotherapeutics : the 
journal of the American Society for Experimental NeuroTherapeutics 4(2):267–
273. 
Tarini BA, Christakis DA, Welch HG. 2006. State newborn screening in the tandem mass 
spectrometry era: more tests, more false-positive results. Pediatrics 118(2):448–
456. 
Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, He LP, Smertenko T, Alston CL, 
Neeve VC, Best A, Yarham JW, Kirschner J, Schara U, Talim B, Topaloglu H, 
Baric I, Holinski-Feder E, Abicht A, Czermin B, Kleinle S, Morris AAM, Vas-
sallo G, Gorman GS, Ramesh V, Turnbull DM, Santibanez-Koref M, McFarland R, 
Horvath R, Chinnery PF. 2014. Use of Whole-Exome Sequencing to Determine the 
Genetic Basis of Multiple Mitochondrial Respiratory Chain Complex Deficiencies. 
Jama-J Am Med Assoc 312(1):68–77. 
Terwindt GM, Ophoff RA, Haan J, Frants RR, Ferrari MD. 1996. Familial hemiplegic 
migraine: a clinical comparison of families linked and unlinked to chromosome 
19.DMG RG. Cephalalgia 16(3):153–155. 
Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J. 
2015. Current status of newborn screening worldwide: 2015. Semin Perinatol 
39(3):171–187. 
Thompson GN. 1992. Inborn errors of propionate metabolism: methylmalonic and 
propionic acidaemias. J Paediatr Child Health 28(2):134–135. 
Thompson K, Majd H, Dallabona C, Reinson K, King MS, Alston CL, He L, Lodi T, 
Jones SA, Fattal-Valevski A, Fraenkel ND, Saada A, Haham A, Isohanni P, 
Vara R, Barbosa IA, Simpson MA, Deshpande C, Puusepp S, Bonnen PE, 
Rodenburg RJ, Suomalainen A, Ounap K, Elpeleg O, Ferrero I, McFarland R, 
Kunji ERS, Taylor RW. 2016. Recurrent De Novo Dominant Mutations in 
93 
SLC25A4 Cause Severe Early-Onset Mitochondrial Disease and Loss of Mito-
chondrial DNA Copy Number (vol 99, pg 860, 2016). Am J Hum Genet 
99(6):1405–1405. 
Thorwarth A, Schnittert-Hubener S, Schrumpf P, Muller I, Jyrch S, Dame C, 
Biebermann H, Kleinau G, Katchanov J, Schuelke M, Ebert G, Steininger A, 
Bonnemann C, Brockmann K, Christen HJ, Crock P, deZegher F, Griese M, 
Hewitt J, Ivarsson S, Hubner C, Kapelari K, Plecko B, Rating D, Stoeva I, Ropers 
HH, Gruters A, Ullmann R, Krude H. 2014. Comprehensive genotyping and 
clinical characterisation reveal 27 novel NKX2-1 mutations and expand the 
phenotypic spectrum. Journal of medical genetics 51(6):375–387. 
Torraco A, Bianchi M, Verrigni D, Gelmetti V, Riley L, Niceta M, Martinelli D, 
Montanari A, Guo Y, Rizza T, Diodato D, Di Nottia M, Lucarelli B, Sorrentino F, 
Piemonte F, Francisci S, Tartaglia M, Valente EM, Dionisi-Vici C, Christo-
doulou J, Bertini E, Carrozzo R. 2016. A novel mutation in NDUFB11 unveils a 
new clinical phenotype associated with lactic acidosis and sideroblastic anemia. 
Clin Genet. 
Tucker EJ, Compton AG, Calvo SE, Thorburn DR. 2011. The molecular basis of human 
complex I deficiency. IUBMB life 63(9):669–677. 
Vahedi K, Denier C, Ducros A, Bousson V, Levy C, Chabriat H, Haguenau M, Tournier-
Lasserve E, Bousser MG. 2000. CACNA1A gene de novo mutation causing 
hemiplegic migraine, coma, and cerebellar atrophy. Neurology 55(7):1040–1042. 
Waisbren SE, Landau Y, Wilson J, Vockley J. 2013. Neuropsychological outcomes in 
fatty acid oxidation disorders: 85 cases detected by newborn screening. Develop-
mental disabilities research reviews 17(3):260–268. 
Waisbren SE, Levy HL, Noble M, Matern D, Gregersen N, Pasley K, Marsden D. 2008. 
Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the 
medical and neurodevelopmental characteristics of 14 cases identified through 
newborn screening or clinical symptoms. Mol Genet Metab 95(1–2):39–45. 
Waisbren SE, Read CY, Ampola M, Brewster TG, Demmer L, Greenstein R, Ingham 
CL, Korson M, Msall M, Pueschel S, Seashore M, Shih VE, Levy HL, New 
England Consortium of Metabolic P. 2002. Newborn screening compared to 
clinical identification of biochemical genetic disorders. J Inherit Metab Dis 
25(7):599–600. 
Valenti D, de Bari L, De Filippis B, Henrion-Caude A, Vacca RA. 2014. Mitochondrial 
dysfunction as a central actor in intellectual disability-related diseases: an overview 
of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev 
46 Pt 2:202–217. 
Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-
Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, 
Altshuler D, Gabriel S, DePristo MA. 2013. From FastQ data to high confidence 
variant calls: the Genome Analysis Toolkit best practices pipeline. Current 
protocols in bioinformatics / editoral board, Andreas D Baxevanis [et al] 
11(1110):11 10 11–11 10 33. 
van der Greef J, van Wietmarschen H, van Ommen B, Verheij E. 2013. Looking back into 
the future: 30 years of metabolomics at TNO. Mass Spectrom Rev 32(5):399–415. 
van Rahden VA, Fernandez-Vizarra E, Alawi M, Brand K, Fellmann F, Horn D, 
Zeviani M, Kutsche K. 2015. Mutations in NDUFB11, encoding a complex I 
component of the mitochondrial respiratory chain, cause microphthalmia with 
linear skin defects syndrome. Am J Hum Genet 96(4):640–650. 
94 
Wang K, Li M, Hakonarson H. 2010. ANNOVAR: functional annotation of genetic 
variants from high-throughput sequencing data. Nucleic acids research 
38(16):e164. 
Verity CM, Winstone AM, Stellitano L, Krishnakumar D, Will R, McFarland R. 2010. 
The clinical presentation of mitochondrial diseases in children with progressive 
intellectual and neurological deterioration: a national, prospective, population-
based study. Dev Med Child Neurol 52(5):434–440. 
Verkaart S, Koopman WJH, van Emst-de Vries SE, Nijtmans LGJ, van den Heuvel 
LWPJ, Smeitink JAM, Willems PHGM. 2007. Superoxide production is inversely 
related to complex I activity in inherited complex I deficiency. Bba-Mol Basis Dis 
1772(3):373–381. 
Wheeler S. 2008. Assessment and interpretation of micronutrient status during 
pregnancy. Proc Nutr Soc 67(4):437–450. 
Vilarinho L, Rocha H, Sousa C, Marcao A, Fonseca H, Bogas M, Osorio RV. 2010. 
Four years of expanded newborn screening in Portugal with tandem mass 
spectrometry. J Inherit Metab Dis 33 Suppl 3:S133–138. 
Wilcken B. 2008. The consequences of extended newborn screening programmes: do 
we know who needs treatment? J Inherit Metab Dis 31(2):173–177. 
Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, 
Cowley D, Ellaway C, Fletcher J, Kirk EP, Lewis B, McGill J, Peters H, Pitt J, 
Ranieri E, Yaplito-Lee J, Boneh A. 2009. Expanded newborn screening: outcome 
in screened and unscreened patients at age 6 years. Pediatrics 124(2):e241–248. 
Wilcken B, Wiley V, Hammond J, Carpenter K. 2003. Screening newborns for inborn 
errors of metabolism by tandem mass spectrometry. N Engl J Med 348(23):2304–
2312. 
Wilson JM, Jungner YG. 1968. [Principles and practice of mass screening for disease]. 
Bol Oficina Sanit Panam 65(4):281–393. 
Wolf NI, Smeitink JA. 2002. Mitochondrial disorders: a proposal for consensus 
diagnostic criteria in infants and children. Neurology 59(9):1402–1405. 
Volsen SG, Day NC, McCormack AL, Smith W, Craig PJ, Beattie R, Ince PG, Shaw PJ, 
Ellis SB, Gillespie A, et al. 1995. The expression of neuronal voltage-dependent 
calcium channels in human cerebellum. Brain Res Mol Brain Res 34(2):271–282. 
von Schenck U, Bender-Gotze C, Koletzko B. 1997. Persistence of neurological damage 
induced by dietary vitamin B-12 deficiency in infancy. Arch Dis Child 77(2):137–
139. 
Wortmann SB, Koolen DA, Smeitink JA, van den Heuvel L, Rodenburg RJ. 2015. 
Whole exome sequencing of suspected mitochondrial patients in clinical practice. J 
Inherit Metab Dis 38(3):437–443. 
Wortmann SB, Mayr JA, Nuoffer JM, Prokisch H, Sperl W. 2017. A Guideline for the 
Diagnosis of Pediatric Mitochondrial Disease: The Value of Muscle and Skin 
Biopsies in the Genetics Era. Neuropediatrics 48(4):309–314. 
Wortmann SB, Zweers-van Essen H, Rodenburg RJ, van den Heuvel LP, de Vries MC, 
Rasmussen-Conrad E, Smeitink JA, Morava E. 2009. Mitochondrial energy 
production correlates with the age-related BMI. Pediatr Res 65(1):103–108. 
Yarham JW, Lamichhane TN, Pyle A, Mattijssen S, Baruffini E, Bruni F, Donnini C, 
Vassilev A, He L, Blakely EL, Griffin H, Santibanez-Koref M, Bindoff LA, 
Ferrero I, Chinnery PF, McFarland R, Maraia RJ, Taylor RW. 2014. Defective 
i6A37 modification of mitochondrial and cytosolic tRNAs results from pathogenic 
mutations in TRIT1 and its substrate tRNA. PLoS genetics 10(6):e1004424. 
95 
 WEB RESOURCES 
CALIPER. Canadian Laboratory Initiative on Paediatric Reference Intervals. This 
project is a multi-centre, nation-wide initiative aimed at developing a com-
prehensive database of healthy reference values (reference intervals) for blood tests 
in children: http://www.sickkids.ca/caliperproject/index.html 
Chromsystems. Chromsystems Instruments & Chemicals GmbH is a company, offering 
technologies for clinical analysis by HPLC and mass spectrometry, including 
validated and ready-to-use assays for newborn screening: 
https://www.chromsystems.com/products/newborn-screening.html 
ClinVar. Database of genomic variation and its relationship to human health: 
https://www.ncbi.nlm.nih.gov/clinvar/  
ERNDIM. The External Quality Assurance Programme for Amino Acids, Quantitative 
Organic Acids, Purines and Pyrimidines, Special Assays in Serum and Urine, 
Cystine in White Blood Cells and Lysosomal Enzymes: http://www.erndimqa.nl/ 
ExAC. The Exome Aggregation Consortium (ExAC) is a coalition of investigators 
seeking to aggregate and harmonize exome sequencing data from a variety of large-
scale sequencing projects, and to make summary data available for the wider 
scientific community: http://exac.broadinstitute.org/ 
GATK. Variant discovery toolkit for high-throughput sequencing data:  
https://software.broadinstitute.org/gatk/  
OMIM. Online Mendelian Inheritance in Man. An Online Catalog of Human Genes and 
Genetic Disorders: http://omim.org  
Picard. A set of command line tools for manipulating high-throughput sequencing data: 
http://broadinstitute.github.io/picard/ 
R4S. Region 4 Stork is a collaborative laboratory performance improvement project 
focused on newborn screening: https://www.clir-r4s.org/ 
Statistics Estonia is a government agency in the area of administration of the Ministry 
of Finance. The main task of Statistics Estonia is to provide reliable and objective 
information on the economic, demographic, social and environmental situation and 
trends in Estonia: https://www.stat.ee/ 
  
96 
SUMMARY IN ESTONIAN 
Uued diagnoosimeetodid kaasasündinud ainevahetushaiguste 
varajaseks avastamiseks Eestis 
Inimese tervisliku seisundi hindamisel peeti tema kehaeritisi väärtuslikuks 
infoallikaks juba Vana-Hiina kultuuris (1500–2000eKr), kuid tõeline revo-
lutsioon organismi ainevahetuse (AV) toimimise osas saabus 20. sajandi 
alguses, kui saksa keemik Eduard Buchner avastas ensüümid ja nende funkt-
siooni. See teadmine nihutas edasiste uuringute fookuse rakusisestele 
protsessidele (sh ensüümaatilised ja biokeemilised reaktsioonid) ning peatselt 
avastas inglise arst Sir Archibald Garrod, et metaboolsete radade muutused on 
põhjustatud monogeensetest geenidefektidest [van der Greef et al. 2013]. Need 
teadmised panid aluse kaasaegsele teadusele pärilikest AV-haigustest. 
Kuigi tegemist on kaasasündinud haigustega, ei ole enamikel vastsündinutel 
sünnihetkel mingeid viiteid sellele, kuna raseduse ajal kompenseerib ema 
organism transplatsentaarselt loote AV puudujäägid ning alles sünni järgselt 
võivad järk-järgult ilmneda haigusele iseloomulikud sümptomid, mis sageli on 
pöördumatud ja põhjustavad olulist eluea lühenemist. Kuid on AV-haigusi, 
nagu fenüülketonuuria (PKU), mis varajase diagnoosimisega on hästi ravitavad/ 
kontrolli all hoitavad. 1960. aastate alguses leidiski aset põhimõtteline suuna-
muutus selliste haiguste diagnostikas, kui dr Robert Guthrie kirjeldas esma-
kordselt vastsündinutel PKU avastamise meetodit [Guthrie and Susi 1963]. See 
teadmine pani aluse vastsündinute sõeltestimisele (VS). 
Järgmine oluline samm pärilike AV-haiguste diagnoosimisel toimus 1990-
ndatel, kui VS-l võeti kasutusele tandem mass-spektromeetria (MS), millega oli 
võimalik ühest proovist ühe analüüsitsükli jooksul määrata >50 erinevat 
metaboliiti. See muutis VS senist kontseptsiooni, kus iga sõeltestitava haiguse 
määramiseks oli vaja üht meetodit, millega määrata üht metaboliiti [Chace D.H. 
2005]. Tandem MS võimaldas sõeltestida ka väga haruldasi haigusi, mida 
eelnevalt ei oleks otstarbekuse kaalutlusel uuritavate haiguste loetellu lisatudki. 
Lisaks andis uus meetod võimaluse eristada iatrogeenseid muutusi VS-i tule-
mustes ning kirjeldada täpsemalt metaboolseid muutusi, mida üks või teine 
haigus endaga kaasa toob.  
Eestis algas VS 1993. aastal ja seda vaid ühe haiguse osas, milleks oli PKU 
ning selleks kasutati fenüülalaniini määramist fluoromeetrilisel meetodil 
[Ounap et al. 1998] ehk siis üks meetod ühe haiguse sõeltestimiseks. Esimese 
süstemaatilise üle-eestilise andmeanalüüsi põhjal selgus, et PKU esinemis-
sagedus Eestis on varasemast hinnangust oluliselt kõrgem – 1:6010 elussünni 
kohta [Ounap 1999]. Kolm aastat hiljem lisandus skriiningprogrammi kaasa-
sündinud hüpotüreoos [Mikelsaar et al. 1998] ning sellisena toimus Eestis VS 
enam kui 20 aastat. 
Tänapäeval on enamikes Lääne-Euroopa riikides ja Ameerika Ühendriikides 
kasutusel tandem MS ning ka sõeltestitavate haiguste arv küündib riigiti 29-ni 
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nagu Austrias [Burgard et al. 2012]. Seega vajas Eestis VS täiustamist, seda 
enam, et meil puudus ülevaade enamike sõeltestitavate haiguste esinemis-
sageduste kohta siin regioonis ning tandem MS oli kliinilises töös (atsüülkarni-
tiinide profiili määramine seerumist) kasutusel juba aastast 2008 [Joost et al. 
2012a]. Kahe rasvhapete beeta-oksüdatsioonidefektide gruppi kuuluva haiguse: 
keskmise ahelaga atsüül-CoA dehüdrogenaasi puudulikkuse (ingl k medium-
chain acyl-CoA dehydrogenase deficiency ehk MCADD) ja pika ahelaga  
3-hüdroksüatsüül-CoA dehüdrogenaasi puudulikkuse (long-chain 3-hydroxyacyl-
CoA dehydrogenase deficiency ehk LCHADD) esinemissagedused on meile 
arvutuslikult teada, kuna juba mõnda aega on meil olnud võimalik määrata 
mõlema haigusseoselise geeni (MCADD-i kahtlusel ACADM geenis ja 
LCHADD-i kahtlusel HADHA geenis) põhimutatsioone. Saadud andmete põhjal 
ilmnes, et ACADM geeni põhimutatsiooni c.985A>G (p.K329E) kandlus on 
Eestis 1:220, seega hinnanguliselt võiks MCADD-i esinemissagedus olla 
1:193 000 [Lillevali 2000] ja HADHA geeni põhimutatsiooni c.1528G> C 
(p.E510Q) kandlust 1:173 ning arvestades, et Eesti LCHADD-i patsientidel 
moodustab põhimutatsioon 87,5% haiguse alleelidest, on LCHADD hinnan-
guline levimus Eestis 1:91 700 [Joost et al. 2012a]. 
Kahjuks ei ole kõik kaasasündinud AV-haigused sõeltestitavad ja ravitavad 
asümptoomses perioodis. Suure grupi selliseid kaasasündinud haigusi moodus-
tavad mitokondriaalsed haigused (MH), mille esinemisel on molekulaarselt 
kinnitatud diagnoosini jõudmine vahel väga keeruline, kuna kliinilised prob-
leemid ja nende algusaeg on äärmiselt varieeruv ka sama pere liikmete seas. 
Sestap on mitokondriaalsete haiguste diagnoosimiseks välja töötatud mitmeid 
juhiseid ja algoritme [Morava et al. 2006b; Nissenkorn et al. 1999; Wolf and 
Smeitink 2002]. Aastal 2012 töötati ka Eestis välja neuroloogiliste probleemi-
dega laste hulgast MH tuvastamiseks algoritm, mis baseerus patsiendi kliinilise 
seisundi ning instrumentaalsete ja biokeemiliste uuringute tulemuste analüüsil, 
jõudmaks ühe geeni sekveneerimiseni [Joost et al. 2012b]. Selle uuringutöö 
raames (2003–2009) tuvastati Eestis lapseea-algusega MH esinemissagedus 
1:20 764 [Joost 2012; Joost et al. 2012b]. Eelkirjeldatud meetod on enamjaolt 
ajamahukas, eeldab invasiivseid uuringuid ning tulemuslikkus jääb sageli 
tagasihoidlikuks [Neveling et al. 2013]. Sestap on viimastel aastatel järjest 
enam MH kahtlusega patsientide uurimiseks kasutama hakatud kogu eksoomi 
sekveneerimist (ingl k whole exome sequencing ehk WES) ning aastast 2013 on 
WES ka Eestis kasutusel.  
 
Käesoleva uuringu eesmärgid 
1. Hinnata vastsündinute laiendatud sõeltestimise programmi metoodikat ja 
efektiivsust Eestis (I ja VI artikkel). 
2. Hinnata kogu eksoomi sekveneerimise efektiivsust kliinilises praktikas 
lapseeas alanud mitokondriaalse haiguse kahtlusega patsientide hulgas (II 
artikkel). 
3. Hinnata ja kirjeldada esmakordselt CACNA1A geeni liitheterosügootse 
mutatsiooni kliinilist efekti (III artikkel). 
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4. Kirjeldada esmakordselt SLC25A4 geeni uustekkese (de novo) mutatsiooni 
põhjustatud molekulaarseid muutusi ning sellest põhjustatud kliinilise feno-
tüübi kolmandat alavormi (IV artikkel). 
5. Kirjeldada NDUFB11 geeni funktsiooni, mutatsioonidest põhjustatud feno-
tüüpe ning võrrelda neid eelnevalt kirjeldatud fenotüüpidega (V artikkel). 
  
Patsientide ja meetodite lühikirjeldus 
Vastsündinute laiendatud sõeltestimine (VLS) Eestis algas 1. jaanuaril 2014a. 
ning esimesed 12 kuud toimus see pilootprojektina, mille jooksul sõeltestisime 
13 643 vastsündinut. Sel perioodil loobusid 49 (0,36%) lapse vanemad 
sõeltestimisest. Alates 2015a. kuulub VLS Eesti Haigekassa poolt tasustatavate 
teenuste nimekirja ning nelja aasta (2014–2017) jooksul oleme sõeltestinud 
54 899 vastsündinut. Selleks on kõigilt vastsündinutelt soovituslikult 3.–5. 
elupäeval kogutud kannast kapillaarveri Whatman 903® filterpaberile ning 
kuivatatud vereplekid on saadetud posti teel või kulleriga Eesti ainsasse VLS 
läbiviivasse laborisse – SA Tartu Ülikooli Kliinikumi ühendlabori kliinilise 
geneetika keskusesse (TÜK ÜL KGK). Analüüsimiseks kasutame Xevo TQD 
Triple Quadrupole tandem MS-i ning kommertsiaalset kitti – MassChrom Kit, 
millega määrame 13 aminohapet, 30 atsüülkarnitiini ning suktsinüülatsetooni. 
Tulemused on derivatiseeritud. Otsustuspiirid võtsime esialgu kirjandusest, kuid 
peale 1000 vastsündinu tulemuste laekumist kalkuleerisime esimest korda 
laborisisesed otsustuspiirid: 1. protsentiil vastab alumisele ja 99. protsentiil 
ülemisele otsustuspiirile. Andmete lisandumisel oleme neid korduvalt ümber 
arvutanud ning hetkel on kasutusel ligikaudu 30 000 vastsündinu tulemuste 
põhjal arvutatud otsustuspiirid. 
Mitokondriaalse haiguse kahtlusega patsientide uuringugrupp koosneb 
kahest osast. Esimese osa moodustavad retrospektiivselt kliinilises töös uuritud 
patsiendid, keda on 2003–2013 aasta vahemikus TÜK ÜL KGK-s uuritud 
päriliku AV-haiguse suhtes ning kellel on jäänud kahtlus MH-le, kuid see pole 
molekulaarselt kinnitunud. Tavapraktika taoliste patsientide puhul on säilitada 
fibroblastide kultuur, mida oleks võimalik kasutada edasisteks uuringuteks, 
nagu ensüümi(-de) aktiivsuse määramine. Selliselt uuritud patsiente oli 181, 
kelle kliinilised andmed ja tehtud uuringud sai uuesti üle vaadatud/hinnatud 
ning ilmnes, et 21 patsiendi puhul püsis raviarstil jätkuvalt tugev kahtlus 
lapseea-algusega MH-le, kuid puudus molekulaarselt kinnitunud diagnoos. Neli 
väljavalitud patsienti jäid uuringugrupist välja kuna patsient loobus selles 
osalemast, puudus kontakt perekonnaga või olid kaebused taandunud. Teise 
grupi moodustavad 11 prospektiivselt (jaanuar 2014 – märts 2016) uuritud 
lapseea-algusega MH kahtlusega patsienti, kes kõik lisati uuringusse. Mõlema 
uuringugrupi patsiendid järjestasime kliiniliste andmete (sh instrumentaalsed ja 
biokeemilised uuringud) alusel kasutades Morava et al. poolt välja töötatud MH 
kliinilist skooringut [Morava et al. 2006b]. 
Kõikidele patsientidele teostati WES, DNA selleks eraldati vere lümfotsüüti-
dest. Haigusseoselised leiud kinnitati ja perekondlik segregatsioonianalüüs tehti 
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Sanger sekveneerimisega. Mitokondriaalse DNA analüüs teostati samuti kõiki-
dele patsientidele kasutades standardset WES-i.  
Mitokondriaalse hingamisahela ensüümide aktiivsust mõõdeti fibroblastide 
kultuurist spektrofotomeetrilisel meetodil. 
 
Peamised tulemused ja järeldused  
1. Nelja-aastase uuringuperioodi tulemuste põhjal saame järeldada, et välja-
töötatud vastsündinute laiendatud sõeltestimise meetodi valik ja ülesehitus 
on end Eestis õigustanud (I ja VI artikkel). 
a. VLS raames oleme uurinud 54 899 vastsündinut ning kinnitanud 29 
lapsel kaasasündinud AV-haiguse, seega antud tulemuste põhjal hinna-
tuna on uuritavate haiguste üldine esinemissagedus Eestis 1:1893 vast-
sündinule. 
b. Meile ootamatult diagnoosisime kõige sagedamini kaasasündinud oman-
datud vitamiin B12 puudulikkust, mille esinemissagedus kolme aasta 
põhjal hinnatuna on 1:2959. 
c. Esinemissageduselt järgmise grupi moodustasid hüperfenüülalani-
neemiaga patsiendid. Antud tulemus on ootuspärane arvestades eelnevaid 
Eesti populatsiooni haaravaid uuringud. 
d. Tuginedes nelja-aastasele VLS-i tulemustele, võime kinnitada, et MCADD 
esinemine Eestis on haruldane. Antud ajaperioodil ei tuvastanud me ühtki 
selle diagnoosiga last.  
e. Nelja aasta jooksul on valepositiivsuse määr olnud 0,1% ja positiivne 
ennustusväärtus on tõusnud 36,7%-ni. Viimase (neljanda) aasta kokku-
võttes oli valepositiivsuse määr 0,07% ja positiivne ennustusväärtus 
52,6%. VLS üldine spetsiifilisus on 99,9% ja kuna me ei ole ikka veel 
valenegatiivset juhtumit diagnoosinud, püsib tandem MS-ga sõeltestimise 
tundlikkus 100%. 
 
2. Tuginedes meie uuringutulemustele ja varasemale sellekohasele kirjan-
dusele, saame järeldada, et kliinilises töös on WES-i kasutamine lapseea-
algusega MH kahtlusega patsientidel väga hea efektiivsusega (II artikkel). 
a. Antud uuringugrupp koosnes 28 patsiendist, kellest 17-l tuvastasime 
WES-ga haigusseoselised geenimutatsioonid, seega on diagnostiline 
saagis väga kõrge – 61%. 
b. Vaid 14%-l (4/28) uuritavatest tuvastasime rakutuuma DNA-s mutat-
sioonid, mis põhjustavad MH-d. Ülejäänud tuumageenides tuvastatud 
mutatsioonid on seostatavad neuromuskulaarsete, neurodegeneratiivsete, 
multisüsteemsete või isoleeritud kardiomüopaatiat põhjustavate geeni-
dega.  
c. Oma töös oleme edukalt välja töötanud ja kasutusele võtnud ka mtDNA 
analüüsimeetodi standardsel WES-l. Antud meetodiga tuvastasime ühel 
juhul mtDNA-s MT-ATP6 geenis punktmutatsiooni, mis kinnitab meetodi 
tõhusust rutiinses kliinilises töös. 
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d. Tuginedes uuringutulemustele, oleme veendunud, et WES peaks olema 
esmane analüüs, mis kliinilises töös teostatakse lapsele, kellel esineb 
multisüsteemne, neuroloogiline ja/või neuromuskulaarne haigus. Seda 
enam, et lapseeas avalduva MH korral prevaleeruvad tuuma DNA-s esi-
nevad mutatsioonid ning antud meetod võimaldab tuvastada punktmutat-
sioone ka mtDNA-s. 
 
3. Kahe sama pere liikme (õe ja venna) kliiniline ja molekulaarne uurimine 
tuvastas CACNA1A geenis liitheterosügootsena mutatsioonid, mis laiendavad 
antud geeniga seotud genotüübi ja fenotüübi spektrit (artikkel III). 
a. Meie uuringugrupp kirjeldas esmakordselt kaht patsienti (õde ja vend), 
kellel esinevad liitheterosügootsena mutatsioonid CACNA1A geenis. 
Eelnevalt kirjeldatud patsientidel on tuvastatud CACNA1A geenis vaid 
heterosügootsed mutatsioonid.  
b. WES-ga tuvastati õel ja vennal CACNA1A geenis varem kirjeldamata 
heterosügootsed mutatsioonid: c.4315T>A p. (Trp1439Arg) 27. eksonis 
ja c.472_478delGCCTTCC p. (Ala158Thrfs_6) 3. eksonis. 
c. Eelkirjeldatud semidominantselt pärandunud mutatsioonid põhjustavad 
suure tõenäosusega varajase algusega epileptilist entsefalopaatiat, 
progresseeruvat suuraju, väikeaju ja N. opticuse atroofiat koos väljen-
dunud lihashüpotoonia ja oluliselt lühenenud elueaga. 
 
4. Kliinilised, molekulaarsed ja funktsionaalsed uuringud tuvastasid varem 
kirjeldamata uustekkese (de novo) mutatsioon SLC25A4 geenis, mis põh-
justab kolmanda, selgelt eelnevatest eristuva kliinilise fenotüübi (IV 
artikkel). 
a. Rahvusvahelises kootöös oleme hinnanud seitsmel patsiendil (sh üks 
patsient on Eestist) funktsionaalset ja kliinilist efekti varem kirjeldamata 
uustekkesest (de novo) ühenukleotiidse vahetusega mutatsioonist 
SLC25A4 geenis. 
b. Neljal patsiendil selles grupis oli c.239G>A (p.Arg80His) mutatsioon ja 
kolmel c.703C>G (p.Arg235Gly) mutatsioon. Mõlemad mutatsioonid 
mõjutavad kõrgelt konserveerunud ja funktsionaalselt olulist aminohapete 
järjestust ning muutused antud piirkonnas on seotud stabiilse AAC1 
valgu taseme langusega patsientide skeletilihastes ja seega on vähenenud 
ATP aktiivne transport in vitro. 
c. Kõigil uuringugrupis olevatel patsientidel esines sarnane fenotüüp: neil 
oli kaasasündinud väljendunud lihashüpotoonia ning lihasnõrkus, mis-
tõttu vajasid nad mehhaanilist ventilatsiooni ja enamik suri varajases 
imikueas. 
d. Eelkirjeldatud geenimutatsioonidega patsientide lihasbiopsia materjali 
histopatoloogilisel uurimisel ilmnesid viited mitokondriaalsele müopaa-
tiale. Edasisel uurimisel ilmnes hingamisahela ensüümide kombineeritud 
defekt, mis põhjustab olulise mtDNA koopiaarvu vähenemise. 
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5. Kliinilised, molekulaarsed ja funktsionaalsed uuringud tuvastasid kahel pat-
siendil varem kirjeldamata mutatsioonid NDUFB11 geenis, mis põhjustavad 
isoleeritud mitokondriaalse hingamisahela esimese kompleksi puudulikkust. 
Meie poolt uuritud patsientide ja 13 eelnevalt kirjeldatud NDUFB11 geeni-
mutatsiooniga patsientide kliiniliste probleemide analüüsi põhjal saame öelda, 
et eelkirjeldatud geeni mutatsioonide korral esineb väga varieeruv kliiniline 
fenotüüp. 
a. Mõlemal meie poolt kirjeldatud patsiendil esines laktaatatsideemia, 
hüpertroofiline kardiomüopaatia ja isoleeritud mitokondriaalse hingamis-
ahela esimese kompleksi puudulikkus, mis oli põhjustatud uustekkesest 
(de novo) hemisügootsest mutatsioonist (c.286C>T ja c.328C>T) 
NDUFB11 geenis.  
b. Eksperimentaalsete uuringutega tõestasime, et mõlema patsiendi rakku-
des oli NDUFB11 valgu ekspressioonitase langenud ning lentiviirus-vek-
toriga metsiktüüpi (wild type) alleeli tutvustamise järgselt mitokond-
riaalse hingamisahela esimese kompleksi aktiivsus taastus. 
c. NDUFB11 geenimutatsioonidega patsientide fenotüübid on äärmiselt 
varieeruvad ja erinevad paljuski teistest isoleeritud mitokondriaalse 
hingamisahela esimese kompleksi puudulikkusega patsientidest. Samas 
histiotsütoidne kardiomüopaatia ja kaasasündinud sideroblastne aneemia 
võivad viidata NDUFB11 geenimutatsioonile. 
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